Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 1 of 155Clinical Study Protocol 
Study Intervention MEDI3506 
Study Code D9180C00002Amendment Number 5.0Date 16 February 2022
A Phase II, Randomized, Double-blind, Placebo-controlled Study 
to Assess the Efficacy, Safety and Tolerability of MEDI3506 in 
Participants with Moderate to Severe Chronic Obstructive 
Pulmonary Disease and Chronic Bronchitis (FRONTIER 4)
Sponsor Name: 
AstraZeneca AB, 15185 SÃ¶dertÃ¤lje, Sweden 
Regulatory Agency Identifier Numb r(s):
IND:147640EudraCT number: 2020-000571 20
This Clinical Study Protocol has been sub ject to a peer review according to AstraZeneca 
Standard procedures. The Clinical Study Protocol is publicly registered, and the results are disclosed and/or published according to the AstraZeneca Global Policy on Bioethics and in compliance with prevailing laws and regulations.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYje, Swwedeneden wwww
er Numb r(s):Numb r(s)
2020-000571 20020-000571 20YHGindin
d TTolerabolerabTTT
to Severe ChSevere C
hronic Bronchnic BroY
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 2 of 155Protocol Number: D9180C00002
Amendment Number: 5.0Study Intervention: MEDI3506Study Phase: Phase 2Short Title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the 
Efficacy, Safety and Tolerability of MEDI3506 in Participants with COPD and Chronic 
Bronchitis 
Acronym: FRONTIER 4 
Medical Monitor Name and Contact Information will be provided separately
International co-ordinating investigator
Medicine Evaluation Unit
The Langley Building, Southmoor Road
Wythenshawe, Manchester
M23 9QZ'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGn w
dPPD
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 3 of 155PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Document Date
Amendment 5 16-Feb-202
Amendment 4 23-Jul-2021
Amendment 3 01-Jun-2021
Amendment 2 08-Feb-2021
Amendment 1 01-Oct-2020
Original Protocol 03-Jul-2020
Amendment 5 (16 February 2022)
This amendment is considered to be substantial  based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union because it either significantly impacts the safety or physical/mental integrity of participants or the scientific value of the study.
Overall Rationale for the Amendment:
To update the sample size and assumptions underlying its calculation and revise certain 
inclusion and exclusion criteria in response to investigator feedback.
Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-
substantial
Section 1.1 Synopsis, 
Section 9.2 Sample 
Size DeterminationParticipants r ndomly 
assign d to study intervention 
and number of evaluable 
participants amended. 
Statistical methods section: 
Updated with new participant numbers and sample size justification. After consideration of newly 
published clinical trial results 
(Rabe et al 2021)  with another 
anti-IL-33 monoclonal antibody in COPD, the number of participants has been re-evaluated and updated.Substantial
Section 1.3 Schedule 
of Activities.Advice on spirometry 
assessment timing clarified.To reduce the risk of a protocol 
deviation.Non-substantial.
Table 2 and Table 3 Salivary 
sample added as an additional option for the SARS-CoV-2 nucleic acid test.To reflect latest procedures and 
provide an additional option to Non-substantial'&3URWRFRO$PHQGPHQW_9970)_
$SSParticipants r ndomly ts r ndo
assign d to study inassign d to study in
and number of evd number $SSURYHGased on thed on t
ament and the Co and the
fety or physical/mor physica
nt:
mptioons underlyinns und
n response to inve ponse to i
cription of on ChangeChanSU
participants amcipan
ical mi$SS$
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 4 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-
substantial
To minimise patient and site 
burden as baseline samples are 
collected at SV3Non-substantial.
To minimise patient and site 
burden.Non-substantial.
Tables 2 and 3: Minor updates 
and reordering of footnotes Consistency Non-substantial.
Section 2.3.1 Risk 
Assessment, Table 4.Updated risk assessment 
related to progression of heart 
failure.To provide information based 
on current data.Non-substantial.
Section 2.3.1 Risk 
Assessment, Table 4 CT risk mitigations revised. The previously stated effective 
dose in mSv is not possible to 
determine accurately on an individual basis, but is still relevant on a population level. This is described in detail in the Radiology Manual. Target radiation exposure levels for the study have not changed.Non-substantial.
Section 3 Objectives 
and Endpoints, Table 5.To simplify operational 
logistics.Non-substantial.
Clarification Non-substantial.
Correction Non-substantial.
Section 4.1 Overall 
DesignNumber of participants to be 
randomized has been updated and the expected percentage of 
participants in baseline and 
ICS strata removedConsistency and to ensure that 
the final recruited population will more closely represent the 
eligible population.Substantial
Advice on ensuring adequate 
time for CT and 
echocardiogram assessmentsTo provide additional guidance Non-substantial.'&3URWRFRO$PHQGPHQW_9970)_
RYHGThe previousprevious
dose in mSv ie in mSv 
determine adetermine a
individuaindivid
relevanrelevan
ThisT
RG
RYHRCCICCI
CCI
CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 5 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-
substantial
Use of eDiary and advice on 
spirometry assessment timing 
clarified. To reduce the risk of a protocol 
deviation and consistency with 
other sections.Non-substantial.
Reduced overall number of 
patients in the CT sub study to 
remain proportionate to the 
reduced size of the main study. To facilitate the sub study as 
optional and not a barrier to 
participation in the main study.Non-substantial.
When to perform 
echocardiogram in cases of 
suspected heart failure clarified.Suspected heart failure should 
always be assessed irrespective 
of whether during an exacerbation or not.Substantial
Section 4.1.2 Study 
Conduct Mitigation 
During Study DisruptionsService not available for this 
studyNon-substantial
Section 4.2 Scientific 
Rationale for Study 
DesignDetails of monitoring the 
phenotype of participants 
removed.To ensure that the final recruited 
population will more closely 
represent the eligible population.Substantial
Reduced overall number of 
patients in the CT sub tudy to remain proportionate to the reduced size of the main study.To facilitate the sub study as 
optional and not a barrier to participation in the main studyNon-substantial
Section 5.1 Inclusion 
Criteria.Criterion 1: Upper age limit 
chang d from 75 years to 80 yearsOlder age allowed as other 
exclusion criteria prevent those with significant comorbidities from being included in the studySubstantial
Criterion 3 relating to 
vaccination removed and vaccination guidance included 
in concomitant medications 
(Section 6.5). Replaced with: This inclusion criterion has been removed.To permit inclusion of patients 
who did not receive pneumococcal and influenza 
vaccination where 
recommended by local guidelines Substantial.
Criterion 4: Acceptable 
documentation for evidence of 
COPD and requirement to document updated.Clarification of acceptable 
documentation. Non-substantial
Criterion 5: Lower limit for 
FEV 1 changed to 20%To permit participation of 
patients with more severe Substantial'&3URWRFRO$PHQGPHQW_9970)_
$on 3 roo$SSCriterion 1: Upper agen 1: Uppeoo
chang d from 75 yechang d from 75 ye
80yearsyear$SSURYHGac
Service noervice n
studydyGYHhe
pantsTo ensure tTo ens
populatip
repres
popYHYHYHRYHrall number of umber of 
the CT sub tudy toCT sub tud
proportionate to the rtionate to t
d size of the main of the ma
dy.TURRRR
$SS$$CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 6 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-
substantial
COPD who are otherwise 
potential treatment responders whilst excluding those with significant comorbidity or end-organ failure such as cor 
pulmonale or requiring LTOT
Criterion 8: Acceptable 
documentation for evidence of 
stable dual or triple therapy 
and requirement to document updated.Clarification of acceptable 
documentation.Non-substantial
Criterion 9: Updated to 
confirmation by participant of 
self-administration of rescue medication for an acute exacerbationClarification of verbal 
confirmation and requirement to 
record in participant's source documentNon-substantial
Criterion 13: Upper limit of 
body mass index increased to 
40 mg/m2High r BMI allowed as other 
exclusion criteria prevent those 
with significant comorbidities from being included in the studySubstantial
Section 5.2 Exclusion 
Criteria, Medical Conditions and Diagnostic AssessmentsCriterion 1: Rescreening 
allowed for participants with a positive diagnostic ucleic acid test for SARS-CoV-2 Clarification that participants 
with asymptomatic or mild disease are eligible.Substantial
Criterion 3a: Excepti n to 
exclusion from participation in study amended for diabetes mellitus Clarification, and removal of 
HbA1c marker example.
Criterion 3c: Arrhythmia noted as including atrial fibrillationClarification
Criterion 3e revised to indicate 
systemic hypertension should be well controlled and stable for at least 3 months according to the investigator and remove 
the upper limit of two 
medications.To include the need for 
investigator assessment and to reflect variation in global practice.
Criterion 3f revised to exclude 
clinically significant cor 
pulmonaleClarification'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGonfirmaonfirm
record in partiord in part
docu mentumHt of 
eased to to High r BMIHigh r
exclusion
with sigw
fromHHH
RYHescreening ening 
participants with a pants wi
diagnostic ucleic ostic ucleic
t for SARS SAR -CoVoV-2CRRRR
erion 3a: Excepti n to3a: Excepti n too
xclusion from particip n from particip
study amended for distudy amended for d
mellitus ellitus SS$Criterioerion 3c: Aoo
d as incluas
n$$$
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 7 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-
substantial
Criterion 5: Reworded asthma 
exclusion criterionClarification 
Criterion 9e removed and 
replaced with: This exclusion criterion has been removedRedundant
Criterion 9g: Chest CT scan 
findings requiring surveillance revisedClarification
Criterion 10: Removed and 
replaced with: This exclusion 
criterion has been removedBased on high intra-patient 
variability nature of NT-
proBNP in the COPD 
population, updated risk assessment (see IB for details) and presen e of other exclusion criteri  ensure absence of heart failure in participants.
Criterion 15: Revised text 
related to LTOTSimplification of text 
Criterion 23: Revised text 
associated with hepatitisSimplification of text
Criterion 24: Revised text 
associated with HIVClarification
Section 5.2 Exclusion 
Criteria, Prior TherapyCriterion 34h: Re ised to 
allow chronic macrolide or other antibiotic therapy provid d criteria re metConsistency with product 
development programNon-substantial
Criterion 34i: Examples of 
PDE4 inhibitors added and guidance revised to allow PDE4 inhibitors provided criteria are metConsistency with product 
development program
Criteria 34k, and l: Updated and aligned with Section 6.5.5  Clarification and consistency
Section 5.2 Exclusion 
Criteria Other ExclusionsCriterion 41: Removed as 
there is no longer capping of strata Clarification. Non-substantial
Section 5.2 Exclusion 
Criteria for Imaging Sub study'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGopulapu
assessment sessmen
and presen e of presen e
criteri  ensure abcriteri  ensu
failure in partifailure YHext SimplificatSimpliYHYHYHRYHsed text ext 
hepatitisatitisSimpRYRYRYRY: Revised text sed te
d with HIV h HIVURRRR
ion 34h: Re ised to 4h: Re isedoo
w chronic macrolide ronic macrolide
other antibiotic therap tibiotic th
provid d criteria reprovid d criteria reS
$Criterioterion 34i: Ex4oo
DE4 inhibito4 inh
nce rev$$$
PPDCCI CCI CCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 8 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-
substantial
Section 6.3.1 
Methods for 
Assigning Study 
Intervention GroupsRemoval of text around strata 
caps and safety alertsTo align with Section 5 and 
correctionNon-substantial
Section 6.3.2 
Methods to Ensure 
BlindingRemoval of text on safety 
alerts for certain hematology 
testsAlerts not necessary Non-substantial
Section 6.5 
Concomitant TherapyVaccination against influenza 
and pneumonia advice revised.To permit inclusion of patients 
who did not receive 
pneumococcal and influenza vaccination where recommended by local guid linesSubstantial
Section 6.5.5 
Restricted and 
Prohibited MedicationsRevised text related to 
Macrolide therapy and LTOTSimplifica ion of text and 
alignment with Section 5.2Non-substantial
Baseline audiometry testing 
required to be documented 
before randomisation.To ensure safety of participants 
during study participation. 
There is an identified risk of macrolides causing ototoxicity. Substantial
Section 8.1.3 Home 
Spirometry and 
eDiaryAdvice on spirometry 
assessment timing clarified. To reduce the risk of a protocol 
deviation and consistency with 
other sections.Non-substantial.
Added text on importance of 
transmitting data dailyTo emphasise the need for this 
to be done
Section 8.5.2 
Immunogenicity AssessmentsRevised text to add 
circumstances in which ADA samples might be collected after the follow up periodClarification Non-substantial
Section 9.2 Sample 
Size DeterminationTo reflect the expectation of 
determining an effect in a smaller sample of 20 patients per arm.Non-substantial
Section 9.4.2.2 
Subgroup AnalysesRemoved numerical range for 
extent of emphysemaRedundant, will be described in 
the SAPNon-substantial'&3URWRFRO$PHQGPHQW_9970)_
$vised text ted 
tan$ SURYHGom
guid linesuid lin
TSimplifica ion omplifica io
alignment with Salignment wGHng 
ted 
.To ensure safTo ensu
during studduring
There is T
macroHHHG
RYHometry y
ming clari clafied. fiedTo 
dRYRYRYR
text on importance of n importa
mitting data daily a dailySUS
$$
CCI
PPDCCI CCI CCI CCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 9 of 155ADA = Anti-drug antibody(ies); BMI = Body mass Index; COPD = Chronic obstructive; pulmonary disease; 
CT = computer tomography; FEV 1= Forced expiratory volume in 1 Second; HbA1c = glycated haemoglobin; 
IB = Investigatorsâ€™ Brochure; IL-33 = Interleukin 33; LTOT = Long term oxygen therapy; NT-proBNP = N-terminal pro-brain natriuretic peptide; PDE4 = Phosphohipidesterase-4; SAP = Statistical analysis plan; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; 
 SV = Study visit.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGCCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 10 of 155TABLE OF CONTENTS
TITLE PAGE ........................................................................................................................ 1
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE .................................... 3
TABLE OF CONTENTS.................................................................................................... 10
1 PROTOCOL SUMMARY ................................................................................ 15
1.1 Synopsis ........................................................................................................... 15
1.2 Schema ............................................................................................................. 181.3 Schedule of Activities....................................................................................... 19
2 INTRODUCTI ON ............................................................................................ 27
2.1 Study Rationale ................................................................................................ 27
2.2 Background ...................................................................................................... 27
2.3 Benefit/Risk Assessment ....................... ........................................................ 28
2.3.1 Risk Assessment ..................................... .... .................................................. 28
2.3.2 Benefit Assessment ................................. ........................................................ 32
2.3.3 Overall Benefit: Risk Conclusion ...... ... ........................................................... 32
3 OBJECTIVES AND ENDPOINTS ....... ........................................................ 33
4 STUDY DESI GN ........................... ............................................................. 38
4.1 Overall Desi gn..................... ....... ................................................................... 38
4.1.1 Study (and Sub-Study) Conduct and P lanned Mitigations During COVID-19 
Pandemic ........................ ............................................................................... 41
4.1.1.1 Vaccination Against COVID-19 ....................................................................... 43
4.1.2 Study Conduct Mitigation During Study Disruptions Due to Cases of Civil 
Crisis, Natural Disaster, or Public Health Crisis ................................................ 44
4.2 Scientific Rationale for Study De sign ............................................................... 45
4.2.1 Rationale for Study P pulation ......................................................................... 46
4.2.2 Rationale for Pr ima y Endpoi nt......................................................................... 47
4.2.3 Rationale for Intervention Period Duration ........................................................ 47
4.2.4 Participant Input into Desi gn............................................................................. 48
4.3 Justification for Dose ........................................................................................ 48
4.4 End of Study Definition .................................................................................... 49
4.4.1 Study Stopping Criteria ..................................................................................... 49
5 STUDY POPULATION ................................................................................... 50
5.1 Inclusion Criteria .............................................................................................. 505.2 Exclusion Criteria ............................................................................................. 535.3 Lifestyle Considerations ................................................................................... 58
5.3.1 Meals and Dietary Restrictions ......................................................................... 58
5.3.2 Caffein e, Alcohol, and Tobacco ........................................................................ 59
5.3.3 Activity ............................................................................................................. 59
5.4 Screen Failures ................................................................................................. 59'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG. ....
...... .... ....... ....
......... .............. ........
n...... ... ................. ....
INTSS....... ............. .
.............. ....... ..
...... ....... ................
) Conduct and Plannduct and
........ ............... .
nst COVID OVID -19-19....
Mitigatatioion During Dur
Disaster, or Publiaster, or Pub
ationale for Study ale for Study
for Studyfor Study P pulP puly ata
le for Prima yor Prima y EndEndy
le for Intervent Interve io
Input into ut i
Do
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 11 of 1556 STUDY INTERVE NTION ............................................................................... 60
6.1 Study Intervention Administered....................................................................... 60
6.1.1 Study Interve ntions........................................................................................... 60
6.2 Preparation/Handling/Storage/Accountability of Interventions .......................... 61
6.2.1 Study Interventio n Inspection ........................................................................... 61
6.2.2 Dose Preparati on Steps ..................................................................................... 61
6.2.2.1 Study Intervention Administration .................................................................... 62
6.2.2.2 Monitoring Dose Administratio n....................................................................... 63
6.2.3 Acc ountability .................................................................................................. 63
6.3 Measures to Minimise Bias: Randomization and Blinding ................................ 63
6.3.1 Methods for Assigning Study  Interventio n Groups ............................................ 63
6.3.2 Methods to Ensure Blinding .............................................................................. 64
6.3.3 Methods  for Unblinding .................................................................................... 64
6.3.3.1 Unblinding for Analy sis Purpos es..................................................................... 65
6.4 Study Intervention Compliance ............. .......................................................... 66
6.5 Concomitant Ther apy.............................. .... .................................................. 66
6.5.1 Required Maintenance Therapy f or COPD ........................................................ 66
6.5.2
6.5.3 Medication Wit hhold Periods ......... ... ..... ....................................................... 67
6.5.4 Treatment of Exacerbations of COPD ............................................................... 67
6.5.5 Restricted and P rohibited Medications ............................................................. 67
6.5.6 COVID- 19 Vaccination .............. ................................................................... 69
6.6 Dose Modification ............ .. ........................................................................ 69
7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL .......................................................... 69
7.1 Discontinuation of Study Intervention............................................................... 697.2 Participant Withdr awal from the Study ............................................................. 70
7.3 Lost to Follow-up ..... ..................................................................................... 71
8 STUDY ASSESSMENTS AND PROCEDURES ............................................. 71
8.1 Efficacy Assessments ........................................................................................ 72
8.1.1 Clinic Spir ometry ............................................................................................. 72
8.1.1.1 General Requi rements ....................................................................................... 72
8.1.1.2 Post-BD Sp irometry .......................................................................................... 73
8.1.2 Airwave Oscillometry ....................................................................................... 73
8.1.3 Home Spirometry  and eDiary............................................................................ 74
8.1.4 Ob jective Cough Monitoring ............................................................................. 75
8.1.5 COPDCompEx ................................................................................................. 76
8.1.6 COPD Ex acerbations (AECOPD) ..................................................................... 76
8.1.6.1 Severity of  AECOPD........................................................................................ 77
8.1.6.2 Duration of AECOPD ....................................................................................... 77
8.1.6.3 COPD Exacerbation eCRF ................................................................................ 78
8.1.7
8.1.8 Patient Reported Ou tcome Questi onnaires ........................................................ 78'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG. .....
...... .... ....... ....
COPD D......................
....... ... ..... ....... ... ..... .
of COPDOPD ............
Medications cations .......
............. ................
....... .. ............ .. .....
ON OF SOF S TUDY ITU
TION/WITHN/WITH DRAD
n of StudyStudyf InterveInteyy
Withiidrawal fromdrawal from  th thmm
llowllo-up..... ..... ....
Y ASSESSMENT SESSMENT
Assessments ssm
ettryr.
PPDCCI
CCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 14 of 155LIST OF APPENDICES
Appendix A Regulatory, Ethical, and Study Oversight Cons iderations....................... 104
Appendix B Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ...................................................................... 109
Appendix C Handling of Human Biological Samples ................................................ 114
Appendix D Optional Genomics Ini tiative Sample..................................................... 116
Appendix E Actions Required in Cases of Increases in Liver Biochemistry and 
Evaluation of Hyâ€™s Law ......................................................................... 119
Appendix F Contraception Guidance ......................................................................... 126
Appendix G Major and Minor Symp toms of COPD ................................................... 127
Appendix H National Institute of Allergy and Infectious Diseases and Food Allergy 
and Anaphylaxis Network Guidance for Anaphylaxis Diagnosis ............ 129
Appendix I Signs and Symptoms and Management of Acute Anaphylaxis ............... 130
Appendix J Example of Patient COVID-19 Scr eening Questionnaire ....................... 133
Appendix K Changes Related to Mitigation of Study Disruptions Due to Cases of 
Civil Crisis, Natural Disaster  or Public Health Crisis ............................ 134
Appendix L Abbreviations ................. .................................................................... 137
Appendix M Protocol Amendment History................................................................. 141'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGOPDOP
d Infectiousnfectious
uidance for Anap e for An
Management of Aagemen
VID- 19 Screening19 Screen
Mitigation of Stud ation of
al Disaster  or Pubisaster  
............... ................ .
endment Himent Hi story.st
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 17 of 155Participants will be enrolled for at least a 4-week screening/run-in period, a 28-week 
intervention period (during which they receive 7 doses SC Q4W), and an 8-week follow-up period.
Participants must be on stable doses of dual therapy (ICS + LABA, or LABA + LAMA) or 
triple therapy (ICS + LABA + LAMA) for â‰¥3 months prior to enrolment and should remain 
so during the study. There should have been no change in maintenance COPD treatment after 
a previous exacerbation prior to entering into the study.
There is one sub-study included as part of the trial: .Disclosure Statement : This is a parallel group treatment study with 2 arms (MEDI3506 and 
placebo) that is participant, investigator, and sponsor blinded.
Number of Participants:
Approximately 144 participants will be randomly assigned to study intervention (MEDI3506 
or placebo) such that approximately 140 participants are evaluable for the primary analysis.
Intervention Groups and Duration:
All participants passing the init ial screening visit w ill enter a run-in period of at least 4 weeks 
on their usual standard of care treatment. Participants will be randomized to MEDI3506 or 
placebo if they continue to meet all eligib ility criteria, including adherence to home 
assessments and spirometry criteria using data from the run-in period. 
Approximately 144 participants will be randomized 1:1 to MEDI3506  SC Q4W or 
placebo for 7 doses.
Data Monitoring Committee: 
A DSMB has been established to oversee the MEDI3506 clinical development program. In 
addition to a full DSMB 6-month periodic review of safety data, the DSMB chair will review 
unblinded safety data summaries every 3 months; the DSMB can meet on an ad hoc basis. A 
blinded study-specific safety committee (or Medical Monitor) will also review SAEs and 
SUSARs.Statistical Methods:
A sample size of 140 participants (70 participants per arm) will provide 80% power to detect a 
difference in mean change from baseline in FEV
1of 90 mL (assumed standard deviation of 
250 mL) between the two randomized groups at a one-sided 10% level of statistical 
significance. To allow for 2% of participants being ineligible for the primary analysis, approximately 144 participants will be randomized in the study (72 per arm). '&3URWRFRO$PHQGPHQW_9970)_
$$$SSURYHGly assignedsigned to sto
cipants are evaluabnts are ev
ening visit will entg visit w
ment. Participants w  Partici
ll eliggibilitibilit y criy crteriii
eria using data frousing da
ants will be randowill be r
ommittee:mmittee:$Sestablished to ovblished to$B 6-momonth $marieCCI
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 18 of 155Statistical Analyses:
The primary estimand is a â€˜Treatment Policyâ€™ estimand, as follows: The difference in mean 
change from baseline in FEV 1at Week 12 (MEDI3506 â€“ placebo) will be estimated using a 
repeated measures mixed effects analysis of covariance model, for the ITT population. This will include all available data from all visits up to and including Week 12, irrespective of 
whether the participant discontinued study intervention or received reliever therapy. The model will include fixed effects for baseline, eosinophil strata, background medication strata, visit, study intervention, and the baseline by visit, and study intervention by visit interactions. An unstructured covariance matrix will be used to describe the correlations between observations on a participant between visits.
A similar approach will be taken for the analysis of cough VAS, BCSS,  SGRQ, and 
. Data may be log-transformed prior to analysis where appropriate. Change 
from baseline in objective cough parameter s and os cillometry param eters at Week 12 w ill be 
analyzed using analysis of covariance.
Analysis of time to event  will include available data (up to 
Week 28 where this is available) for all participants  Time to event endpoints will be analyzed using a Cox proportional hazards model. 
Safety endpoints including AEs,  SAEs, AESIs, laboratory parameters, vital signs, ECGs, and 
physical examinations will be summarized using descriptive statistics.
1.2 Schema
The general study design is summarized in Table 1.
Table 1 Study Design
Study 
PeriodScreening 
/ Run-inIntervention Period Follow-up
Visit 
NumberSV1 and 
SV2SV3 SV4 to 
SV7SV8 SV9 to 
SV11SV12 SV13 and 
SV14
Study Week-5 to -1 0 0 to 8 12 16 to 
2428 32 to 36
Enrolment, 
Screening, 
Run-inRandomization 
and Dose 1Doses 2 
and 3Primary
Endpoint 
Assessment 
and Dose 4Doses 
5 to 7End of 
Intervention 
VisitFollow-up
R = randomization; SV = study visit.'&3URWRFRO$PHQGPHQW_9970)_
SV3$SSURYHGscillocillo
wil
articipants  Time to pants  Tim
. 
AEs, AESIs, labora AESIs, 
mmarized using de rized usin
is summarized inmmarized in T
dy Designdy Design
ng$$$S$$CCI
PPDCCICCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 19 of 155Participants will receive 7 administrations of study intervention Q4W. SV12 (Week 28) will 
serve as the end of intervention visit (see Section 4.1). The primary endpoint visit occurs at 
SV8 (Week 12).
1.3 Schedule of Activities
Patient reported outcome questionnaires to be completed at site visits must be completed prior 
to study intervention administration and ideally before any discussions of h ealth s tatus or 
other study procedures, such as collection of laboratory samples, to avoid biasing the participantâ€™s responses to the questions. All daily ePRO assessments for the morning and evening eDiary at home should be completed within the set time window programmed into the 
device; device alerts will notify the participant when it is time to respond to the questions. After each study visit, participants will return to the normal schedule of answering the eDiary at home.
Order of procedures:
!All assessments should be performed prior to administration of investigational product 
except where otherwise indicated (eg, post-dose vital signs)
!Participants will be instructed to perform all home spirometry assessments before use of 
their usual standard-of-care inhaled medication. Whenever vital signs, ECGs, and blood draws are scheduled for the same nominal time, the order should be as follows: ECG, 
vital signs (vital signs can occur imm diately after ECG using the same rest period), then 
blood draws. The timing of the fir t 2 assessments should be such that it allows the blood 
draw (eg, PK blood sample) to occur at the assigned nominal t ime.
!AO assessments should take place before spirometry.
!Sputum samples should be taken after procedures requiring a BD withhold (including 
spirometry and AO).
!If both nasal epithelial li ing fluid and mucosal samples are required on the same day 
then the epithelial lining fluid sample should be taken prior to the mucosal sample.
Refer to Section 8for additional information on assessment ordering (eg, pre-, post-dose or 
multiple timepoints within a visit).'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGior to administratioo administ
post--dose vital sigdose vit
rform all hom all h me spi
ed medicat dicat ioion. Whn
me no minal t minal t ime, th
cur imm diately afmm diate
the fir t 2 assessmir t 2
le) to occur at the o occur at 
d take place before place b
ould be taken after be taken after 
O).
ithelial li ing fluidelial li ing fluid
lial lining fluid ning flu s
ona
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 20 of 155Table 2 Screening Procedures
Study Period Screening / Run-in
Visit Number SV1 SV2
Procedure / Study DayDay -35 to 
Day -28Day -21 to Day -7
Study Week Week -5 to -4 Week -3 to -1
Written informed consent/assignment of E-codeaX
Written informed consent for future use and/or genetic 
analysis (optional)a X
Written informed consent for CT sub-study (as applicable)aX
Verify eligibility criteria X X
Safety Assessments
Demography X
Medical and COPD/chronic bronchitis history including assessment of COPD exacerbations and evaluation of predominant emphysema by physician diagnosisX
Smoking History X
Physical examination (full) X
Weight, height X
ECG X
Vital signs X
Assessment of AEs/SAEs X X
Concomitant medications X X
Echocardiograma, bX
CTa, b, cX
SARS-CoV-2 nucleic acid test (nasopharyngeal swab or 
salivary sample)d XX
Efficacy assessments
Clinic Spirometry (pre-BD) X
Clinic Spirometry (post-BD) X
Airwave oscillometry X
Provision, and training on use, of at home spirometer and 
eDiary for use every dayX
Assess adherence to the completion of eDiary entries and 
home device useX
Provision of and training of use of cough monitoring 
followed by 24 hour monitoring post clinical visitX'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGGXGGGHGHHHYHYHYHYHYHYYYYRURSUSSS$Sacid test (nasopharyn test (nasopharyn$S$
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 21 of 155Table 2 Screening Procedures
Study Period Screening / Run-in
Visit Number SV1 SV2
Procedure / Study DayDay -35 to 
Day -28Day -21 to Day -7
Study Week Week -5 to -4 Week -3 to -1
On-site ePROs: 
CAT X
Collect blood for:
Serum chemistry X
NT-proBNP X
Haematology X
Coagulation parameters X
Hepatitis B, C; HIV-1; virology X
Serum pregnancy test (female participants of childbearing 
potential only)X
FSH (if needed to confirm post-menopausal status in female 
participants aged < 50 years)X
IGRA (TB test) X
Collect other samples:
Collect urine for:
Urinalysis X
Pregnancy test (female participant  of childbearing potential 
only)fX
See CT scan collected as part of the safety assessments above
Pandemic impact assessment XX
bEchocardiogram and CT dates will be scheduled at SV1, to occur post-confirmation of eligibility at SV2.
dMay be performed on a separate day ahead of study visit if required. The analysis can either be performed 
locally or centrally.
fOnly required if a CT scan as part of SV2 is performed. If required must be done prior to CT scan.'&3URWRFRO$PHQGPHQW_9970)_
$See CT scan coCT s$SSURYHGGGGXGGGGaringXGGGYHGus in female female YHYHYHYHRYYYYRSUS
ticipant  of childbeari nt  of childbeariSS$S$$CCI
CCI
CCI
PPDCCICCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 22 of 155AE = Adverse event; BD = Bronchodilator; CAT = COPD assessment test; COPD = Chronic obstructive 
pulmonary disorder; CT = Computed tomography; ECG = Electrocardiogram; ePRO = Electronic patient reported outcomes; FEV
1= Forced expiratory volume in 1 second; FSH = Follicle stimulating hormone; HIV = 
Human immunodeficiency disease; IGRA = Interferon gamma release assay; NT-proBNP = N-terminal pro-brain 
natriuretic peptide; PEF = Peak expiratory flow; SAE = S erious adverse event; SARS-CoV-2 = severe acute 
respiratory syndrome coronavirus 2; SGRQ = St George â€™s Respiratory Questionnaire; SV = Study visit; 
TB = Tuberculosis.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 23 of 155Table 3 Schedule of Activities: Study Intervention and Follow-up
Study PeriodIntervention Period Follow-up
E/D E/AaVisit Number SV3 SV4 TC SV5 SV6 SV7 SV8 SV9 SV10 SV11 SV12 SV13 SV14
Study Day (SV5 to SV14 window: Â± 3 
days)1 2 15 29 57 85 113 141 169 197 225 253
Study Week 0 0 2 4 8 12 16 20 24 28 32 36
Efficacy assessments
Clinic spirometry (pre-BD) X X X X X X X X X X X X
Clinic spirometry (post-BD) X X X
Airwave oscillometry X X X X
Use of at home spirometry b
and eDiarycEvery day throughout inter ention and follow-up periods
Assess adherence to the completion of 
eDiary entries and home device use 
(including PEF)XXX XXXXXX X X X X X
Cough mon itoring (24 hour monitoring 
post clinic visit)X
ePRO: SGRQ X X X X X
Study Participant Feedback 
Questionnaire (Optional)XX X X
Assessment of COPD exacerbations X X X X X X X X X X X X X X
Safety assessments
Physical examination a, cX X XXXXXX X X X X X
Weight X X X X
ECG X X X X X
Vital signs dX X XXXXXX X X X X'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGGGGGXXX XGGGHHGHHHGHGHGYHHGXYHYHYHHHRYHH
aythroughout ghout y interention er ention and follRRRYHYHYHHH
XXX XXUUURRR
$SSSUR
$$$SSSSSSSS$$SSS$$$$$SSS
X$CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 24 of 155Table 3 Schedule of Activities: Study Intervention and Follow-up
Study PeriodIntervention Period Follow-up
E/D E/AaVisit Number SV3 SV4 TC SV5 SV6 SV7 SV8 SV9 SV10 SV11 SV12 SV13 SV14
Study Day (SV5 to SV14 window: Â± 3 
days)1 2 15 29 57 85 113 141 169 197 225 253
Study Week 0 0 2 4 8 12 16 20 24 28 32 36
Assessment of AEs/SAEs X X X X X X X X X X X X X X
Concomitant medications X X X X X X X X X X X X X X
Echocardiogram eX fX f
Injection site reactions X X X X X X X X X X X
Nasopharyngeal swab or salivary 
sample for SARS-CoV-2 nucleic acid 
test gX X XXXXXX X X X X
Collect blood for
Serum Chemistry X X X X X X X X X
NT-proBNP eXX X
Haematology X X X X X X X X X
P K X X X X X X XXX X
Immunogenicity X X X X X X X X X X
Genetic analysis (optional) X i
SARS-CoV-2 serology test (serum) X X X X'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGGXXGGGGXXX XGGGHHGHHHGHGHGYHHGXXXX XXYHYHYHHHRYHH
XXXX XRRRYHYHYHHH
SSURYSSSUSUSURRR
XX X XSSSSSSSS$$SSS$$$$$SSSSSSSS$$SSS$$$$$SSS$$S$$$$CCI
CCI
CCICCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 25 of 155Table 3 Schedule of Activities: Study Intervention and Follow-up
Study PeriodIntervention Period Follow-up
E/D E/AaVisit Number SV3 SV4 TC SV5 SV6 SV7 SV8 SV9 SV10 SV11 SV12 SV13 SV14
Study Day (SV5 to SV14 window: Â± 3 
days)1 2 15 29 57 85 113 141 169 197 225 253
Study Week 0 0 2 4 8 12 16 20 24 28 32 36
Collect urine for
Urinalysis X X X X X
Pregnancy test (female participants of 
childbearing potential only)X XXXXXX X XX
Collect other samples
Nasal epithelial lining fluid X X X X X X X
Verify eligibility criteria X
Randomization X'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGGGGGGGGHHGXXXXXHHHGHGHGYHHGRRRYHYHYHHHRRRYYYURY
XXX XUUURRRSSURSSSUSUSU$SSSU$$$SSSSSSSS$$$$$SSSSSSSS$$SSS$$$$$S$$$$$$CCICCI
PPDCCI CCICCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 27 of 1552 INTRODUCTION
MEDI3506 is a human IgG1 mAb that binds to human IL-33, which is being developed for 
the treatment of asthma, atopic dermatitis, COPD, and diabetic kidney disease. 
2.1 Study Rationale
The MEDI3506 pre-clinical profile suggests that MEDI3506 can reduce airway inflammation, 
improve epithelial integrity, reduce mucus production, and improve muco-ciliary transport. As 
such, MEDI3506 is hypothesized to impact COPD status by increasing FEV 1(and other 
physiolog ical measures of lung function) and reducing frequency and severity of COPD 
exacerbations, thereby improving quality of life.
One Phase I clinical study of MEDI3506 (Study D9180C00001) was completed in 
December 2019. Study D9180C00001 was a first-in-human, randomized, placebo-controlled, blinded (investigator and participant blinded; sponsor unblinded) clinical study in 88 participants to evaluate the safety, to lerability, PK, and immunogenicity of single and 
repeated doses of MEDI3506. MEDI3506 was generally found to be safe and well tolerated. 
For further details refer to the IB.
The purpose of this proof-of-concept study is to  evaluate the safety and efficacy of MEDI3506 
in participants with COPD and chronic bronchitis. 
2.2 Background
Chronic obstructive pulmonary disease is the fourth leading cause of death in the world and is projected  to be the third leading caus  of death worldwide by 2030 (Adeloye et al 2015) . 
Chronic obstructive pulmonary disease is char acterized by persistent respiratory symptoms 
and airflow limitation (post-BD FEV
1/FVC < 0.70) that is due to airway and/or alveolar 
abnormalities, usually caused by significant exposure to noxious particles or gases, and 
influenced by host factors including abnormal lung development. Significant comorbidities may have an impact on morbidity and mortality ( GOLD 2020) . Chronic obstructive 
pulmonary disease is not fully reversible, usually progressive and associated with an enhanced chronic inflammatory response in the lung. Patients with active chronic bronchitis symptoms bear a greater burden of disease than those without and are characterized by more rapid loss of lung function, increased mortality and increased risk of exacerbation ( Kim et al 2011;
de Oca et al 2012; Corhay et al 2013; Kim and Criner 2013; Woodruff et al 2016;Lahousse et al 2017) . Mucus hypersecretion wit h accumulation in  the small airways in COPD 
is present independent of symptoms of cough and sputum production ( Caramori et al 2004;
Burgel and Nadel 2008)  and can coexist with extensive emphysema (Dunican et al 2021;
Kim et al 2021) . Mucus plugging is evident at all stages  of severity of COPD, but is greatest 
in those with most severe disease. The correlation between extent of emphysema and mucus plugging is not well defined but both inde pendently negatively correlate with FEV
1. Patients '&3URWRFRO$PHQGPHQW_9970)_
-hu
nsor unblinor unbl
y,PK, and immuK, and im
as generally foundenerally fo
study iiys to eva st oe v a luate
nic bronchit ronchit is.
arydisease iisease iy s the fs t
ading caus  of deang caus  of d
monaryary disease idisease iyy s s 
(post(post -BD FE V D FEV 11/F/
lly caused bycaused byy signsignyy
ctors includins inc
orbiditrb
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 28 of 155with recurrent COPD exacerbations have higher sputum inflammatory markers 
(Bhowmik et al 2000)  which suggests that underlying inflammation may lead to disease 
progression ( Crooks et al 2000; Anzueto 2010) . Interleukin-33 expression is upregulated in 
the lungs of patients with COPD, is inversely correlated with lung function, and has a role in 
inflammatory and epithelial processes in COPD. 
MEDI3506 is a mAb that binds to IL-33 and potently and specifically blocks all forms of 
IL-33 to prevent their signalling. Interleukin-33 is  an alarmin cytokine from the IL-1 family. 
Interleukin-33 is localized in the nucleus, a nd following injury, stress or cell death, it is 
released from the cell, and exerts a pro-infl ammatory biological function, which is skewed 
towards a pro-inflammatory Th1 cytokine profile and broad responder cell population on the background of smoke-induced inflammation (Kearley et al 2015) . Interleukin-33 pathway 
blockade prevents exacerbation of viral-indu ced inflammation in a mouse smoke exposure 
model ( Kearley et al 2015) , and IL-33 has been shown to have a role in goblet cell 
hypertrophy, mucus hypersecretion and the ratio of mu us producing to ciliated cells in 
airway epithelium in mouse models of prolonged lung inflammation ( Schmitz et al 2005;
Allinne et al 2019) . As such, MEDI3506 mode of action is hypothesized to impact airway
inflammation, mucus and cough symptoms and lung function endpoints in COPD, and through modification of these factors, reduce frequency and severity of exacerbations. This proposed mode of action of MEDI3506 suggests that COPD patients with chronic bronchitis may be most likely to gain benefit from MEDI3506 treatment, and therefore COPD participants with chronic bronchitis are an appropriate population to begin efficacy testing of 
MEDI3506. 
A detailed description of the chemistry, phar macology, mechanism of action, and safety of
MEDI3506 is provided in the IB.
2.3 Benefit/Risk Assessment
More detailed information about the known and expected benefits and potential risks of MEDI3506 may be found in the IB.
2.3.1 Risk Assessment
To date, there are no identified risks associated with MEDI3506. Potential risks for 
MEDI3506 are described in Table 4 and in more detail in the IB.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGwn twn
of muummus prus 
ed lung inflamma g inflam
de of action is hypf action is 
s and lung functd lung fun io
educe frequency an e frequ
06 suggests that COuggests tha
from MEDI3506 trMEDI3m
tis are an approprire an appr
he chemistryhemistry , phar, p
in the IB.e IB
t/RiRiskskAssessm Assessmkk
ation about thn ab
in the n
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 32 of 155As per above, serious infections (including those with SARS-CoV-2) are also a potential risk 
of MEDI3506. AstraZeneca is not aware of any current evidence of a direct link between IL-33, or IL-33 suppression, and contracting SARS-CoV-2 and early stages of COVID-19 illness post infection. Moreover, it is hypothesised that IL-33 suppression might be beneficial in the later, hyperinflammatory phase of severe COVID-19 illness; MEDI3506 will be tested 
in patients with severe COVID-19 infections as part of the ACcelerating COVID-19 Research 
and Development (ACCORD) Study 2 (ACCORD-2; EudraCT number 2020-001736-95).
2.3.2 Benefit Assessment
The purpose of this p roof-of-concept study is to evalu ate the safety and efficacy of MEDI3506 
in participants with COPD and chronic bronchitis. For participants randomized to MEDI3506, 
there is a potential benefit in terms of improvement of their COPD disease status and reduction in COPD exacerbations. However, since at this early stage of clinical development, 
it is yet to be determined if MEDI3506 has an  effect in patients with COPD with chronic 
bronchitis, participants might not receive any individual benefit from participating in this 
study. Participants will be required to continue all their COPD maintenance treatment throughout the study to minimize the risk of disease status worsening during the study. 
To date, efficacy of MEDI3506 has not been assessed in patients with COPD and, hence, there 
are no clinical data that show benefit in th is population. However, safe ty data obtain ed during 
Phase I in participants with COPD and the pre-clinical scientific data support clinical 
development of MEDI3506 in COPD.
2.3.3 Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize risk to participants in this study, the potential risks identified in association wi th MEDI3506 are justified by the anticipated 
benefits that may be afforded to participants with COPD with chronic bronchitis.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGt t
ect in patt in pa
ndividual benefit ual bene
ue all their COPD m l their COP
of disease status wsease stat
t been assessed in n assess
t in this populationhis pop
D and the pre d the pre --clinicc
COPD. D.
it:Risk ConclusRisk Con
measures taken tosures taken to
ied in associated in associat ioion n
e afforded to partiforded to parti
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 35 of 155Table 5 Objectives and Endpoints
Objective Endpoint'&3URWRFRO$PHQGPHQW_9970)_
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 38 of 1554 STUDY DESIGN
4.1 Overall Design
For an overview of the study design see Table 1.  For details on study interventions given 
during the study, see Section  6. For details on what is included in the efficacy and safety
endpoints, see Section 3. For further details on assessments, including screening assessments, 
see Section 8.
This is a Phase II, randomized, double-blind, pl acebo-controlled, proof-of-concept study to 
assess the efficacy, safety and tolerability of MEDI3506, administered SC Q4W for 7 doses, in participants with moderate or severe  COPD receiving standard of care (dual or triple 
therapy) as maintenance therapy, with a history of â‰¥1 moderate or severe acute exacerbation 
in the previous 24 months while on stable background treatment, and moderate to severe chronic bronchitis, with active sputum and cough symptoms. The intervention period lasts 
28 weeks (7 doses).
Improvement in FEV
1(primary endpoint) is considered important but not sufficient to show 
the potential of MEDI3506 to meet the unmet medical need in COPD. Therefore, 
COPDCompEx (secondary endpoint) will be used to assess whether MEDI3506 has wider clinical efficacy, specifically, that treatment with  MEDI3506 has the potential to reduce acute 
exacerbations. To enable evaluation of COPDCompEx, an intervention period of 28 weeks (7 doses) has been selected (see Section 4.2.3) .
Approximately 144 participants will be randomized in a 1:1 ratio to placebo or  of 
MEDI3506 SC Q4W, for 7 doses. The randomization will be stratified by 
 and background medication (includes ICS vs 
does not include ICS). 
There are 3 study periods: screening and run-in; intervention period; and follow-up (Table 1) .
Screening/Run-in Period
Informed consent and evaluatio n of inclusion/exclusion criteria (with the exception of CT, 
echocardiogram measures, and eDiary compliance) will be assessed at SV1. Only participants 
who meet all other eligibility criteria will be required to perform echocardiogram, CT and 
other scheduled assessments at screening SV2. Echocardiogram and CT dates will be scheduled at SV1, to occur post-confirmation of eligibility at SV2. SV1 and SV2 may be conducted over more than one clinic appointment to accommodate informed consent, echocardiogram, CT and sputum assessments; however, these must be completed in accordance with the SV window, per Table 2,  and to allow sufficient time for a radiologist 
review prior to SV3 (Randomization Visit). '&3URWRFRO$PHQGPHQW_9970)_
SURYHGymptoymp
considered importidered imp
met medical need medical n
ill be used to assese used 
atment wint w ththii MEDIMhh
n of COPDCoCOPDC mpE
Section on4.2.34.2.3 )).
nts will be randomwill be ran
doses. The randoses. The ra
eriods: screening s: scree
PPDCCI
CCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 39 of 155At the completion of initial enrolment at SV1, participants will proceed to the run-in period 
for at least 4 weeks, to allow adequate time for all the eligibility criteria to be evaluated. At approximately 1 to 3 weeks into the study period, SV2 will be conducted to further assess participant eligibility, including CT assessment of emphysema and echocardiogram. Sites should ensure there is adequate time to ensure results of CT and echocardiogram are available 
to determine eligibility. Computed tomography emphysema percentage will be calculated 
using automated software by an external vendor. Where an automated report is not possible due to technical issues, if possible, the CT scan emphysema percentage will be reported by a suitably qualified radiologist provided by the external vendor. Moreover, a suitably qualified radiologist at the clinic site (for clinical findi ngs outside of emphysema and morphometric 
assessment) will be required to review the CT for additional findings, before SV3. 
Presence or absence of excessive improvement in FEV
1will be assessed between SV1 and 
SV3 (period of at least 4 weeks). Acceptable adherence of eDiary completion, at-home 
assessments, and BCSS average score in cough and sputum domains will be assessed over the 
14 days preceding SV3. Participants who meet th e eligibility criteria will be randomized to 
study intervention.
During the screening period, the participant must undergo all assessments per Table 2
including biosampling and baseline CT evalua tion, with the exception of blood sampling for 
genomic assessments, which is optional. A previously performed chest CT scan may be acceptable for baseline evaluation, see Section 8.1.9.
Participants will be given a device at SV1, incorporating a spirometer for PEF/FEV
1and an 
eDiary for recording symptom and medication use including as-needed medication at home. 
This will be used to collect baseline data of spirometry, the eDiary (ER-S:COPD, BCSS, cough VAS item), and adherenc  during the screening/run-in period (at least 4 weeks). Participants will be instructed to perform all home spirometry assessments before use of their usual standard-of-care inhaled medication.
Participants entering the sub-study will have additional requirements during the 
screening period as set out in Section 8, as long as sub-study eligibility is confirmed for the 
individual participants. Sub-study participati on is dependent on site expertise / capability.
Participants will continue with stable doses  of permitted concomitant COPD medications from 
the screening through to the randomization visit. '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGencenc
nd sputum sputum
the eligibilit igibilit y ycri
ant must undergo must unde
T evaluataluat ioion, withn
onal. A previously A prev
n, see Sectione Section 8.1.98
evice at SV1, incoe at SV1, i
tomand medicat nd medicm io
ect baseline data o aseline data o
d adherenc enc during du
instructed to perfotructed to perfo
are inhaled medi haled m
bstu
PPDCCICCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 40 of 155Intervention Period: 7 doses and EOT visit
Section 6.5.5 provides a list of medication restrictions and prohibitions to be followed 
throughout the conduct of the clinical trial.
A DSMB has been established to oversee the MEDI3506 clinical development program. 
Further details of the DSMB are found in Section 9.6.
Participants will be maintained on their currently prescribed maintenance therapies from 
enrolment throughout the run-in, intervention period and follow-up period. During the intervention period, the participant must undergo all assessments per Table 3,  with the 
exception of blood sampling for genomic assessments which is optional, and repeat 
 which is at the investigatorâ€™s discretion as detailed in 
Section 8.6.1.2.
Intervention Period
Participants fulfilling all eligibility criteria, including hose requiring a review of data gathered 
at SV2 assessment and SV3 pre-dose, will begin a randomized, placebo-controlled intervention period of 7 doses. The primary endpoint assessment occurs at Week 12. The final 
dose is administered at Week 24. The End of Intervention visit is at Week 28. MEDI3506 or 
placebo will be administered by SC injection Q4W.
Participants will be reviewed by a telephone visit after first dose visit and attend on site visits 
to perform assessments including biosampling, sp irometry and other functional measurements 
such as AO, as per the SoA (Secti n 1.3).
Participants will remain at the investigational site:
!After the first and second dose of study intervention: At least 2 hours post dose for 
observation; or until participant is stable; or the time taken to complete SoA, whichever is 
longest
!After Doses 3, 4, 5, 6 and 7: At least 1 hour post dose for observation; or until participant 
is stable; or the time taken to comp lete SoA, whichever is longest
Participants will be asked to complete the eDiary, home spirometry. In addition, all 
participants will be asked to wear a cough monitoring device for 24 hours immediately 
following study visits as per SoA (Section 1.3).
An automated alert will be provided to the participant and site if there is a significant 
deterioration in the eDiary data points, prompti ng the participant to co ntact the site or their 
treating physician for further clinical review and management of a possible AECOPD.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGcluding hose requing hose r
begin a rando a rando mized
aryendpoint assessdpoint asy
End of Interventof Interv io
injectctioion Q4W. n Q
a telephone visit aephone vi
ing biobiosampling, ssamplin
(Secti nti n1.33)).
at the investhe invest igattioio
and second dose ofsecond dose of
until part paicipani
dCCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 41 of 155At clinic visits, participants will undergo a short assessment to confirm moderate or severe 
AECOPD including assessments of appropriate management.
Follow up Period
Follow-up visits will occur 4 and 8 weeks after EOT visit to allow for determination of 
immunogenicity and potential prolonged PD effects, and evaluation of safety. Participants will be discharged from follow-up 3 months af ter the last dose of study intervention.
The maximum amount of blood collected from each pa rticipant over the duration of the study, 
including any extra assessments that may be required, will not exceed 450 mL in 3 months. 
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
Additional Visits
A clinical assessment of any potential exacerbation during the intervention and follow up 
periods will occur either at the next scheduled visit or, if necessary, an additional E/A visit 
prior to the next scheduled visit (see the SoA in Section 1.3).
For any participants with suspected heart failure during participation in the study, an ad hoc 
echocardiogram and NT-proBNP measurements are required. In addition, for these participants, vital signs, physical examinations and any other examinations (eg, chest X-ray) can be performed at the investigatorâ€™s discretion, following local standard practice.
4.1.1 Study (and Sub-Study) Conduct and Planned Mitigations During 
COVID-19 Pandemic 
Coronavirus disease 2019 has emerged as a worldwide pandemic disease with significant 
implications for public health. AstraZeneca accepts that a careful risk-benefit analysis should be performed in each region before init iating clinical research that impacts the clinical 
resources needed for the COVID-19 pandemic. Hence, AstraZeneca will monitor countries and sites, and the study will not begin until local and national governments and clinical sites have indicated that it is acceptable to conduct clinical studies, any stay-in-place or lockdown 
orders have been lifted, and the safety of site staff and participants can be ensured. 
Furthermore, each study site must have appropri ate measures to ensure safety of site staff and 
participants.
It is recognised that depending on the location and facilities of a clinical site, study visit 
attendance may place participants at risk of exposure to SARS-CoV-2. Where visits need to occur at locations other than the primary study site (eg, CT scans or echocardiograms), then '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGfet
cerbation during thation duri
duled visitd visi or, if n
he SoA in SectionAi nS e c
d heart failure durart failure
NPmeasurements aasurem
ical examinatexaminat ioions 
vestigatorâ€™s discretgatorâ€™s dis
nd Sub b-Study) CStudy) C
-19 Pandemic 19 Pandemic 
2019 has eme9 has
altlth. Ah
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 42 of 155the investigator should select appropriate locations given the current environment. It is 
accepted that additional visits (eg, as part of  participation) necessarily entail an additional risk of exposure to SARS-CoV-2.
Furthermore, it is recognised that more ge neral population- level measures to reduce infection 
rates (eg, travel restrictions) may inhibit the ability of participants to attend study visits. 
Necessary healthcare responses at sites to the pandemic (eg, additional infection control 
measures) may also inhibit the ability of a clinical site to effectively and properly conduct the study. Study visit attendance for dosing and for clinical assessments of treatment response are critical for the scientific value of the study.
Therefore, investigators should not enrol participants unless they have reasonable confidence 
that throughout the duration of the study:
!Participants will be able to attend study visits, whilst avoiding contact with concentrations 
of COVID-19 patients (eg, hospital entr ances used by such patients); and
!The site will be able to conduct the study eff ectively and safely, considering relevant 
national and local factors.
The primary endpoint will be analyzed using a repeated measures mixed effect model which, 
in the event of missing data, uses all data that are available.
AstraZeneca will routinely conduct risk-based enrolment assessments on a country and site 
level during the pandemic phase of COVID-19, and study monitoring will include:
!AEs associated with new onset SARS-CoV-2 infection
!Participants withdrawn due to COVID-19 illness
!Missed visits due t  COVID-19 related issues
!Other missing data.
It is accepted due to age, disease under study  and common comorbidities the target population 
has risk-factors for severe COVID-19 illness. The ability to exclude the most at-risk patients whilst maintaining the target population and the relevance of the study is  necessarily limited.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGwhilst whils
es used by ed by sucsuyy
effectctively ively and saan
using a repeag a repe ted m
data that are availa that ar
uct risk sk-based enroased
se of COVIDf COVID -19, 
new onset SARS onset SAR -C
awn due to COVID due to COVID
e t  COVIDt C O V -19 re19 re
data.
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 43 of 155COPD may be a risk-factor for severe COVID-19 illness, and the following participants will 
not be included in the study (see Exclusion Criteria 1and2, Section 5.2):
1 Participants with active COVID-19 infection at screening.  
2 Participants with a history of significant C OVID-19 illness within 6 months of enrolment 
defined as:
(a) A diagnosis of COVID-19 pneumonia based on radiological assessment. 
(b) A diagnosis of COVID-19 with significant new findings from pulmonary imaging 
tests.
(c) A diagnosis of COVID-19 requiring hospitalisation and/or oxygen supplementation 
therapy.
Because the screening/run-in period is at least 4 weeks, participants will be tested for active 
SARS CoV-2 infection using a nucleic acid test targeting SARS-CoV-2 at both screening visits (see SoA [Table 2] ), and those with a positive result at either screening visit will become 
screen failures. This test may be performed  either at a local laboratory or at the central
laboratory.
Participants suspected of having contracted COVID-19 should be managed according to local 
and national guidelines to prevent spread of COVID-19 infection to staff and patients. These participants, as well as any who test pos itive for SARS-CoV-2, should not be au tomat ically 
discontinued from investigational product or be withdrawn from the study. Investigators should refer to Section  7when considering participant discontinuation or withdrawal 
decisions. Sites  will be required to provide docu mentation of a COVID-19 screening and 
mitigation plan that describes how and where participants would be tested if they are 
suspected to have SARS-CoV-2 infection. The plans should also describe mitigation activities designed to protect site staff a d others at the site, including other participants and patients. Appendix J contains an example screening questionnaire that may be used prior to each visit 
to identify participants with symptoms of, or recent risk factors for, SARS-CoV-2 infection.
Infection control measures should be followed in accordance with local and national 
guidelines including, but not limited to, staff screening and use of personal protective equipment.
4.1.1.1 Vaccination Against COVID-19
There is no clinical data available to assess the interaction (if any) of MEDI3506 with any 
COVID-19 vaccine.
The sponsor accepts that vaccination against COVID-19, when and where it is available and 
participants are eligible according to applicable guidelines, is in the participantâ€™s best interest. '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGeks
argeting SAgeting 
itive result at eithresult at 
ithier at a lr at a l ocalocal llab
acted COVID COVID -19 s
pread of COVIDd of CO -1
est positive for SAositive for
nal product or be w oduct or
n considering partonsidering 
uired to provid to proviii de dod
ribes how and whs how and wh
RS-CoVV-2 infect 2 infe io
site staff a d othere staff a d other
s an example screxample
with symph s
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 44 of 155Consequently, vaccination during the study is, in general, permitted and any delays in 
vaccination due to study participation should be minimized.
To help ensure the interpretability of safety d ata, receipt of COVID-19 vaccine (either first or 
subsequent dose) is prohibited within 30 days be fore randomization or within 7 days before or 
after any dose of IP (Section 6.5.5) . Receipt of, at least, the first dose of COVID-19 vaccine 
more than 30 days before randomization, without significantly delaying enrolment, should be 
preferred but may not be possible, eg, not locally available at the time, participant not eligible at the time, express participant decision not to be vaccinated. Otherwise, vaccination may be performed at any time outside the prohibited 7-day window before or after any dose of IP. If the (approximate) date of a subsequent dose of COVID-19 vaccination is known, then enrolment of the participant should be timed so that that dose is not within 30 days prior to scheduled randomization. If this d ate is not known then enrolment into study s hould not be 
delayed. If an enrolled participant does (unexpectedly) receive COVID-19 vaccine within 30 
days prior to scheduled randomization, the site should contact the AstraZeneca Study
Physician for advice on how the situation should be managed.
4.1.2 Study Conduct Mitigation During Study Disruptions Due to Cases of 
Civil Crisis, Natural Disaster, or Public Health Crisis
The guidance given below supersedes instructions provided elsewhere in this protocol and 
should only be implemented during cases of civil crisis, natural disaster or public health crisis 
(eg, during quarantines and resulting site closures, regional travel restrictions, and 
considerations if site personal or study participants become infected with SARS-CoV-2 or similar pandemic infections), which would prevent the conduct of study-related activities at sites, thereby compromising the study site sta ff or the participantâ€™s ability to conduct the 
study. The investigator or designee should contact the study Sponsor to discuss whether the mitigation plans below sho ld be implemented.
To ensure continuity of the c linical study during a civil crisis, natural disaster or public health 
crisis, changes may be implemented to ensure the safety of study participants, maintain 
compliance with GCP, and minimise risks to study integrity.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGdly) rly
hould contauld cont
ld be managed. managed
During Study Dring Stu
aster, or Public Hr, or Pub
es instructions provstructio
g cases of civil crises of civ
lting site closuressite 
l or study tudy partipartiyy cipa
s), which would pr ich wou
ing the studythe study sisiyte te iiii
r or designee shou signee shou
ow sho lw sho l d be impld be impl
f the clinicae clf
lemel
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 45 of 155Where allowable by local health authorities, ethics committees, healthcare provider guidelines 
(eg, hospital policies) or local government, these changes may include the following options:
!Pausing recruitment and screening of new participants
!If, for reasons related to the COVID-19 pandemic, a participant is not able to attend their 
scheduled visit within the Â± 3 day visit windo w, they can have their visit rescheduled 
within 14 days of the original scheduled visit; however, visits that cannot be rescheduled 
within a 14 day window must be  skipped and participants should continue at the next 
scheduled visit.
!During the COVID-19 pandemic, on-site visits may be replaced by a telemedicine visit. 
Having a telemedicine visit with the participan ts will allow collection of data for AEs, 
concomitant medications, and adherence to the eDiary and ePRO measures to be reported 
and documented. The term telemedicine visit refers to remote contact with the 
participants using telecommunications technology including phone calls, virtual or video 
visits, and mobile health devices.
!Performance of clinic spirometry at an alterna tive location where the participant may 
perform spirometry manoeuvres under supervision, eg  conducted at participantâ€™s home 
by qualified site staff.
For further details on study conduct during civil crisis, natural disaster or public health crisis, 
refer to Appendix K.
4.2 Scientific Rationale for Study Design
Chronic obstructive pulmonary disease is a heterogeneous disease (Segal and Martinez 2018)
and as such any proposed treatment should be targeted at the participants within that diagnosis most likely to respond, and with the greatest unmet burden of disease. Chronic obstructive pulmonary disease is characterized by airflow limitation (post-BD FEV
1/FVC < 0.70) that is 
not fully reversible, usually progressive and associated with an enhanced chronic inflammatory response in the lung. The Evaluation of COPD Longitudinally to Identify
Surrogate Endpoints (ECLIPSE) observation al study of 2163 participants with
moderate-to-severe COPD found a mean rate of decline of FEV
1of 33 mL/year over 3 years, 
with higher rates of FEV 1decline in the presence of current smoking, emphysema, and BD 
reversibility ( Vestbo et al 2011) . Research on the impact of chronic bronchitis in COPD 
patients on mortality and FEV 1decline in a population-based cohort, showed that COPD 
participants with chronic bronchitis (n = 172) had a greater FEV 1decline (-38 mL/year, 95% 
CI -61.7 to -14.6; p = 0.024) compared with COPD participants without chronic bronchitis, and also a higher risk of respiratory mortality (hazard r atio 2.16, 95% CI 1.12 to 4.17; 
p = 0.002) and increased risk of acute exacer bations (objective re sponse 4.0, 95% CI 2.7 to 
5.9; p < 0.001) (Lahousse et al 2017) . However, emerging evidence (Dunican et al 2021;
Kim et al 2021)  demonstrates mucus hypersecretion at all stages of COPD, evident on CT 
imaging alongside even very extensive emphysema. This accumulation of mucus in the small airways can occur in the absence of significant symptoms ( Hogg et al 2007) , likely as a result '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGnativee locatiolocatio
pervisio on, eg  condn, eg  c
ing civil crisis, natcivil cr
ale for Study Dfor Study
ydisease iease i y s a heters a h
eatment should be ent should
d with the greatestth the greate
haracteri terized by airzed by air
usuallysually progressive progressivyy
onse in the l in the l ung. Tung. Tlll
ECLIPSE) oLIPS
founf
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 46 of 155of the lack of cough receptors in the peripheral airways (Burgel and Nadel 2008) . Patients 
with recurrent exacerbations have higher sputum inflammatory markers (Bhowmik et al 2000)
which suggests that underlying inflammation may lead to disease progression, but yet may still contribute to the ongoing inflammation associated with disease progression (Anzueto 2010; Crooks et al 2000) . 
Patients with COPD and mucus hypersecretion therefore present a high unmet need. Current 
therapy for these patients consists of dual (ICS + LABA or LABA + LAMA) or triple therapies (ICS + LABA + LAMA), with add-on in the event of increased exacerbation historyof such treatments as PDE4 inhibitors, and chronic macrolide (such as azithromycin) 
treatment. These add-on treatments, however, have issues associated with individual tolerability and antibiotic resistance which have hampered their use. 
As discussed in Section 2.2, MEDI3506 mode of action is hypothesized to impact airway 
inflammation, mucus and cough symptoms, and lung function endpoints in COPD, and 
through modification of these factors, reduce frequency and severity of exacerbations.
This study tests the hypothesis that MEDI3506 will improve lung function in participants with 
COPD and chronic bronchitis, using FEV
1as the primary outcome measure. The study uses 
secondary outcomes to gather evidence to support the mode of action of MEDI3506, 
concentrating on lung physiology, mucus, cough, and ePROs related to symptoms and disease impact. 
There will be one sub-study in this trial: 
4.2.1 Rationale for Study Population
Chronic bronchitis by physician assessment of participant disease history (presence of cough 
and phlegm on most days for â‰¥ 3 months/year for â‰¥ 2 years) and BCSS average score â‰¥ 2 in 
cough and sputum domains over the 4-week run-in period allow not only the standard definition of chronic bronchitis history to be used to define participants who could benefit, but also to increase the chances of seeing a measurable effect size in BCSS and other symptom related measures. This BCSS inclusion criterion helps to identify those patients with 
symptomatic mucus hypersecretion most likely to respond to MEDI3506 due to its mechanism 
of action. However, the ability to score severity of emphysema on CT scan will also allow for '&3URWRFRO$PHQGPHQW_9970)_
S YHGtio
ung functng func
equen ncy and sevcy and s
506 will improve lwill imp
V1as the primary othe prima
e to support the moupport t
mucus, cough, and 
n this trihis tr al: : 
PPDCCICCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 47 of 155analysis of subpopulations of patients with COPD based upon extent of emphysema to further 
examine the relationship between emphysema and response to MEDI3506.
During the ongoing COVID-19 pandemic, as a result of changed patient behaviour, there has 
been a significant reduction in exacerbation frequency compared with previous years. Data from the UK suggested a 50% reduction in exacerba tion related-hospital admissions compared 
with pre-pandemic (Tan et al 2020; Alsallakh et al 2021) , and a 39% reduction in primary care 
consultations related to COPD. This picture is replicated in other countries. Leaving the requirement for at least one moderate or severe exacerbation in the previous 12 months unchanged would lead to the exclusion of patients who in previous years would have been included.
In this study, participants are required to have at least one moderate or severe exacerbation in 
the previous 24 months, as participants with frequent exacerbations have been shown to have an increased symptom burden and likelihood of subsequent exacerbations ( Hurst et al 2010) , 
and a history of exacerbation also results in poor outcomes irrespective of ICS use and for 
exacerbation history of â‰¥ 1 moderate exacerbation (Calverley et al 2017) . Participants should 
be clinically stable and free from an exacerbation of COPD for 1 month prior to SV1 and prior to Day 1.
4.2.2 Rationale for Primary Endpoint
The primary endpoint is change from baseline to Week 12 in clinic pre-BD FEV 1.
Forced expiratory volume in 1 second is a validated and clinically important endpoint in 
COPD studies, and has been used extensively in trials used to support registration of add on 
therapy to current standard of care (dual/triple th erapy) in a similar chronic bronchitis patient 
population (Martinez et al 2015) . 
4.2.3 Rationale for Intervention Period Duration
The last dose is administered at Week 24 and the end of treatment is 4 weeks later (Week 28).
Based on available data, the improvement in FEV 1assumed in the sample size determination 
(Section 9.2) is expected to be achieved by Week 12. However, improvement in FEV 1is 
considered important but not sufficient to meet the unmet medical need in COPD. To enable 
evaluation of the secondary endpoint of COPDCompEx, the treatment is continued after collection of primary endpoint data, to collect further events.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGnt e
ubsequentseque
or outcomes irres comes ir
ationn((Calverley eCalverl
batioon of COPD fn of CO
y Endpointndpoin
from baseline to W baseline 
n 1 second is a vali cond is a 
en used extensiveused extensiv
ard of care (dual/t f care (dual/t
et al 2015et al 2 )).
ale for Intervor 
da t
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 48 of 1554.2.4 Participant Input into Design
The AstraZeneca Patient Partnership Program is an internal working group that enables study
participant feedback on clinical trial study designs. During study development, the Patient 
Partnership Program influenced the following aspects of the study design:
!Provision written into the CSP to rotate injection sites.
!Participant training for the eDiary and spirometry devices used at home will be supported 
by trouble shooting and technical guidance
!Participants may be provided with a sing le source study guide providing study rationale 
and guidance in seeking additional support from sites (does not directly affect the CSP).
!There may be ongoing communications with participants such as newsletters and regular 
site contact (does not directly affect the CSP).
!Site facilities were explored to  support participant focused visits such as out of office or 
TC visits (does not directly affect the CSP).
!A centralized recruitment program may be used.
!Nasal sampling will not be repeated in participants that are unsuitable for repeat sampling 
as judged by the Investigator.
In addition, a study coordinator review of the SoA took place in order to ensure the SoA was 
feasible and realistic, particularly in terms of visit duration. This consultation led to the following alterations to the SoA:
!Provision for allowing informed c nsent at a separate, stand-alone visit has been included 
in the CSP.
!Detailed guidance has been included to clarify the order of assessments in Section 8.
!Duration estimates for visits were confirmed.
4.3 Justification for Dose
In this proof-of-concept st udy, a dose regimen of  Q4W SC will be administered for 
7 doses. This dose is predicted to have a lower exposure, in terms of C max,ss (approximately 
2.4-fold) and AUC (approximately 1.1-fold), compared with the highest dose administered (ie, single dose of  IV MEDI3506) in the Phase I clinical study (Study D9180C00001; refer to IB for further details).
Exposures (ie, C
max,ss of 1276Î¼g/mL and AUC 0-4 weeks of 28012 Î¼g day/mL) achieved at the 
26-week no observed adverse effect level of 150 mg /kg in cynomolgus monkeys (refer to the 
IB for further detail) are approximately 38- to 47-fold higher than predicted at the proposed 
maximum dose of  SC Q4W in this Phase II clinical study. '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGant 
used.
articipants that areipants tha
w ofthhe SoA took pe SoA t
terms of visit durms of vis
nformed c nsent atmed c nsen
as been included toeen included t
s for visits were c isits we
ation for Doon 
udyd, a
CCI
CCICCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 49 of 155The optimal serum concentration for MEDI3506 efficacy in COPD is not known. A mouse 
challenge model suggests a target concentration of 20 Î¼g/mL (refer to the IB for additional 
details). Analysis of the PK data from the Phase I clinical study of MEDI3506 predicts that 
 SC Q4W will achieve an average steady-state concentration of 21 Î¼g/mL, similar to 
the target concentration established in the mous e model. In addition, this dose is predicted to 
achieve > 90% suppression of IL-33 in the sputum based on the theoretical PK/PD model. If
replicated in humans with COPD,  SC Q4W is anticipated to achieve near-maximum efficacy based on the mouse and PK/PD models.
4.4 End of Study Definition
The end of the study is defined as the date of last scheduled procedure shown in the SoA (Table 3)  for the last participant in the study globally.
4.4.1 Study Stopping Criteria
Discontinuation of specific sites or of the study  as a whole are handled in accordance with 
Appendix A9 .
The study may be put on hold pending a full safety  data review, if any of the following criteria 
are met:
!Five or more (in different participants) reports of new onset symptomatic heart failure 
confirmed by echocardiography1
!Four or more (in different participants) reports of Grade 5 severity infection (excluding 
COVIDâ€‘19 infection), not ass ciated with a COPD exacerbation1
!Two or more (in different participants) reports of new onset non â€‘infective colitis, 
confirmed histopathologically
!Two or more cases of â‰¥Grade 4 severity hypersensitivi ty reactions (e g, anaphylaxis), 
except where a specific alternative causative allergen is identified1
!Ten or more (in different participants) other clinically significant ( â‰¥ Grade 4 severity)
AEs (excluding those described in any of the preceding criteria) in the same system organ 
class (excluding COVID-19 infection and C OPD exacerbations) that preclude continuing 
dosing of the participant, unless obviously not related to the IP (eg, motor vehicle 
accident)1
!Participant enrolment is unsatisfactory
!Non-compliance that might significantly jeopardize the validity or integrity of the trial, or 
safety of the participant(s)
!Sponsor decision to terminate development.
                                               
1Except if the DSMB confirm that there is no evident significant adverse imbalance between treatment groups 
and hence this criterion need not apply.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGas a whowle are hle ar
full safetsafet y data revy data
ticipants) reports oants) repo
aphy1
t participants) repoticipants) 
not ass ssciated withciated
ferent participants)nt participants
thologically gically
ses of s of â‰¥â‰¥Grade 4 sGrade 4 s
specific alternatcific alter i
fferent partent
descrdCCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 50 of 155If the sponsor determines that temporary suspension  or termination of the study is required, 
the sponsor will discuss the reasons for taking such action with all participating investigators 
(or heads of the medical institutions, where applicable). When feasible, the sponsor will provide advance notice to all participating investigators (or heads of the medical institutions, where applicable) of the impending action.
If the study is suspended or terminated for safety reasons, the sponsor will promptly inform all 
investigators, heads of the medical institutions (where applicable), and/or institutions conducting the study. The sponsor will also promptly inform the relevant regulatoryauthorities of the suspension/termination along with the reasons for such action. Where 
required by applicable regulations, the investigator or head of the medical institution must 
inform the IRB/IEC promptly and provide the reason(s) for the suspension/termination. If the 
study is suspended for safety reasons and it is deemed appropriate by the sponsor to resume 
the study, approval from the relevant regulatory  authorities (and IRBs/I ECs when applicable) 
will be obtained prior to resuming the study. The investigator shall also promptly inform the participant of the study suspension/terminatio n and should assure a ppropriate participant 
therapy and/or follow-up.
5 STUDY POPULATION
Each participant must meet all the inclusion criteria and none of the exclusion criteria 
(excluding sub-study specific criteria) for this study in order to be assigned/randomized to the 
study intervention. Under no circumst nces can th ere be exceptions to this rule. Participants 
who do not meet the eligibility requirements are screen failures (refer to Section 5.4). 
Participants who provide informed consent to  participate in the CT sub-study but are 
subsequently found not to meet all of the inclusion  criteria and/or meet any of the exclusion 
criteria, applicable to the sub study, should not participate further in the sub-study but should 
continue to participate in the main study so long as they are eligible as described above.
In this CSP, â€œenrolledâ€ participants are defined as those who sign the ICF. â€œRandomizedâ€ 
participants are defined as those who undergo randomization within the RTSM system. 
Prospective approval of CSP deviations to eligibility criteria, also known as CSP waivers or 
exemptions, is not permitted.
5.1 Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age:
1 Participant must be 40 to 80 years of age inclusive, at the time of signing the ICF.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGed aed
uthorihorititiiiiies e
he investigator sh estigator
on and should assund should 
ON
inclusiousion crin criteria tiiii
iteria) for this stud ) for
circumst nces canmst nces ii
lity requirements equireme
informed consentormed consent
t to meet all of the eet all of the
o the subhe sub studystudy , sh, sh
ate in the main sn the ma
ticipai
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 51 of 155Type of Participant and Disease Characteristics:
2 Participants who are current or ex-smokers with a tobacco history of â‰¥10 pack-years. 
Pack-years are calculated as average number of cigarettes per day Ã— number of years / 20. 
For example, 1 pack-year = 20 cigarettes smoke d per day for 1 year or 10 cigarettes per 
day for 2 years.
3 This inclusion criterion has been removed.
4 Participants who have a documented history of COPD for at least 1 year. A verbal history
of symptoms consistent with COPD from the participant is not sufficient. Acceptable documentation includes
âˆ€Clinic visit (primary or specialist HCP) notes or emergency room/hospital records 
listing COPD as a current diagnosis
âˆ€Verbal discussion confirming the diagnosis of COPD between the investigator and 
physician who has access to the participantâ€™s medical record. The investigator is required to clearly document this conversation in participantâ€™s source document. 
5 Participants who have a post-BD FEV
1/FVC < 0.70 and a post-BD FEV 1> 20% and 
< 80% predicted normal value at screening. Centralized spirometry will be used for this criteria assessment.
6 Participants who have a physician confirmed hi story of chronic bronchitis as defined as 
presence of cough and sputum on most days for â‰¥3 months/year in at least the 2 year 
period immediately prior to SV1 (screening). Assessment based on a verbal historyconsistent with chronic bronchitis is sufficient.
7 Participants who have an av rage BCSS score of â‰¥2 in cough and â‰¥2 in sputum domains 
assessed over the 14 days preceding SV3.
8 Participants who h ve a documented stable regimen of dual therapy or triple therapy for 
â‰¥3 months prior to enrolment; there should have been no change in treatment after the 
previous exacerbation prior to entering into the study. Where dual therapy consists of
ICS + LABA or LABA + LAMA, and triple therapy consists of ICS + LABA + LAMA. Both dual and triple therapy may be in the form of separate inhalers of fixed dose 
combination inhalers but may not be in nebulized form. However, all inhalers must be locally approved for the maintenance treatment of COPD. See Section 6.5.1.  Acceptable 
documentation includes:
âˆ€Recent, active medication list as per HCP note
âˆ€Filled prescriptions based on a pharmacy record
âˆ€Another acceptable medical record as per local clinical practice
âˆ€Verbal discussion confirming treatment regimen between investigator and HCPs who 
have access to participantâ€™s medical record. The investigator is required to clearlydocument this conversation in participantâ€™s source document.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGis os offCO
pantâ€™s medical s medica
versatatioonnin partiin pa c
/FVC <<0.70 and 0.70
eening. Centralizeng. Centra
ian confirmed hist onfirme
m on most dayn most day s foff
o SV1 (screening)V1 (screen
bronchitchiis is sufficis su
e an av rage BCSS av rage BCS
4days preceding Sys preceding S
o h ve a documh ve a docum entent
or to enrolment; t enrolment; t
tion prin pror to
AA+L
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 52 of 1559 Participants who have a documented history of â‰¥1 moderate or severe AECOPD 
requiring systemic corticosteroids and/or antibiotics for at least 3 days duration (or 
1 injection of depot formulation), or hospitalization for reason of AECOPD in the previous 24 months prior to screening. A verbal history from the participant of AECOPD is not sufficient. Acceptable documentation is:
âˆ€Clinic visit (primary or specialist HCP) notes or emergency room/hospital records 
providing evidence of â‰¥1 moderate or severe AECOPD in the previous 24 months 
prior to enrolment.
âˆ€Documented prescription of systemic corticosteroids of at least 3 days duration (or 
1 injection of depot formulation) and/or antibiotics for treatment of exacerbation
âˆ€Discharge summaries from a hospital, emergency room, or an urgent care facility 
indicating that a participant was hospitalized or treated with systemic corticosteroids for a COPD exacerbation.
âˆ€Verbal confirmation from the patient that they have self-administered rescue 
medication for an acute exacerbation, characterised as above, in the previous 24 months, despite confirmation of compliance with usual inhaled medication. This needs to be clearly documented in the participant's source document by the investigator.
10 Participants who are clinically stable and free from an exacerbation of COPD for 1 month 
prior to SV1 (screening) and prior to Day 1.
11 Participants who are at least 70% compliant with the eDiary and home spirometry during 
the 14 days preceding SV3 based on the eDiary. 
12 Participants who are able to r ead, write, and use electronic devices.
Weight:
13 Body mass index within the range 18 to 40 kg/m
2(inclusive).
Sex/Reproduction:
14 Female participants of childbearing potenti al, must have negative pregnancy tests at 
screening SV1 (serum pregnancy test), and then subsequently at SV2 (urine pregnancy test, only if a CT scan is performed) and pre-dose of study intervention at SV3 (Day 1; urine pregnancy test).
15 Female participants of childbearing potential who are sexually active with a male partner 
must agree to use a highly effective method of contraception from screening until the end of the follow-up period at SV14 of the study. See Appendix F for definitions of 
childbearing potential and highly effective methods of contraception. In countries where spermicide is available, it is strongly recommended for the male partner of a female participant of childbearing potential to also use male condom plus spermicide throughout '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGat theyeyhhyyave ave 
characterised as a cterised
mpliance with usuance with
n the participant's e participa
able and free from and fr
prior to Day to Day 1.1
t 70% com% com pliant wpmm
V3 based on the eD ased on th
able to read, wri to read, wr te, ii
ex wit ithin the ranhin the
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 53 of 155this period. 
In countries where spermicide is not available, it is strongly recommended for the male partner of a female participant of childbearing potential to also use male condomthroughout this period.Note there are no contraception requirements for female participants who are not of 
childbearing potential. However, all female participants should refrain from egg cell 
donation and breastfeeding throughout the study.
16 In countries where spermicide is available, male participants who are sexually active with 
a female partner of childbearing potential must agree to use a male condom with
spermicide and another highly effective method of contraception during the intervention 
and follow-up periods from Day 1 through to SV14 of the study. In countries where spermicide is not available, male participants who are sexually active with a female partner of childbearing potential must agree to use a male condom and another highly effective method of contraception during the intervention and follow â€‘up 
periods from Day 1 through to SV14 of the study.SeeAppendix F for definitions of childbearing potential and highly effective methods of 
contraception. Male participants should also refrain from biologically fathering a child or 
donating sperm during the same period.
Informed Consent:
17 Capable of giving signed informed consent as described in Appendix A,  which includes 
compliance with the requirements and restrict ions listed in the ICF and in this CSP.
Informed Consent (Sub-studies):
18 Provision of signed and dated written informed consent for sub-study enrolment (if 
applicable). 
5.2 Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions and Diagnostic Assessments
1 Participants with a positive diagnostic nucleic acid test for SARS-CoV-2 at SV1 or SV2. 
Subjects with mild or asymptomatic disease could be rescreened.
2 Participants with a significant COVID-19 illn ess within 6 months of enrolment defined 
as:
(a) A diagnosis of COVID-19 pneumonia based on radiological assessment. 
(b) A diagnosis of COVID-19 with significant new findings from pulmonary imaging 
tests.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGion durion du
studyy.
aring potentg potent iaial an
d also refrain fro refrain m
od.
formed consent as ed consent
rements and restrients and r
studies):dies):
ed and dated writteed and dated w
Criterri
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 54 of 155(c) A diagnosis of COVID-19 requiring hos pitalisation and/or oxygen supplementation 
therapy.
3 As judged by the investigator, any evidence of any active medical or psychiatric condition 
or other reason (at screening [SV1 and SV2] and SV3 [pre-dose]) which in the 
investigator's opinion makes it undesirable for th e participant to participate in the study.
This includes but is not limited to:
(a) Diabetes mellitus, except for participants with type 2 diabetes mellitus who are well 
controlled in the opinion of the investigator.
(b) History of heart failure.
(c) Clinically significant or unstable ischemic heart disease, arrhythmia including atrial 
fibrillation (except first degree heart block), or cardiomyopathy, including acute coronary syndrome within the last 6 months; or any history of myocardial infarction. 
(d) Clinically significant aortic stenosis.(e) Systemic hypertension, except if well controlled and stable for at least 3 months in 
the opinion of the investigator.
(f) Pulmonary arterial hypertension to excl ude participants with known history of
primary pulmonary arterial hypertensi on or clinically significant cor pulmonale.
(g) History of an underlying condition that predisposes the participant to infections 
(eg, history of splenectomy, known primary or secondary immune deficiencysyndromes).
(h) History of ulcerative colitis  Crohnâ€™s disease, or microscopic colitis diagnosed by 
either a gastroenterologist or by histopathology.
4 This exclusion criterion has been removed.
5 Current diagnosis of asthma or past diagnosis of asthma which persisted beyond the age 
of 25 years. A misdiagnosis of asthma is not exclusionary if any of the following are met:
(a) A diagnosis of asthma that was, within 2 years of original diagnosis, determined to be 
a misdiagnosis by he then treating physician.
(b) A brief episode of asthma-like symptoms without longer-term asthma treatment 
confirmed by the investigator to be a misdiagnosis.
(c) A diagnosis of asthma made when the subject was aged â‰¥40 years, confirmed by the 
investigator to be a misdiagnosis after discussion with and agreement of the 
AstraZeneca Study Physician.
6 Clinically important pulmonary disease other than COPD (eg, active lung infection, 
clinically significant bronchiectasis, pulmonary  fibrosis, cystic fi brosis, hypoventilation 
syndrome associated with obesity, lung cancer, alpha-1 anti-trypsin deficiency and 
primary ciliary dyskinesia) or anot her diagnosed pulmonary or systemic disease that is 
associated with elevated peripheral eo sinophil counts (eg, allergic bronchopulmonary
aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome), '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGontrolled and olled and
exclude partude parll icipa
ertensionsion or clinican or cli
dition that predispn that pre
y, known primary own pri oy
olitis  Crohnâ€™s disis  Crohnâ€™
ologist or byist or by histohy
on has been remas been rem ovo
of asthma or past hma or past 
misdiagnosis of astsdiagnosis of ast
is ofasthma thatasthma 
by he theh
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 55 of 155radiological findings, and/or laboratory findings  suggestive of a respiratory disease other 
than COPD that is contributing to the participant's respiratory symptoms.
7 Increased pre-BD FEV 1at randomization visit (SV3) compared to Screening SV1 of 
â‰¥400 mL or â‰¥25% of SV1 FEV 1.
8 Known history of allergy or reaction to any component of the study intervention 
formulation, including hereditary fructose intolerance. 
9 Any other clinically relevant abnormal findings on physical examination, laboratory
testing including hematology, coagulation, serum ch emistry, or urinalysis; or chest CT 
scan at screening or randomization, which in the opinion of the investigator or medical 
monitor may compromise the safety of the participant in the study or interfere with
evaluation of the study intervention or reduce the participantâ€™s ability to participate in the 
study. Abnormal findi ngs include, but are not limited to:
(a) ALT or AST > 2 Ã— ULN.
(b) TBL > 2 Ã— ULN (unless due to Gilbertâ€™s diseas )(c) Evidence of chronic liver disease
(d) Abnormal vital signs, after 10 minutes of be ing in a comfortable supine position 
(confirmed by 1 controlled measurement), defined as any of the following:
(i) Systolic BP < 80 mmHg or â‰¥ 150 mmHg.
(ii) Diastolic BP < 50 mmHg or â‰¥ 95 mmHg.
(iii) Pulse < 45 or > 100 beats per minute.
(e) This exclusion criterion has been removed.(f) Any clinically significant rhythm, condu ction, or morphology abnormalities in the 
12-lead ECG including but not limited to corrected QT interval (Fridericia) (Vandenberk et al 2016)  > 450 ms.
(g) Chest CT scan finding  requiring further investigation or repeat CT surveillance 
before SV14.
10 This exclusion criterion has been removed.11 A family history of heart failure defined as either of the following: â‰¥2 first degree 
relatives with clinically significant heart failure, or â‰¥1 first degree relative with heart 
failure known to be heritable (eg, hypertroph ic cardiomyopathy), unless inheritance is 
excluded by genetic testing.
12 A LVEF < 45% measured by echocardiogram during screening, between the time of 
signing informed consent and prior to randomization. 
13 History of a clinically significant infection (viral, bacterial, or fungal) within 4 weeks 
prior to Day 1 (SV3) (including unexplained d iarrhea) or clinical suspicion of infection at 
time of dosing. Clinically significant infections are defined as requiring systemic antibiotics, antiviral, or antifungal medication for > 7 days. '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGs diseas )eas )
utes of beof be ing in a ng
surement), definedment), defi
or â‰¥ 150 mmHg.150 mm
mHg or r â‰¥ 95 mmHgâ‰¥ 95 m
0 beats per minute. ts per min
on has beenas been remro
nificant rhyant rhy thm, cothmyyy
cludingingbut not limbut not lim
etal2016016)) > >450 4
scan finding  requin finding  requi
4
on has n
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 56 of 15514 Prior history of/planned: lung pneumonectomy for any reason, or lung volume reduction 
procedures (including bronchoscopic volume reduction) for COPD. Note: Surgical biopsy, or segmentectomy, or wedge resection, or lobectomy for other diseases would not be excluded.
15 Long term oxygen therapy (a requirement for continuous oxygen therapy > 16 hours per 
day). 
16 Use of any non-invasive positive pressure ventilation device. 
17 Current diagnosis of cancer.
18 History of cancer, except if treated with apparent success with curative therapy (response 
duration of > 5 years).
19 A known history of severe reaction to any medication including biol ogic agents or human 
gamma globulin therapy. 
20 A helminth parasitic infection diagnosed within 6 months prior to SV1 that has not been 
treated with, or has failed to respond to, standard of care therapy.
21 History of herpes zoster within 3 months prior to r ndomization (Day 1). 
22 History of, or a reason to believe a participant has a history of, drug or alcohol abuse 
within the past 2 years prior to screening.
23 Positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core 
antibody, at screening
24 A positive test for HIV or known to have HIV infection. 
25 Evidence of active or untreated latent TB infection (LTBI) as evidenced by
(a) Positive IGRA test and evidence of symptoms suggestive of active TB
(b) Positive IGRA, or repeated indeterminate IGRAs, no evidence of active TB and 
untreated for latent infection, unable to be treated for, or declines treatment of latent TB infection. 
(c) Participants newly diagnosed with LTBI on initial screening could be considered for 
rescreening if they complete a full course of treatment for latent TB in accordance with recommended treatment guidelines prior to rescreening. In this situation, repeat IGRA test is not required after completion of treatment for LTBI.
(d) Participants with an indeterminate IGRA should undergo repeat test and if st ill 
indeterminate may only be enrolled after treatment for latent TB infection.
26 Change in smoking status in 12 weeks prior to enrolment or intention to change smoking 
status between enrolment and end of follow-up.
Prior/Concomitant Therapy
27 Participants currently receiving background therapy that is not approved by regulatory
authorities in the country of study for COPD are not eligible for the study. '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGn 6 mon 6 m
ndard of care td of care
prior to r ndoor to r ndo miz
ticipant has a histopant has a
ening.g.
patitis B virus surfs B virus 
nown to have HIVn to have H
reated l d latent TB inatent T
t and evidence of d evidence
or repeated indeteepeated indete
latent infection, ulatent infection, 
on. 
newlyly diagno diyy
ey coycm
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 57 of 15528 History of treatment with cardiotoxic medications (eg, as part of cancer therapy) 
including thiazolidinediones.
29 Major surgery within 8 weeks prior to screening or planned inpatient surgery or 
hospitalization during the study period. Elective hospitalizations that ca nnot be delayed 
until after the end of the study need to be discussed with the sponsorâ€™s medical monitor. 
30 Treatment with broad spectrum antibiotic with in 4 weeks prior to randomization (Day 1). 
31 Donation of blood or blood products in excess of 500 mL within 3 months prior to 
screening. 
32 History of allogeneic bone marrow transplant. 33 Treatment with allergy immunotherapy within 90 days prior to SV1. 
34 Receiving any of the prohibited concomitan t medications as specified in the CSP:
(a) Acute systemic (oral or injectable) corticosteroids within 4 weeks of SV1 
(b) Any other immunosuppressive therapy (including methotrexate, cyclosporine or 
maintenance systemic steroid treatment) within 3 months of rando mization.
(c) Immunoglobulin or blood products  within 4 weeks of SV1.
(d) Live or attenuated vaccines within 4 weeks of SV1. (Note: Vaccines with adenoviral 
vectors that are unable to replicate, eg  ChAdOx1, are not considered live or attenuated).
(e) Interferon gamma within 3 months of randomization.
(f) Investigational products within 4 months or 5 half-lives of rando mization, whichever 
is longer.
(g) Marketed biologics within 4 months or 5 half-lives of randomization, whichever is 
longer.
(h) Any add-on therapy for COPD including theophylline. Chronic macrolide or other 
antibiotic therapy is allowed provided the participant has been on a stable dose/regimen for â‰¥ 3 months prior to enrolment and has had at least one COPD 
exacerbation while on stable therapy.
(i) PDE4 inhibitors (e.g. roflumilast, DaxasÂ®, DalirespÂ®) commenced within 3 months 
of SV1. PDE4 inhibitors are allowed provided the participant has been on a stable dose/regimen for â‰¥ 3 months prior to enrolment and has had at least one COPD 
exacerbation while on stable therapy. 
(j) Vaccination against COVID-19 (either first or subsequent dose) within 30 days prior 
to randomization.
(k) Any immunotherapy within  3 months of randomization.
(l) Antitussive and mucolytic medications commenced within 4 weeks prior to SV1. 
Antitussive and mucolytic medications are allowed provided the participant has been on a stable therapy/regimen for greater than 4 weeks.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGncluding cludin
nt) within 3 mo hin 3 m n
within 4 weeks of in 4 weeksii
n 4 weeks oweeks o ffSV1S
cate, eg  ChAdOx eg  Ch
3 moontnths of randohs of r
ts within 4 months hin 4 m
cs wiiththiiiin 4 monthsin 4 mo
therapyherapy fyor COPDr COPDff
therapy is allowedapy is allowed
n for â‰¥ 3 mâ‰¥ 3on
le on se
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 58 of 15535 Participation in, or scheduled for, an intensive COPD rehabilitation program at any time 
during the intervention period (note: participan ts are permitted to be in the maintenance 
phase of a rehabilitation program). 
Prior/Concurrent Clinical Study Experience
36 Concurrent enrolment in another clinical study involving an investigational treatment.
Exclusion Criteria for Optional Genetic Sample Only
37 Non-leukocyte depleted whole blood transfusion within 120 days of optional genetic 
sample collection.
Other Exclusions
38 Participant is an investigator, sub-investigator, study coordinator, or employee of the 
participating site or Sponsor, or is a first-degree relative of the aforementioned. 
39 Inability to perform tec hnically acceptable spirometry.
40 Pregnancy or intention to become pregnant during the study, breastfeeding, or 
unwillingness to use a highly effective method of contraception throughout the study in female participants of childbearing potential. 
41 This criterion has been removed.
5.3 Lifestyle Considerations
Participants must abstain from donating blood and plasma from the time of informed consent, 
and for 16 weeks (5 half-lives) after last dose of study intervention.
5.3.1 Meals and Dietary Restrictions
Participants should avoid eating a large meal fo r at least 2 hours prior to all scheduled lung 
function and AO assessments at the site.'&3URWRFRO$PHQGPHQW_9970)_
URYHGr, study costudy 
egree relative o relative 
ble spiropiromemetrytry
gnant during thnt during t
tive method ofmethod
ng potential.otenti
ed.
PPDCCI
CCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 59 of 1555.3.2 Caffeine, Alcohol, and Tobacco
Chronic alcohol or drug abuse within 2 years is restricted prior to SV1 and throughout the 
conduct of the study.
Current tobacco smokers or prior tobacco smokers, with smoking history â‰¥10 pack-years 
(1 pack-year = 20 cigarettes smoked per day for 1 year) at SV1 are allowed. Never smokers are not allowed to enter the study. Any change in smoking status in 12 weeks prior to enrolment or intention to change smoking status  between enrolment and end of follow-up will 
result in a screen failure. However, following ch ange in smoking status, they will be eligible 
for re-screening. Smoking status changes during the course of the study will be captured on the eCRF but the participant will be permitted to continue in the study. See also Section  8.
The use of e-cigarettes (eg, JUUL) is allowed during the course of the study. 
5.3.3 Activity
1 Participants should avoid engaging in st renuous exertion for at least 30 minutes prior to 
all scheduled l ung function assessments, AO and blood collection at the site.
2 Participants should avoid showers/bath ing and any activity that will cause heavy
perspiration whilst wearing the cough monitor, as the cough monitor must not come into contact with water.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently randomly assigned to study intervention. A minimal set of screen failure 
information is required to ensure t ansparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials publishing requirements and to respond to queries from regulatory authorities. Minimal i nformation includes demography, screen failure 
details, eligibility criteria, and any SAEs.
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened, if there is reason to believ e the reason for ineligibility was temporary (eg. 
exacerbation and/or background medication stability periods). Only one rescreening per 
participant is allowed in the study, when there is a reasonable expectation that the participant 
will become eligible for the study. Prior to rescreening, participants must be reconsented. Participants in rescreening retain their previous E-code.
Where individuals are rescreened, the results of echocardiogram and IGRA (TB test) carried 
out as part of the original screening process can be included as long as they are within the last 3 months and there have been no specific risks of TB infection such as foreign travel to a high '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGrenuous exertion fous exertio
ts, AO and blood AO and bl
bathing and any acing and
ough monitor, as th monitor,
es
d as partparticicipants whipant
ndomly assigned toly assigned to
d to ensure td to ensure t anspans
tandards of Reportards of Report
ory authoriuty tiiies.
and anan
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 60 of 155incidence area and no recent cardiac events which may affect the echocardiogram. 
All other tests must 
be performed as per the schedule of events (Table 2) .
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be admin istered to a study participant according to 
the CSP. Study intervention in this study refers to MEDI3506 and placebo.
6.1 Study Intervention Administered
6.1.1 Study Interventions
Table 6 Study Interventions
ARM Name MEDI3506 Placebo
Intervention Name MEDI3506 Placebo
Type Biologic Drug
Dose Formulation
Unit Dose Strength(s) Not applicable
Dosage Level(s)
Route of Administration
Use Experimental Placebo-comparator
IMP and NIMP IMP IMP
Sourcing Provided centrally by the Sponsor Provided centrally by the Sponsor 
Packaging and Labelling
IMP = Investigational medicinal product; NIMP = Non-investigational medical product; Q4W = Every 4 weeks; 
SC = Subcutaneous; w/v = Weight per volume.'&3URWRFRO$PHQGPHQW_9970)_
PGHGHH
SSSS$Snn$S$S$S$SExperimeExperime$S$S$S$SIMP$$$$Pro$$$$CCI CCI
CCI
CCI CCICCI CCI
CCICCICCI
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 61 of 1556.2 Preparation/Handling/Storage/Accountability of Interventions
1 The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are reported and resolved before use of the study intervention.
2 Only participants enrolled in the study may receive study intervention and only authorised 
site staff may supply or administer study intervention. All study intervention must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labelled storage conditions with access limited to the investigator and authorised site staff. 
3 MEDI3506 does not contain preservatives and, therefore, any unused portion must be 
discarded.
The unblinded study intervention manager will select the appropriate kits allocated by the 
RTSM system to prepare the participantâ€™s dose. The unblinded study intervention manager 
must ensure that only the unblinded team members have access to the areas of the pharmacy 
where the study intervention is being stored and prepared.
6.2.1 Study Intervention Inspection
Each vial allocated for dose preparation should be inspected. MEDI3506 and placebo are supplied as a clear to opalescent sterile liquids  
If there are any defects noted with the study intervention, the investigator and site monitor 
should be notified immediately. Refer to the Product Complaint section in the IMP manual for 
further instructions.
6.2.2 Dose Preparation Steps
No incompatibilities between MED I3506 and plastics (ie, polypropylene and polycarbonate 
syringes) have been observed.
MEDI3506 and placebo do not contain preservatives and any unused portion must be 
discarded. Preparation of study intervention is to be performed aseptically. Total in use 
storage time from needle puncture of the study intervention vial to start of administration 
should not exceed 4 hours at room temperature or 24 hours at 2 Â°C to 8 Â°C (36 Â°F to 46 Â°F). If 
storage time exceeds these limits, a new dose must be prepared from new vials assigned by the RTSM system.
A vial should be used only 1 time to prepare a single dose.To prepare the participantâ€™s dose, the unblinded study intervention manager will select study
intervention for administration according to th e kit identification numbers assigned. A '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGct thct t
The unblinde unblind
mbers have access ave acc
and prepared.prepared.
ectionon
tion should be inspshould 
terile liquidse liquids  
withii the studythe studyh iynte
tely. Refer to the P Refer to 
eparation Stepsparation Steps
betweeween MED
rved.ed
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 62 of 155summary of the study intervention volumes required and syringes to prepare for SC dose 
administration in each study intervention group is provided (Table 7) .
Table 7 Study Intervention Dose Preparation
Contents of 
vial(s)Number of kitsVolume 
requiredSyringes to 
prepareSize of 
syringeTotal volume of 
study 
intervention
 MEDI3506 intervention group 
MEDI3506
Placebo intervention group
Placebo
The dose preparation steps are as follows:
1 Prepare the assigned MEDI3506 and/or placebo vials for the particular study intervention 
group as per Table 7.
2 Withdraw the required volume of MEDI3506 or placebo from each vial using a separate, 
appropriately sized syringe and a separate  18 to 20-gauge 1 to 1.5 inch needle, 
respectively.
6.2.2.1 Study Intervention Administration
The first day of dosing is considered SV3 (Day 1).
Female participants of childb ring potential, must have a negative urine pregnancy test prior 
to receiving each dose of study intervention.
MEDI3506 and placebo are  The syringes should be 
kept out of sight of all blinded persons, including the participant, to maintain the blind. Study
intervention will be administered by unblinded site personnel 
to the abdomen, back of the arms, or thigh. 
apart in the same anatomical region. 
administering the dose will wipe the skin surface of the administration sites with alcohol and allow the skin surface to air dry. The skin will be pinched to isolate the SC tissue from the muscle. The needle will be fully inserted at a 45 degree angle into the SC tissue. The study intervention will be slowly injected (at least 5 seconds duration is recommended). The area 
should not be massaged after injection.'&3URWRFRO$PHQGPHQW_9970)_
$SS YHGacebo vials for th vials fo
EDI3506 506 or placebor pla
eparate 18ate 18 tot20-g
ntion Administran Admini
s considered SV3 nsidered SV3 
of childb ring pochildb ring po
ose of study f study iynteCCI
PPDCCI
CCI
CCI
CCI
CCICCI
CCI
CCICCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 63 of 155It is advised that the site of injection be rotated so that the participant receives study 
intervention injections in different anatomical regions from one visit to the next. In cases 
when rotation of the injection site is not feasible and/or the participant prefers not to rotate injection sites, the reason for not rotating the injection site should be documented in the source documents.
Each injection site must be documented on the eCRF and in the source documents at each 
study intervention visit.
6.2.2.2 Monitoring Dose Administration
After the administration of study interve ntion, vital si gns will be assessed according to the 
SoA (Section 1.3), and SC injection sites will be assessed for any reactions as detailed in 
Section 8.2.3.
As with any biologic product, allergic reactions to dose administration are possible. Therefore, 
appropriate drugs and medical equipment to treat acute anaphylactic reactions must be immediately available, and study personnel must be trained to recognize and treat anaphylaxis 
(Appendix I) .
6.2.3 Accountability
The siteâ€™s designated unblinded study intervention manager is required to maintain accurate 
study intervention accountability records. U pon completion of the study, copies of study
intervention accountability records will be returned to AstraZeneca. All unused studyintervention and vials will be disposed of following site procedures and upon author ization by 
AstraZeneca, or will be returned to an AstraZeneca-authorized depot if a site is unable to 
dispose of unused study intervention. The outer carton should be kept onsite to assist with kit 
assignment checks, if permitted by site procedures.
6.3 Measures to Minimise Bias: Randomization and Blinding
6.3.1 Methods for Assigning Study Intervention Groups
All participants will be centrally assigned to randomised study intervention using an RTSM system and will be stratified by baseline eosinophil count (< 300 cells/ Î¼L, â‰¥300 cells/ Î¼L) and 
background medication usage (ICS or no ICS). 
Before each site is initiated, the login informatio n and directions for the RTSM system will be 
provided.
Study intervention will be dispensed at the study visits summarized in SoA (Section 1.3). 
The RTSM system will provide to the investig ator(s) or pharmacists the kit identification 
numbers to be allocated .'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGdose addose a
at acute anaphyute anaph
must be trained to r be trained
udyiyntterventierventi on m
records. Upon coords. Upon
ords will be returns will be re
e disposed of foposed of f llo
turned to an Astraed to an Astr
yiynterventrven ion. Then. The
f permitted bypermitted by sisiyyte teiii
es to Minimo M
Assi
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 64 of 155Routines for this will be described in the RTSM sys tem user manual that will be provided to 
each centre.
6.3.2 Methods to Ensure Blinding
Participants will be randomly assigned in a 1:1 ratio to receive study intervention (MEDI3506 
 or placebo). Investigators will remain bli nded to each participantâ€™s assigned study
intervention throughout the course of the study.
Since MEDI3506 and placebo are not identical, study intervention will be handled by an 
unblinded study intervention manager at the site and will be administered by an unblinded study team member who w ill not be involved in the management of study participants. An 
independent study intervention monitor will also be unblinded to perform study intervention accountability. In the event that the study inte rvention allocation for a participant becomes 
known to the investigator or other study staff involved in the management of study
participants, AstraZeneca must be notified immediately . If the study intervention allocation for 
a participant needs to be known to treat an individual participant for an AE (Section 6.3.3) , the 
investigator must notify AstraZeneca immediately . The site will maintain a written plan 
detailing which staff members are blinded/unblinded and the process of study intervention preparation and administration used to maintain the blind.
In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded 
study intervention records at the site(s) to verify that randomization/dispensing has been done 
accurately.
To facilitate the in-stream analy is of PK and ADA samples, the randomisation schedule may 
be provided to limited personnel who have responsibility for analysing the samples. These unblinded sample analysts will not have any other involvement with the conduct of the study.
MEDI3506 could reduce eosinophil counts in blood over time. As a precaution, eosinophil, 
basophil, and monocyte data from the hematology  laboratory tests will not be communicated 
to blinded sponsor or site personnel during the intervention and follow-up periods. These data do not require blinding at baseline (SV1 to SV3 pre-dose).
6.3.3 Methods for Unblinding
The randomization code s hould not be broken except in medical emergencies when the 
appropriate management of the participant requires knowledge of the study intervention randomization. The investigator documents and re ports the action to AstraZeneca, without 
revealing the study intervention given to  participant to the AstraZeneca staff.
AstraZeneca retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally related to study interve ntion and that potentially require expedited '&3URWRFRO$PHQGPHQW_9970)_
ved ved in
ediately ely. If. If the  thff
dividual participandual partic
diately y. The siThe te wii
d/unblinded and thblinded an
maintain the blindntain the
e audit, the auditordit, the au
site(s) to verify ths) to verifii
analy is of PK anly is of PK a
personnel who hav nnel who hav
alysts will not havelysts will not hav
duce eosinophi eo
data fromta
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 65 of 155reporting to regulatory authorities. Randomization codes will not be broken for the planned 
analyses of data until all decisions on the ev aluability of the data from each individual 
participant have been made and documented.
The RTSM system will be programmed with blind-breaking instructions. In case of an 
emergency, in which the knowledge of the specific blinded study intervention will affect the 
immediate management of the participantâ€™s condition, the investigator has the sole 
responsibility for determining if unblinding of a participantsâ€™ intervention assignment is warranted. Participant safety must always be the first consideration in making such a determination. If a participantâ€™s intervention assignment is unblinded, the sponsor must be notified within 24 hours after breaking the blind. The investigator documents and reports the action to AstraZeneca, without revealing the study intervention given to participant to the AstraZeneca staff.
6.3.3.1 Unblinding for Analysis Purposes
An interim analysis may be included in this study prior to the Primary Analysis. Should an 
interim be conducted, the purpose will be to inform decisions on future development options 
for MEDI3506 or other programs. No termination of this study or adjustments to the studydesign are planned since the interim analysis would be for administrative purpose only. 
An interim analysis will require unblinding of a group of sponsor staff or designated 
representatives including those with clinical  medical, statistical, and programming expertise, who will form a firewalled unblinded r view committee for administrative purposes. The unblinded review committee will be responsible for reviewing the interim results and will 
ensure that the review is performed in a way that maintains the integrity of the trial, and in 
accordance with the interim analysis unblinding plan, which will be prepared prior to the 
interim analysis. Sponsor staff and designated sponsor representatives who conduct the interim analysis will take no f rther part in any study activities after they are unblinded. They will not reveal the interim analysis results or study intervention codes to any of the study team
member (sponsor staff or representative) who will remain blinded and continue to be involved in the studyâ€™s conduct until completion as originally planned. In addition, interim analysis results will not be shared with investigators  or participants. The scope and additional details 
on interim analyses are provided in Section 9.5.
There are 3 planned analyses for this study as described in Section 9.5. Personnel from 
AstraZeneca or its representatives directly asso ciated with the conduct of this study will
remain blinded until the completion of the Primary Analysis. Personnel from the study sites, and the study participants, will remain bli nded until the completion of the Final Analysis.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGdypriiyor to the Pror to the
inform decisions orm decisio
minat ioionn ofo thihifs stu
lysis would be fors would be
linding of a groupng of a
ith clinical  medica inical  me
linded r view com d r view
will be responsiblbe respon
erformed in a way med in a w
rim analysis unblinanalysis unblin
sor staff andsor staff and desigd
l take no f rther pke no f rther p
nterim analysis m analy
r represeepr
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 66 of 1556.4 Study Intervention Compliance
When participants are dosed at the site, they will receive study intervention directly from an
unblinded Product Administrator, who is appropriately trained. The date and time of the dose administered (first injection) in the clinic will be recorded in the source documents and recorded in the eCRF.
6.5 Concomitant Therapy
The investigator must be informed as soon as possible about any medication taken from the time of screening until the final study visit. Any concomitant medication(s), including herbal preparations, taken during the study will be recorded in the eCRF.
Investigators may prescribe concomitant medications or treatments that are:
!not prohibited (see Section 6.5.5) ,
!neither compromise participant safety not aff ect study data, as judged by the investigator; 
and
!deemed necessary to provide adequate supportive care.
Specifically, participants should receive full supportive care during the study, including 
intermittent treatment with antibiotics, anti metics, an ti-diarrheals, and analgesics, and other 
care as deemed appropriate, and in accordance with their institutional guidelines. The Medical Monitor should be contacted if there are any que stions regarding concomitant or prior therapy.
Participants are recommended to be vaccinated against influenza and pneumonia according to 
local schedule. Vaccination is permitted during the study but not within Â±7 days of dosing.
6.5.1 Required Maintenance Therapy for COPD
All participants are required to be treated with stable doses of maintenance dual inhaled (ICS + LABA or LABA + LAMA) or triple inhaled therapy (ICS + LABA + LAMA) for COPD for at least 3 months prior to enrolment (SV1). Both dual and triple therapy may be in the form of separate inhalers or fixed dose combination inhalers but may not be in nebulized form. However, all inhalers must be locally approved for the maintenance treatment of COPD. Maintenance treatment should remain unchanged throughout the duration of the study (except 
for treatment of COPD ex acerbations, see Section 6.5.4) . If a change in COPD maintenance 
treatment is required, it must be discussed with the medical monitor.
Note: The Spiriva Respimat device is considered to be an inhaler.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGffect study study  datadayy
supporti ortive care. ve ciiii
e full supportive cl suppor
cs, antantiimmetics, a
n accordance wit ordance w h 
here are any quest are any q
ed to be vaccinate be vacc
on is permitted durpermitted du
d Maintenance Td Maintenance
required to be tr red to b
+LAMALA
pri
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 67 of 1556.5.2
6.5.3 Medication Withhold Periods
The following medication withhold periods should be observed prior to scheduled spirometry
and AO at site:
!SABA and SAMA for at least 6 hours prior.
!Twice daily LABA or LAMA-containing therapies for at least 12 hours prior.
!Once daily LABA or LAMA-containing therapies for at least 24 hours prior.
If any of the restrictions are not met and th e spirometry s ssion cannot be sufficiently delayed 
on the day, it should be  rescheduled within the allowed visit window.
Spirometry assessments will also be performed at home daily (except on days when the 
participant is attending at site visits). Instructions regarding the participantâ€™s medication and home spirometry sequence are described in Section 8.1.3
6.5.4 Treatment of Exacerbations of COPD
In general exacerbations of COPD should be treated according to the judgment of the treating 
physician in line with local guidelines.
Both systemic corticosteroids and antibiotics used to treat a COPD exacerbation should not be 
used for more than 14 day  If treatment duration is expected to exceed 14 days, the medical monitor must be contacted  An increased dose of ICS may be used alongside OCS, however it 
should be returned to usual maintenance dose at resolution of the exacerbation.
Medications may be administered by nebulizer if required during the course of an 
exacerbations. Scheduled use of SABA/SAMA and oxygen supplementation is permitted during the course of an exacerbation.
6.5.5 Restricted and Prohibited Medications
The following medications are restricted from SV1 to the end of the follow-up period, unless 
clinically indicated, as determined by a physician:
!Acute systemic (oral or injectable) corticosteroids within 4 weeks of SV1 until the end of 
the follow-up period, except for treatment of acute exacerbations of COPD during the course of the study.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGometrytrys ssios ssi
allowed visit wined visit
rmed at home daild at home
structions regardinctions r
bed in Sectin Sec ion8.1
erbations of COations of
COPD should be tre D should b
 guidelinedeline s.s.
teroids and ant s and an ibio
4 day  If treatmenday  If treatmen
ntacted  An incre ed  An i
sual maintel m
PPDCCI
CCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 68 of 155!Macrolide therapy except for:
âˆ€ Chronic macrolide or other antibiotic therapy is allowed provided the participant has 
been on a stable dose/regimen for â‰¥ 3 months prior to enrolment and has had at least 
one COPD exacerbation while on stable therapy OR
âˆ€Acute use of macrolides to treat infections and exacerbations of COPD is permitted.
âˆ€Participants who received â‰¥ 6 months of macrolide treatment in the previous year 
must have a hearing assessment per local standard practice 3 months prior to enrolment or during the screening period; these participants must be interviewed for potential hearing issues/tinnitus at enrolment and any reported issues will be recorded as part of medical history.
!Long term oxygen therapy (continuous oxygen therapy for > 16 hours per day). 
The following medications are prohibited (for the time periods stated):
!Any immunosuppressive therapy (other than corticosteroids) within 3 months of 
randomization until the end of the follow-up period.
!Any immunotherapy within 3 months of randomization
!Interferon gamma within 3 months of randomization until the end of the follow-up period.
!Investigational products other than MEDI3506 within 4 months or 5 half-lives (whichever 
is longer) prior to randomization until the end of the follow-up period.
!Marketed biologics within 4 months or 5 half-lives (whichever is longer) prior to 
randomization until the end of the follow-up period.
!Immunoglobulin or blood products within 4 weeks of SV1 until the end of the follow-up 
period.
!Live or attenuated vaccines within 4 weeks of SV1 until the end of the follow-up period 
(Note: Vaccines with adenoviral vectors that are unable to replicate, eg, ChAdOx1, are 
not considered live or attenuated).
!Vaccination against COVID-19 (either first or subsequent dose) within 30 days before 
randomization or within 7 days be fore or after any dose of IP
!Antitussives medications commenced within 4 weeks prior to SV1 until the end of the 
follow-up period
!Mucolytic medications (eg. carbocysteine) commenced within 4 weeks prior to SV1 until 
the end of the follow-up period 
!Roflumilast (DaxasÂ®, DalirespÂ®) and other PDE4 inhibitors commenced within 3 months 
of randomization until the end of the follow-up period.'&3URWRFRO$PHQGPHQW_9970)_
r the time pe time p
ther than corticostthan cortic
follow-wup periup pe od.
months of rando hs of ran mi
onths of rando hs of rando miz
ther than MEDI35than MED
mizat tioion untuntil the l
ithiin 4 months or n 4 months
the end of the foend of the fo ll
or blor blood producood produc tst
d vaccines wicc
h adenovad
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 69 of 155Other than the permitted medications, use of concomitant medications or therapies from 
screening through to the early discontinuation visit/end of study is discouraged. Medications or therapies that are not prohibited and neither compromise participant safety nor affect studydata, as judged by the investigator, will be permitted.
6.5.6 COVID-19 Vaccination
If and when a participant receives a COVID-19 vaccination, the following information (if available) should be recorded in the participant notes:
!Brand name (or alternatively name of manufacturer)
!Date of administration
!Whether dose was first or second dose
!Dose
!Anatomical site/region of administration (eg, left deltoid)
!Lot number
Details for how this information should be entered into the eCRF will be provided in separate 
guidelines.
Any AEs suspected due to the vaccination should be captured in the AE form along with the 
causality assessment if r elated to COVID-19 vaccine.
6.6 Dose Modification
Not applicable.
7 DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL
7.1 Discontinuation of Study Intervention
The PI may determine it necessary on medical grounds for a participant to permanently 
discontinue (definitive discontinuation) study intervention. Note that discontinuation fromstudy intervention is NOT the same thing as withdrawal from the study.
If study intervention is permanently discontinued, the participant w ill remain in the study and 
attend all remaining intervention period and follow-up period visits.
See the SoA (Section 1.3) for data to be collected at the time of discontinuation of study
intervention and follow-up and for any further evaluations that need to be completed.
An individual participant will not receive any further study intervention if any of the 
following occur in the participant in question:'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG left deltoideft delto
entered into the eered into t
natioon shoul n shou d be c
COVIDVID--19 vaccin19 va
ationn
NTINUATIONNTINUATION
ICIPANT DISIPANT DIS
uation otio
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 70 of 1551 Withdrawal of consent to further treatment with study intervention.
2 Lost to follow-up.
3 Any anaphylactic reaction to study intervention requiring epinephrine administration.
4 Any treatment-emergent AE that is Grade â‰¥ 4 in severity (see Appendix B) .
5 Any treatment-emergent SAE that is in the cardiac disorders system organ class, except 
atrial arrhyth mias.
6 Confirmed diagnosis of new onset of heart failure during the study (except for transient 
heart failure secondary to atrial arrhythmia). F or a participant with suspected new onset of 
heart failure, the participant should not be administered study intervention unless and 
until the diagnosis is refuted. Study interve ntion should also be temporarily withheld 
during any episode of transient heart failure secondary to atrial arrhythmia.
7 Any other AE that, in the opinion of the investigator or the sponsor, warrants 
discontinuation of further dosing of study interv ntion.
8 Pregnancy.9 Following randomization, the par ticipant meets â‰¥1 of the exclusion criteria or fails to 
meet all of the inclusion criteria for study participation.
10 Any AECOPD with duration > 14 days.
11 The participant misses 2 consecutive doses.
7.2 Participant Withdrawal from the Study
!A participant may withdraw from the study at any time at his/her own request. This is 
expected to be uncommon.
!A participant who considers withdrawing from the study must be informed by the 
investigator about modified follow-up options (eg, telephone contact, a contact with a relative or treating physi ian, or information from medical records).
!At the time of withdrawal from the study, if possible, an E/D should be conducted, as 
shown in the SoA (Section 1.3). See SoA for data to be collected at the time of study
withdrawal and follow-up and for any further evaluations that need to be completed.
âˆ€The participant will discontinue the stud y intervention and be withdrawn from the 
study at that time.
!If the participant withdraws consent for disclosure of future information, the sponsor may
retain and continue to use any data collected before such a withdrawal of consent.
!If a participant withdraws from the study, it should be confirmed  if he/she still agrees for 
existing samples to be used in line with the original consent. If he/she requests withdrawal 
of consent for use of samples, destruction of any samples taken and not tested should be 
carried in line with what was stated in the informed consent and local regulation. The
investigator must document the decision on use of existing samples in the site study
records and inform th e Global St udy Team.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGrv ntiovn
t meetsets â‰¥â‰¥1 of the e1o ft
udypartipartiy cipaticipat on.
days.
utive doses.dose
hdrawal from tawal fr
draw fro from ththe studs
mon.
considers wit ders wit hdrawraw
t modified fot modified fo llollw
ing physi ian, or ig physi ian, or i
withdrawal fro raw m
Sectionctio 1
up
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 71 of 1557.3 Lost to Follow-up
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.
!The following actions must be taken if a participant fails to return to the clinic for a 
required study visit:
!The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study.
!Before a participant is deemed lost to follow up, the investigator or designee must make 
every effort to regain contact with the participant (where possible, 3 telephone calls and, 
if necessary, a certified letter to the participantâ€™s last known mailing address or local 
equivalent methods). These contact attempts shoul d be documented in the participantâ€™s 
medical record.
!Should the participant c ontinue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
!Site personnel, or an independent third party,  will attempt  to collect the vital status of the
participant within legal and ethical boundaries for all participants randomised, including 
those who did not get study intervention. Pub lic sources may be searched for vital status 
information. If vital status is determined as deceased, this will be documented and the 
participant will not be considered lost to follow-up. Sponsor personnel will not be 
involved in any attempts to collect vital status information.
Discontinuation of specific sites or of the study as a whole are handled as part of 
Appendix A9 .
8 STUDY ASSESSMENTS AND PROCEDURES
!Study procedures and their timing are summarized in the SoA (Section 1.3). Clinical 
study protocol waivers or ex emptions are not allowed.
!Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study intervention.
!Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
!All screening evaluations must be completed and reviewed to confirm that potential
participants meet all eligibility criteria. The i nvestigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.'&3URWRFRO$PHQGPHQW_9970)_
ou
chable, he/she w e, he/sh
d party ty, will, will attemal m
oundaries for all pdaries for a
entionn. Public sour. Publi
ermined as deceasined as
red lost to followlost to fol
collect vital status ct vital sta
sites or of the stud or of the s
ASSESSMENASSESSMEN
es and their tim d their 
vers or exes or
ns
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 72 of 1558.1 Efficacy Assessments
8.1.1 Clinic Spirometry
8.1.1.1 General Requirements
All spirometry is performed pre-dose.
Lung function (FEV 1and FVC) will be measured by spirometr y using equipment provided by 
a central vendor. Spirometry will be performed by the investigator or authorized delegate 
according to ATS/ERS guidelines (Miller et al 2005) .
The vendor providing central spirometry is responsible for assuring that the spirometer meets 
ATS/ERS recommendations and that the site personnel who will be performing the testing are properly certified. Spirometry calibration and data quality checks (including monitoring of unexpectedly high variability of results) will be detailed in a separate spirometry procedures 
manual and in the monitoring plan. Participants who exhibit unexpectedly high variability ofFEV
1will be evaluated by the investigator for etiology of variability, necessary follow-up 
actions, and assessment of continued participant eligibility. The investigator will discuss 
unexpectedly high variability with the AstraZeneca Study Physician.
Participants should observe the relevant medication withhold periods and other restrictions 
beforehand (see Section 5.3and Section 6.5.3)  If any of the restrictions are not met and the 
session cannot be sufficiently delayed on the day, the site visit and dosing should be 
rescheduled within the allowed visit window. All lung function measurements should take place prior to dosing, if dosing is also scheduled at the same visit.
Usual infection control measures should be followed including use of filters, per the 
instructions of the central vendor  Any additional infection control measures in accordance 
with COVID-19 related loc l and nati onal guidelines should also be followed.
Time of day for scheduled site visit spirometry
Spirometry testing should be performed at sp ecified visits according to the SoA (Section 1.3). 
Spirometry testing must be initiated in  the morning between 6:00 AM and 11:00 AM during 
the screening period and at the randomization visit (SV3). 
All post-randomization spirometry assessments should be performed within Â± 1.5 hours of the 
time that the randomization spirometry was performed. For example, if the randomization spirometry was started at 8:00 AM, then all subsequent spirometry testing needs to be initiated between 6:30 AM and 9:30 AM.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGailedail
who exhibito exhib
etiologygyoffyvvfariaba
pant eligibiliteligibilit y. Thy
raZeneca Studyneca Stud  Phy
nt medicatidicati on wion thii
tion6.5.36.5.3 ))If any  
ayed on the dayd on the da , th
visit window. Allt window
ng is also schedule also sched
measures should be ures should be
tral vendor  Any ndor  An ay
ted ld loc loc l and nat and natll ioio
duled site ved s
ep e
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 73 of 155Spirometry technique
Detailed procedure for performing spirometry will be described in an instruction manual. 
Details regarding assessment of the quality of spirometry and the Best Test Review process 
will also be detailed in the manual and Monitoring Plan. 
Spirometry references
The Global Lung Function Initiative equations will be used to determine the PNV and are pre-
programmed into the spirometer (Quanjer et al 2012) . 
Forced expiratory volume in 1 second expressed as percent of the PNV, will be calculated as 
follows:
FEV 1% of PNV = (FEV 1measured/FEV 1PNV) Ã— 100
8.1.1.2 Post-BD Spirometry
Post-BD spirometry will be performed at sp ecified visits as detailed in the SoA (Section 1.3).
Endpoint maximal BD will be induced using albuterol (90 Î¼g metered dose) or salbutamol 
(100Î¼g metered dose) with or without a spacer  device up to a max imum of 4 inhalations 
within 30 minutes Â± 15 minutes of the fin al pre-BD spirometry measurement. Post-BD 
spirometry will be performed 15 to 30 minute  later.
Order of administration for the COPD maintenance medication and study intervention
relative to the scheduled pre- and post-BD spirometry
The participantâ€™s usual COPD morning maintenance therapy must not be given until 
spirometry are complete in order to maintain th e integrity of planned efficacy analyses around 
lung function improvement. Study intervention dosing should also be withheld until pre-BD/post-BD spirometry is complete. 
Record keeping
A signed and dated copy of the pre- and post-BD printout must be kept at study centre for 
source data verification. The printout must be marked with the study code, enrolment code, date and time of measurement, visit number. If a printout cannot be printed, the mean value of the measurements will be recorded in the participantâ€™s charts.
8.1.2 Airwave Oscillometry
Airwave oscillo metry will be performed at specified visits as detailed in the SoA
(Section 1.3), using the endpoints of R5-R20, R5, R20, and AX. Airwave oscillometry is a 
non-invasive lung function test included in this study, which will be assessed using an AO 
device. It is assessed during quiet, tidal breathing with no participant effort required, by superimposing a multi-frequency oscillation onto the participantâ€™s natural breathing, to '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGfied visits as deta isits as d
ng albuterol buter (90(lÎ¼g
spacer device up tcer device 
final pre pre--BD spiBD roii
30 minute  later. inute  
e COPD maintenOPD ma
-and pos t d post --BD spBD
PD morning mainmorning m
in order to maintarder to mainta
ment . StudyStudy iiyyntnerv
rometmetryryiiyys cos compmplele
he
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 74 of 155evaluate study intervention effect on small airway  function. A centralized vendor will provide 
the equipment for testing.
A calibrated system will be used for measurements. Detailed procedures for equipment 
calibration, performance of measures, recording and analyzing AO data will be described in a separate manual provided to each site. Details regarding assessment of the quality of the AO 
process will also be detailed in the manual.
!All AO function measurements should take place prior to dosing, if dosing is also 
scheduled at the same visi t, and prior to spirometry.
!Participants should observe the medication wi thhold periods and lifestyle considerations 
stated in Section 6.5.3 and Section 5.3, respectively.
Note: If any of the above restriction are not met, the AO assessment should be rescheduled 
within the allowed visit window and should be conducted prior to spirometry.
8.1.3 Home Spirometry and eDiary
During the intervention period, participants w ill be required to monitor lung function at home 
using an at â€‘home spirometry device for daily recording of FEV 1and PEF. This will be done 
once daily in the morning, with the same  time window recommendation as the clinic 
spirometry; however, the time window is not compulsory (ie, all data will be used for 
analyses). Participants will be instructed t  perform all home spirometry assessments before 
use of their usual standard-of-care inhaled medication.
Further details will be provided in a separate instruction manual provided to each site.
Participants will be trained on at-home use of the eDiary at SV1. The site staff will set 
assessment reminder alarms on the device (morning and evening). Training will emphasize the 
importance of completi g the eDiary assessments as scheduled to capture the participantâ€™s experience and meet the objectives of the study. 
The investigator/authorized delegate will check participantâ€™s adherence to the eDiary 
assessment schedule and also emphasize the importance of transmitting data daily as is necessary, to minimize missing data, and at each study visit. 
Every morning participants will perform home spirometry and use the eDiary answer the 
following questions / questionnaires:
!Major COPD symptoms (dyspnea, sputum volume, and sputum color, see Appendix G)
âˆ€Participant-reported worsening of 1 or more major COPD symptoms will trigger 
assessment of minor COPD symptoms (sore throat, cold, fever without other cause, cough, and wheeze).'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGnducted ducted
y
ts will be required ll be requ
dailyyrecording of  recoryy
me time window rme wind
ow is not compulss not co
ructed t  perform ed t  perf
re inhaled mhaled m edica
ed in a separate inn a separat
d on at at-home use -home use
arms on the devic on the devic
eti g the eDiary ati g the eDiary a
et the object obje ives oiv
d deled
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 75 of 155!Nighttime awakening due to respiratory symptoms
!Maintenance medication adherence (not considering reliever usage).
Every evening participants will use the eDiary to answer the following questions / 
questionnaires:
!BCSS individual symptoms scores (cough, sputum, breathlessness, see Section 8.1.8.3)
!The ER-S:COPD (see Section 8.1.8.1)
!Cough VAS (see Section 8.1.8.2)
The eDiary will generate an alert to the participant and the investigational site if any of the 
following criteria are met:
!Worsening of 1 major COPD symptom and at least 1 other major or minor symptom for 
2 consecutive days.
!Fall in PEF by â‰¥30% from bas eline for 2 consecutive days
Baseline is defined as the average of 14 days prior to first dose of investigational product.
This alert should trigger a contact betwe n the participant and the investigational site. Alerts 
will only be received by site when eDiary upl oads/syncs, subject to connection availability, 
therefore participants may initiate contact with the investigator for assessment of possible 
AECOPD regardless of any prompts from the site, or the eDiary and spirometry.
The investigator then makes th  decision whether or not to initiate (or escalate, as appropriate) 
treatment for a COPD exacerbation. The investigator site is responsible for documenting the action taken for every alert, in the source notes and relevant eCRF modules, regardless who 
initiates contact (site or participant).
8.1.4 Objective Cough Monitoring
Objective cough frequency over 24 hours will be measured using an ACM (VitaloJAKâ„¢; Vitalograph, Buckinghamshire, UK), which will be fitted and worn by the participants for approximately 24 hours after the visits detailed in the SoA (Section 1.3). Set up of the cough 
monitors should be performed as th e final assessment at each visit.
The sites will receive training to ensure the ACM is correctly fi tted and activated by site staff, 
and the site staff will be given instructions to provide to the participants on how the ACM should be worn during the 24 hour period, to ensure data are recorded correctly. Advice '&3URWRFRO$PHQGPHQW_9970)_
$SSUR Gat least 1 othast 1 oth
2 consecutive day i
of 14 days prior to4 days pr
act betwe n the pabetwe n th
when eDiaryn eDiary uply o
initiiiiate contact wate contact w
any propromptmpts fros fromm
n makmakes th  decises th  decis
D exacerbat acerba ion
ert, i, in theiii
i
PPDCCI
CCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 76 of 155includes avoiding showers/bathing and any activity that will cause heavy perspiration whilst 
wearing the cough monitor, as the cough monitor must not come into contact with water (see Section 5.3.3) .
The digitally rec orded data recorded on the ACM will be sent to Vitalograph who will 
undertake cough counting for all participants using a standardized process. Details on the 
process to follow will be provided to the sites as part of the ACM training.
Detailed procedures for set up of device, recording and analyzing objective cough data will be 
described in a separate manual provided to each site. Details regarding assessment of the quality of objectiv e cough monitoring undertaken by the Vendor will also be detailed in the 
manual.
8.1.5 COPDCompEx
The COPDCompEx is a composite endpoint for exacerbations in COPD. The COPDCompEx 
combines exacerbations with events defined from participant e-Diaries and PEF. The 
definitions for both types of exacerbation are as follows:
!COPDCompEx defined exacerbations: episodes leading to one or more of the following: 
hospitalization, emergency room visit, treatment wi th OCS, or treatment with antibiotics. 
Note, this definition is not exactly the same as is used in Section 8.1.6.
!Diary events: defined by threshold and lope criteria using the following diary and home 
spirometry variables: overall symptom rating, nighttime awakenings due to symptoms, 
.
More details on the derivation and analy is of this variable will be given in the SAP.
8.1.6 COPD Exacerbations (AECOPD)
An AECOPD will be defined as a change in the subjectâ€™s usual COPD symptoms that lasts 
2 or more days, is beyond normal day-to-day variation, is acute in onset, and may warrant a 
change in regular medication. The change in symptoms must include at least one major COPD symptom and at least one other major or minor symptom from the list below:
!Major COPD symptoms: dyspnea, sput um volume, and sputum color 
!Minor COPD symptoms: cough, wheeze, sore throat, cold symptoms (rhinorrhea or nasal 
congestion), and fever without other cause.
These symptoms are captured by the eDiary (see Section 8.1.3) . If an AECOPD event is not 
associated with eDiary alert due to COPD symp toms (eg, technical issue with the eDiary), the 
investigator should interview the participant and evaluate potential worsening and duration of major and minor symptoms.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGexacerbaterbat ioin
ompartirticipant ecipan -D
e as ffololfffflolows:ws
ons: episodes leadi episode
visit, treatmt, treatm ent wien
tly the same as is uhe same
sholld and l d and l ope crop
all symptom ratingymptom r
..
ation and analy isn and analy is
Exacerbations (xacerbations (
defined as a ned
normno
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 77 of 155If symptoms are acute or have progressed rapidly and require treatment less than 2 days from 
onset of symptoms, the investigator will have to justify the decision for defining the event as an exacerbation and record it in the eCRF.
If a subjectâ€™s symptoms and the overall clinical findings support the diagnosis of a COPD 
exacerbation, but the subject has not experienced a worsening of at least one major COPD 
symptom and at least one other major or mi nor symptom (eg, rapid worsening leading to 
intubation), the investigator will have to just ify the decision for defining the event as an 
exacerbation and record it in the eCRF.
A clinical assessment of any potential exacerbation during the intervention and follow up 
periods will occur either at the next scheduled visit or, if necessary, an additional E/A visit 
prior to the next scheduled visit (see the SoA in Section 1.3).
8.1.6.1 Severity of AECOPD
An AECOPD will be classified as mild, moderate, or severe based on the following criteria.
An AECOPD will be considered severe if it results in:
!An inpatient COPD-related hospitalization (documentation stating that the subject was
hospitalized for the COPD exacerbation or a record of the subject being admitted for â‰¥24 hours to an observation area, the emergency department, or other equivalent 
healthcare facility depending on the c ountry and healthcare system).
!COPD-related death
An AECOPD that is not considered severe will be considered moderate if it results in:
!Use of systemic corticosteroids and/or antibiotics for at least 3 days; a single depot
injectable dose of cortic steroids will be considered equivalent to a 3-day course ofsystemic corticosteroids
Exacerbations that are neither considered moderate or severe will be considered mild.
8.1.6.2 Duration of AECOPD
The start and stop dates of COPD exacerbations will determined as follows:
The start and stop dates of mild AECOPD will be the onset and resolution of worsened 
symptoms respectively.
The start dates of moderate and severe AECOPD will be the earliest of:
!Start date of systemic corticosteroids for AECOPD
!Start date of antibiotics for AECOPD'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGte, or severe bar severe 
results in:lts in
lizatioion (documenn (do
rbatioon or a recordn or a re
ea, the emergencyhe emer
on the countrythe country any
onsidered severe wdered seve
orticosteroids andorticosteroids an
of cortic steroids cortic steroids 
osteroids oids
er c
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 78 of 155!Date of hospital admission due to AECOPD
The stop dates of moderate and severe AECOPD will be the latest of:
!End date of systemic corticosteroids for AECOPD
!End date of antibiotics for AECOPD
!Date of hospital discharge due to AECOPD
If less than 7 days have elapsed since the end date of an AECOPD and the start date of a new 
AECOPD, the second event will be considered a relapse of the prior AECOPD in the 
statist ical analysis.
8.1.6.3 COPD Exacerbation eCRF
The investigator should record all pertinent findings and symptoms associated with the 
exacerbation event and their duration in source documents and in the COPD exacerbation eCRF. In particular, the investigator should also note any changes in medications related to 
cardiovascular function at any AECOPD event to enable cardiac event evaluation in this eCRF module.
Associated symptoms of COPD are considered as symptoms of disease under study and will
not be recorded as AEs unless considered an SAE.
All COPD related SAEs will also be recorded on the SAE eCRF. 
8.1.7
8.1.8 Patient Reported Outcome Questionnaires
Electronic PRO questionnaires will be completed every day at home and at site visits (as 
specified in the SoA [Section 1.3]) using a hand-held device. Site personnel and participants 
will be provided training on the use of the device. For home use, the device will be programmed to automatically alert the participants when to fill out the ePROs. In addition, participants will bring their device to study vi sits, to use for collection of clinic ePROs, which 
should be completed as the first clinic assessment. The clinic ePROs will be filled out in this order: ER-S:COPD, cough VAS, BCSS,  SGRQ, CAT, and Study 
Participant Feedback Questionnaire. Detailed procedures for using the device will be 
described in a separate instruction manual provided to each site.'&3URWRFRO$PHQGPHQW_9970)_
SURYHGs and a
ocuments auments
o note any  an changchay
nt to enable cardiao enable ca
onsidered as sympt ered as s
dered an SAE.d an SA
o be recorded on recor
CCI CCI
PPDCCI
CCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 79 of 1558.1.8.1 Exacerbations of Chronic Pulmonary Disease Toolâ€“ Patient-reported 
Outcome (EXACT-PRO) and Evaluating Respiratory Symptoms in COPD 
(E-RSâ„¢:COPD)
The EXACT-PRO is a 14-item ePRO instrument developed to assess the frequency, severity 
and duration of COPD exacerbations (Jones et al 2011; Leidy et al 2011) . The instrument was 
developed for daily, at home, administration using a handheld electronic device. Respondents are instructed to complete the diary each evening just prior to bedtime and to answer the questions while considering their experiences â€œtodayâ€. The daily EXACT-PRO total score has 
a range of 0 to 100 with higher scores indicative of greater severity. Total score changes are 
used to identify the onset and recovery from  an EXACT-PRO defined exacerbation event. In 
identifying event onset and recovery, the EXACT-PRO can provide information on event frequency and duration as well as event severity.
The E-RSâ„¢:COPD is an 11-item ePRO developed to evaluate the severity of respiratory
symptoms of COPD (Leidy et al 2014a; Leidy et al 2014b) . The E-RSâ„¢:COPD is a subset of 
items from the EXACT-PRO. The E-RSâ„¢:COPD was designed to be captured as part of the daily EXACT-PRO assessment. Summation of E-RSâ„¢:COPD item responses produces a total 
score ranging from 0 to 40, with higher scores i ndicating greater severity. In addition to the 
total score, symptom domain scores can be calculated for breathlessness (5 items; score range: 0 to 17), cough and sputum (3 items; score range: 0 to 11) and chest symptoms (3 items; score range: 0 to 12) by summing the responses of items within a respective domain. As with the total score, higher domain scores indicate greater  severity. The EXACT-PRO will be captured 
daily each evening in this study via the eDiary.
8.1.8.2 Cough Visual Analogue Scale (Cough VAS)
Participants will be asked to complete a cough severity VAS (100 mm linear scale marked 
with a horizontal line by the participant , with 0 mm representing â€˜â€˜no coughâ€™â€™ and 100 mm 
representing â€œworst cough ) m asuring subjective assessment by the participant of the prior 
24 hrs for severity of cough symptoms (Smith et al 2006) . The cough VAS will be completed 
each evening in the eDiary.
8.1.8.3 Breathlessness, Cough and Sputum Scale (BCSSÂ©)
The BCSSÂ©, is a 3-item daily diary ( Leidy et al 2003)  that assesses the severity of the 
3 symptoms: breathlessness, sputum, and cough, each on a 5-point scale. Item scores can be reported as domains scores and are summed to yield a total score. Higher scores for each domain, and thus for total score, indicate more severe symptoms. The BCSS will be captured each evening via the eDiary.
8.1.8.4'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGo e
al 2014b2014b )
PD was designed as desig
of E-RSâ„¢:COPD RSâ„¢:CO
ores indicat indicat ing grein
be calculated for balculated 
score range: 0e range: 0 to1
ponses o s f fititemes wi
indicate greater secate greate
yvia the eDiarya the eDiay .
Analogue Scale (alogue Sca
d to complete a cocomplete a co
byythe participartici y pant,paniiii
cough ) m asurinugh ) m asurin
f cough symptough symf
ry.
CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 80 of 1558.1.8.5 St Georgeâ€™s Respiratory Questionnaire (SGRQ)
The SGRQ is a 50-item ePRO instrument de veloped to measure the health status of 
participants with airway obstruction diseases (Jones et al 1991) . The questionnaire is divided 
into 2 parts: Part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; Part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individualâ€™s respiratory condition. The SGRQ yields a total score and 3 domain scores (symptoms, activity, and impacts). The total score indicates the impact of disease on 
overall health status. This total score is expressed as a percentage of overall impairment, in 
which 100 represents the worst possible health status and 0 indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment. Based on empirical data and interviews with patients, a change of 4 units is associated with a minimum clinically important difference. Specific details on the scoring algorithms are provided by the developer in a user manual (Jones and Forde 2009) . The 
SGRQ will be completed using eDiary in accordance with the SoA (Section 1.3)and a 4 week 
recall version will be used.
8.1.8.6 COPD Assessment Test (CAT)
Participants will be asked to complete a CAT at SV1. The CAT is designed to measure the 
impact of COPD on a person's life ( Jones et al 2009) . The CAT consists of eight questions that 
ask the participant to rate items relating to symptoms and impact on quality of life (such as 
normal activity and sleep). Each question is performed on a scale from 0 to 5 with 0 being the 
best possible health status or least impairment and 5 being the worst health status or greatest 
impairment. The CAT will be performed at the baseline visit (SV1) only to enable 
sub-analyses based on baseline disease activity status via the eDiary, which will be further 
described in the SAP.
8.1.8.7'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGhe SGhe 
al score indscore in
sed as a percentag a percen
lth status and 0 indatus and 0
from 0 to 100, wim 0 to 100 ti
data and interviewa and in
lly important diffemportant d
eloper in a user mr in a us
eDiary ryiiyyn accordann accor
ment Test (CAT)nt Test (CAT
$SSed to complete a C complete a C
$Sa person's life (person's life ( JJonon$Sto rate items relatte items relat ii$leep). Each qu). Ea$or leaorCCI
CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 81 of 1558.1.8.8 Study Participant Feedback Questionnaire
This study will include as an option for part icipants to complete an anonymized questionnaire, 
â€˜Study Participant Feedback Questionnaireâ€™ for participants to provide feedback on their clinical trial experience. Individual participant level responses will not be reviewed by 
investigators. Responses will be used by AstraZeneca to understand where improvements can 
be made in the clinical trial process. This questionnaire does not collect data about the participantâ€™s disease, symptoms, study intervention effect or AEs and therefore would not be study data. The Study Participant Feedback Questionnaire will be captured electronically at time points indicated in the SoA (Section 1.3) and is subject to agreement in the ICF.
8.1.9 Chest CT
Where an inspiratory chest CT scan has been performed within 6 months of informed consent 
and can be obtained and is adequate for quantitative as essment it shall serve as the baseline 
scan. Otherwise, a CT scan will be performed, per Table 2,  to serve as the baseline scan.
In order to avoid unnecessary radiation exposure  a CT scan to serve as the baseline scan 
should only be performed if all of the following criteria are met.
!The participant has nothad an inspiratory chest CT scan within 6 months of informed 
consent, which can be obtained and is adequate for quantitative assessment, and
!The participant is believed to be eligible, at the time, according to all inclusion and 
exclusion criteria
Quantitative assessment for the extent of emphysema of the baseline scan will be performed, 
using procedures described in the Vendor manual provided to sites. 
All CT scans performed (or used) for the purposes of this study should be locally reviewed by 
a suitably qualified radiologist for clinical fi ndings outside of emphysema and morphometric 
assessment, to ensure any incidental clinically important findings are identified and referred/treated appropriately (eg, suspected cance r). (This local review may be performed 
remotely in accordance with local practices.) If a participant is found to have low-risk abnormalities (eg. nodules) that, according to local guidelines, only require surveillance where the first surveillance scan would be required after SV14 then that participant may be included '&3URWRFRO$PHQGPHQW_9970)_
SURYHGrformed withinmed with
itative as essmentve as essm
ed, perperTableTable 2,to
exposureosure  a CT sc a
follolowing criteriwing
an inspiratorynspiratory chey
ained and is adequd and is a
edto be eligible, o be eligCCI
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 82 of 155at the discretion of the investigator. Participants that require earlier surveillance scans or more 
active investigation must notbe randomized, per Exclusion Criterion 9(g).
New CT scans must be performed in a standardized way:All new CT scans should be performed post-BD, ie, within 60 minutes of using up to 
4 inhalations of albuterol or salbutamol. When these are undertaken at the same visit as 
spirometry and small airway measurements, CT should be performed after these assessments, 
so as not to confound the BD withhold periods. If BD is performed as part of the spirometryassessments, this should be repeated if the BD occurred in excess of 60 minutes prior to the CT scan.
A radiology manual, as well as further training by the imaging vendor, will describe both the 
process of obtaining new scans and how to submit scans (historical and new) to the imaging vendor. An optimized CT protocol will also be provided to the sites that includes all required scan parameters.
Any clinical findings from historical CT should be recorded on the specific imaging eCRF 
page for SV1. Any findings based on the local assessment of a new CT scan performed during screening/run-in must be recorded in the corr sponding eCRF section for SV3.
All CT images submitted to the imaging vendor must first be de-identified at the site to 
remove any participant identifiers. No clinical interpretation of the CT scans will be 
performed by the central imaging vendor.
8.1.9.1'&3URWRFRO$PHQGPHQW_9970)_
SURYHGovided tovided
uld be recorded obe recor
local aalssessment ossessme
e corr sponding err spon
aging vendor must vendor
s. No clinicao clinica l lintier
ing vendor.vendor.
CCI
CCI
CCI
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 83 of 1558.1.10
8.2 Safety Assessments
Planned time points for all safety assessments are provided in the SoA (Section 1.3).
8.2.1 Medical, Surgical, and COPD History
Complete medical a nd surgical history will include history of COVID-19 and COVID-19 
vaccination if applicable, prior and current, medical conditions, past or present cardiovascular disorders, respiratory, gastrointestinal, renal, hepatic, neurological, endocrine, lymphatic, hematologic, imm unologic, psychiatric, genit urinary, drug and surgical history, or any other 
diseases, disorders, or surgical procedures
The participantâ€™s COPD history will also be collected including questions related to the 
participantâ€™s COPD history, durati n of C OPD, and COPD medications (both past and 
current).
8.2.2 Physical Examinations, Weight and Height
!Complete and brief physical examinations will be performed by a licensed HCP 
(eg, physician, physicianâ€™s assistant, or licensed nurse practitioner). A complete physical 
examination will include, but will not be limited to, assessment of general appearance, 
head, ears, eyes, nose, throat, neck, skin, as well as cardiovascular, respiratory, 
abdominal, and nervous systems. 
!A brief physical examination will include, at a minimum, assessments of cardiovascular, 
respiratory, and nervous systems. Each clinically significant abnormal finding will be recorded in the medical history, and each treatment emergent abnormality, including 
injection site reactions identified by assessing SC injection sites, will be recorded as an 
AE.
!Physical examinations, weight and height will be recorded at timepoints specified in the 
SoA (Section 1.3).'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGrovidrov
History ry
include historyude histo ofy
nt, medical conditmedical con
renal, hepatic, neul, hepati
ric, genit urinarygenit u
ocedures ures
rywillilly  also be colalso bell
, duratiatin ofn of COPDCff
l ExaExaminations,minations,
ief physical exhysif
icianâ€™s aan
ebCCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 84 of 1558.2.3 Vital Signs
The nominal timing of vital signs is described in the SoA (Section 1.3). The participant should 
be in a resting supine position for at least 10 minutes prior to the collection of vital signs, as 
follows: 
!Oral or tympanic temperature
!DBP
!SBP
!Heart (pulse) rate
!Respiratory rate
For the first 2 doses of study intervention, pa rticipants are to remain at the site for â‰¥2 hours or 
until stable, whichever is later. In addition, vital signs will be taken before and immediately after administration of study intervention, and at 30, 60, and 120 minutes (Â± 5 minutes) thereafter or until stable, whichever is later. For the subsequent doses of study intervention, 
participants are to remain at the site for â‰¥ 1 hour or until stable, whichever is later. In addition,
vital signs will be taken before and immediately after administration of study intervention, and at 30 and 60 minutes (Â± 5 minutes) thereafter  Following the observation period, participant discharge will be at the discretion of the investigator.
8.2.4 Electroca rdiograms
Electrocardiograms will be performed t timelines as specified in the SoA (Section 1.3) and 
prior to vital signs, and blood sampling. El ectrocardiograms will be done as a single 
measurement. 
The nominal timing of ECGs is described in the SoA (Section 1.3). The ECG assessment 
should be performed before interventions wi th the participant (eg, spirometry and 
administration of the COPD related medications and study intervention). The participant should be in a resting supine position for at least 10 minutes prior to the collection of ECGs. At baseline, pre-dose of study intervention at SV3 (Day 1), triplicate ECGs will be performed 
(all 3 ECGs within a 5-minute time period, at least 1 minute apart). The mean value of each parameter from the triplicate will be used as th e baseline value. Electrocardiograms taken at 
all other times will be single assessments. 
Electrocardiograms will be recorded with 12-lead digital ECG devices at a speed of 
25 mm/second with amplitude recording of 10 mm/mV. Where possible the same make and model ECG device should be us ed for recording all ECGs for a particular participant. At least 
3 full complexes must be recorded. Date and time settings should be checked regularly and following time changes for daylight savings time. Skin preparation should be thorough and electrode positions should be according to standard 12-lead ECG placements.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGns wns w
30, 60, and 60, and 
or the subsequent ubseque
hour or until stable or until st
diately after admin ly after ad
eafter  Following ter  Follo
the investnvest igator . igato
ms
erformed t timelirmed t tim
od sampling. Elampling. ec
of ECGs is describf ECGs is describ
d before intervenfore inte
OPD relateD r
ep o
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 85 of 155Electrocardiogram device software will be used to assess ECG parameters. All ECGs must be 
reviewed by the PI or a qualified designee before the participant is permitted to leave the clinic. Abnormalities and obvious changes in ECG parameters from baseline will be assessed by the principal investigator for clinical significance.
Electrocardiogram variables will be collected, as follows:
!Heart (pulse) rate
!RR interval
!QRS interval
!PR interval
!QT interval
8.2.5 Echocardiogram
A transthoracic echocardiogram to assess LVEF will be performed and reported locally (see 
the SoA in Section 1.3).
It should be performed using local guidelines and standards. All echocardiograms must assess 
left ventricular end-diastolic and end-systolic volumes, and LVEF by 2D examination. An accepted, objective quantitative method must be used to calculate LVEF (eg, the modified biplane Simpsonâ€™s rule). For each participant, the same quantitative method used to assess LVEF at their first echocardiogram undertaken, during the screening period, must be applied to all subsequent assessments of LVEF.
Routine examination beyond left ventricular end-diastolic and end-systolic volumes, and 
LVEF is not required unless clini ally indicated. However, a standard 2D echocardiogram must be performed in any parti ipant with an abnormal LVEF (< 40%), in order to identify 
potential causes of depressed left ventricular function.
8.2.6 Clinical Safety Laboratory Assessments
The nominal timing of blood draws is described in the SoA (Section 1.3). A Laboratory
Manual will be provided to the sites that specifies the procedures for collection, processing, storage, and shipment of samples, as well as laboratory contact information, specific to this clinical research study. Clinical laboratory safety tests will be performed in a central clinical laboratory with the exception of the SARS-CoV-2 nucleic acid test which may be performed 
either locally (according to local standards) or centrally. Urine pregnancy tests may be 
performed at the site using a licensed test (dips tick). Clinically significant abnormal laboratory
results should be repeated as soon as possible (preferably within 24 to 48 hours).'&3URWRFRO$PHQGPHQW_9970)_
EF will be perform ill be perf
elines and standardes and s
systolic volumes, olic volum
thod must be used must be
h participant, the srticipant, t
gram undertaken, m undertak
ts of LVEF. LVEF.
yond llefet ventriventriff culcul
unless clini ally inunless clini ally 
in anyanypartipartiy ipantipant
epressed lssed eft vff
L
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 86 of 155The following laboratory variables will be measured (Table 8) . For haematology, see blinding 
procedures for eosinophil, basophil, and monocyte data in Section 6.3.
Table 8 Laboratory Safety Variables
Haematology/haemostasis (whole blooda) Clinical chemistry (serum)
B-Haemoglobin (Hb) S-Creatinine
B-Leukocyte count S-Bilirubin, total
B-Leukocyte differential count (absolute count) S-Alkaline phosphatase (ALP)
B-Platelet count S-AST
B-Haematocrit S-ALT
B-Red blood cell count (RBC) S-Albumin
Urinalysis S-Potassium
U-Appearance and Color S-Sodium
U-Specific gravity S-Gamma-glutamyl transferase (GGT)
U-Hb/Erythrocytes/Blood S-Blood urea nitrogen
U-Glucose S-Total Protein
U-Ketones S-Hb1Ac
U-pH S-NT-ProBNP
U-Bilirubin S-Tryptase (only to be taken in event of suspected 
anaphylaxis see Appendix I)
U-Leukocytes
U-Protein Fibrinogen (plasma)
Microscopy including white blood cell/RBC and casts 
Pregnancy test (dipstick- urine hu an chorionic 
gonadotropin) as per SoA; NOTE: addi ional timepoint 
for female participants of CT sub s dy
Coagulation
Endocrinology
Serum FSH b
aWhole blood samples will be collected concurrently for both haematology 
.
bIf needed to confirm post-menopausal status in female participants aged < 50 years.
Note for serum chemistry: Tests for AST, ALT, ALP and S-bilirubin must be conducted concurrently and assessed concurrently.ALP = Alkaline phosphatase; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; B = Blood; 
 FSH = Follicle stimulating hormone; GGT = Gamma-glutamyl transferase; 
Hb = Haemoglobin; HbA1c = Hemoglobin A1c; NT-ProBNP = N-terminal pro-brain natriuretic peptide; RBC = Red blood cells; S = Serum; SoA = Schedule of activities; U = Urine.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG--SodS
S-GammaGamma -glgGGS-Blood urea niBlood ureGGGHGS-S-Total ProtetaHGHGHGYHGS-SHb1AcHbYHYHYHYHS-SNT-PYYYYS-T
anRYYYYURSUlood cell/RBC and ca cell/RBC and cS
ine hu an ua n chohorionic ic ooo
A; NOTE: addi ional tA; NOTE: addi ional
s of CT subCT sub sdysd ySS$$CCI
CCICCI
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 87 of 155Note: In case a participant shows an AST orALT â‰¥3 Ã— ULN together with TBL â‰¥2 Ã— ULN 
please refer to Appendix E â€˜Actions required in cases of increases in liver biochemistry and 
evaluation of HLâ€™, for further instructions. 
Pregnancy Test
!Serum beta-human chorionic gonadotropin
!Urine human chorionic gonadotropin
Other Safety Tests
!HbA1c
!Hepatitis B (HBsAg, anti-HBs, and anti-HBc) and C antibodies
!HIV-1 and HIV-2 antibodies
!IGRA (TB test)
!Serum tryptase will only be taken in the event of suspected anaphylaxis (Appendix I)
!SARS-CoV-2 (serology and nucleic acid test)
It is recognised that frequent routine testing of asymptomatic participants for SARS-CoV-2 at 
visits SV3 onwards may be unnecessary and not  actually contribute to participant safety. In 
regions where there is no community spread  of covid infection (sporadic/imported cases or 
outbreaks only) and is expected to remain as  such, the medical monitor, at the request of the 
PI of a site, may authorise a less demanding schedule of SARS-CoV-2 nucleic acid testing from SV3 onwards at that site. This authorisation may be ended by the medical monitor, at any time, should the local epidemi logy change (or be expected to change).
8.3 Adverse Events and Serious Adverse Events
The PI is responsible for ensuring that all staff involved in the study are familiar with the 
content of this section
The definitions of an AE or SAE can be found in Appendix B.
Adverse events will be reported by the pa rticipant (or, when appropriate, by a caregiver, 
surrogate, or the participant's legally authorised representative). 
The investigator and any designees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE.
8.3.1 Time Period and Frequency for Collecting AE and SAE Information
Adverse events and SAEs will be collected by the investigator from informed consent throughout the intervention period and including the follow-up period.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGnt of suspectef suspect
test)
ng of asymptomatf asymptom
y and not actuallyd not ac
yspread of covid inead of 
remain as such, thain as suc
demanding scheanding sc d
. This authorisatis authoris io
pidemimilologygy chan yy
Events and Sernts and Ser
e for ensuring thatfor ensuring that
on
SAE
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 88 of 155If the investigator becomes aware of an SAE with a suspected causal relationship to the IMP 
that occurs after the end of the clinical study in a participant treated by him or her, the investigator shall, without undue delay, report the SAE to the sponsor.
8.3.2 Follow-up of AEs and SAEs
Any AEs that are unresolved at the participantâ€™s last AE assessment in the study are followed up by the investigator for as long as medically indicated, but without further recording in the eCRF. AstraZeneca retains the right to request a dditional information for any participant with
ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.
Adverse event variables
The following variables will be collected for each AE:
!AE (verbatim)
!The date and time when the AE started and stopped
!Severity grade 
!Whether the AE is serious or not
!Investigator causality rating against the study intervention (yes or no)
!Action taken with regard to the study intervention
!AE caused participantâ€™s withdrawal from study (yes or no)
!Outcome
In addition, the following vari ables will be collected for SAEs:
!Date AE met criteria for serious AE
!Date investigator be ame aware of serious AE
!AE is serious due to
!Date of hospitalisation
!Date of discharge
!Probable cause of death
!Date of death
!Autopsy performed
!Causality assessment in relation to Study procedure(s)
!Causality assessment to other medication'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGstopped e
the studystudy iiyynterven
udyiiyntnterventerv ioin
awal frol from studystu (yy
ariables will be coles will b
a for seriseriff ous AEous A
r be ame aware of be ame aware of
ue to
ion
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 89 of 1558.3.3 Causality Collection
The investigator should assess causal relationship between study intervention and each AE, 
and answer â€˜yesâ€™ or â€˜noâ€™ to the question â€˜Do you consider that there is a reasonable possibility 
that the event may have been caused by the study intervention?â€™
For SAEs, causal relationship should also be assessed for other medication and study
procedures. Note that for SAEs that could be associated with any study procedure the causal relationship is implied as â€˜yesâ€™.
For COVID-related events, the investigator should add â€˜COVIDâ€™ as part of the verbatim term.
A guide to the interpretation of the causality question is found in Appendix B.
8.3.4 Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by the participant or reported in response to the open question 
from the study site staff: â€˜Have you had any health probl ms since the previous visit/you were 
last asked?â€™ or revealed by observation will be collected and recorded in the eCRF. When collecting AEs, the recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately.
8.3.5 Adverse Events Based on Examinations and Tests
The results from the CSP-mandat d la oratory tes ts and vital signs will be summarized in the 
CSR. 
Deterioration as compared to baseline in CSP- mandated laboratory values, spirometry values 
and vital signs s hould therefore only be reported as AEs if:
!They fulfil any of the SAE criteria, or
!Are the reason for discontinuation of tr eatment with the study  intervention, or
!Are considered to be clinically relevant as judged by the investigator (which may include 
but not limited to consideration as to whether treatment or non-planned visits were 
required or other action was taken with the study intervention, eg, dose adjustment or 
study intervention interruption).
If deterioration in a laboratory value/vital sign is associated with clin ical signs and symptoms, 
the sign or symptom will be reported as an AE  and the associated laboratory result/vital sign 
will be considered as additional information. Wherever possible the reporting investigator uses the clinical, rather than the laboratory term (eg, anaemia versus low haemoglobin value). '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGd Syd S
ant or reported in reported
healthhll probl probl ms sinm
be collected and collected
es is preferred (wh preferred 
agnosis is known a is is kno
gnosis, t is, the diagnohe d
Based on Examsed on E
mandat d la oratndat d la ora
mpared to baselinered to baselinemm
d therefore onl refo
E
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 90 of 155In the absence of clinical signs or symptoms, clinically relevant deteriorations in 
non-mandated parameters should be reported as AE(s).
Any new or aggravated clinically relevant abnormal medical finding at a physical examination 
as compared with the baseline assessment will be reported as an AE unless unequivocally related to the disease under study.
8.3.6 Adverse Events of Special Interest
Adverse events of special interest are events of scientific and medical interest specific to understanding of MEDI3506 and may require close monitoring and rapid communication by the investigator to AstraZeneca. An AESI may be serious or non-serious. The rapid reporting of AESIs allows ongoing surveillance of these events in order to characterize and understand them in association with the use of MEDI3506.
The following AESIs will be particu larly monitored in this study:
!Hepatic function abnormality meeting the definition of HL as described in Section 8.3.7.
!Serious hypersensitivity (including Type 1 to 4 hypersensitivity reactions), for example 
anaphylaxis and severe allergic reactions  and immune complex disease.
!Injection site reactions.
!Cardiac events (including angina or myocardial infarction, congestive heart failure, 
symptomatic atherosclerotic vascular disease, cor pulmonale, or arrhythmia).
!Serious infections (including opportunistic infections and viral reactivations), for example 
herpes simplex virus/varicell  zoster virus, Epstein Barr virus/cytomegalovirus, TB, and 
all other opportunistic infections listed in the Guidelines for the Prevention and Treatment 
of Opportunist ic Infections in HIV Infected Adults and Adolescents: Reco mmendations 
from the Centers for Disease Control and Prevention, the National Institutes of Health, 
and the HIV Medicine A ociation of the Infectious Diseases Society of America 
(NIH 2019) .
!Gastrointestinal AEs
!Malignancy
8.3.7 Hyâ€™s Law
Cases where a participant shows elevations in liver biochemistry may require further 
evaluation and occurrences of AST or ALT â‰¥ 3 Ã— ULN together with TBL â‰¥2 Ã— ULN may 
need to be reported as SAEs. Please refer to Appendix E for further instruction on cases of 
increases in liver biochemistry and evaluation of HL.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGred in this stin this st
he definit finitioon of HLno
ype 1 to 4 hyperse1 to 4 hypyy
ctions  and immunns  and 
ina or myor my ocardialar l
vascular disease, cular disea
ing opportunistopportunis ic 
aricell  zoster virus l  zoster
c infectectioionsns listed ilisted
fectioonsns in HIV InHIV In
for Disease Contro ase Co
edicine A ociatcine A ociat ioio
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 91 of 1558.3.8 Disease-Under Study
Symptoms of disease under study are those which might be expected to occur as a direct result 
of COPD. Events which are unequivocally due to disease under study should not be reported 
as an AE during the study unless they meet SAE cr iteria or lead to discontinuation of the study
intervention. 
Acute exacerbations of COPD should be reported as AEs.
8.3.9 Reporting of Serious Adverse Events
All SAEs have to be reported, whether or not considered causally related to the study
intervention, or to the study procedure(s). All SAEs will be recorded in the eCRF.
If any SAE occurs in the course of the study, then investigators or other site personnel inform 
the appropriate AstraZeneca representatives within one day, ie, immediately but no later than 
24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the investigator to ensure that all the 
necessary information is provided to the AstraZeneca Patient Safety data entry site within 
1 calendar day of initial receipt for fatal and life threatening events and within 5 calendar
days of initial receipt for all other SAEs.
For fatal or life-threatening AEs where important or relevant information is missing, active 
follow-up is undertaken immediately. Investigators or other site personnel inform AstraZeneca representatives of any follow-up information on a previously reported SAE within 1 calendar 
day ie, immediately but no later than 24 hours of when he or she becomes aware of it.
For further guidance on the definiti n of an SAE, see Appendix B of the CSP.
The reference document for definition of expectedness/listedness is the IB for MEDI3506.
8.3.10 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to AstraZeneca except if the 
pregnancy is discovered before the study participant has received any study intervention.
8.3.10.1 Maternal Exposure
If a participant becomes pregnant during the course of the study, study intervention should be 
discontinued immediately.
Pregnancy itself is not regarded as an AE unless there is a suspicion that the study intervention 
may have interfered with the effectiveness of a contraceptive medication. Congenital anomalies/birth defects and spontaneous miscarriages should be reported and handled as '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGnvenv
in one dayone da ,
t.
works with the inrks with t
AstraZeneca PatieraZeneca P
tal and lifend life ththreatehh
AEs.
s where important re im
ediately ely. Invest . Inves iga
w-up infor m inform ataion 
no later than 24 hater than 24 h
on the definitn the definit iin on 
ent for definitfor d
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 92 of 155SAEs. Elective abortions without complications should not be handled as AEs. The outcome 
of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth or congenital anomaly) should be followe d up and documented even if the participant 
was discontinued from the study.
If any pregnancy occurs in the course of the study, then the investigator or other site personnel 
informs the appropriate AstraZeneca representatives within 1 day ie, immediately but no later 
than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the investigator to ensure that all 
relevant information is provided to the AstraZeneca Patient Safety data entry site within 1 or 5 calendar days for SAEs (see Section 8.3.10)  and within 30 days for all other pregnancies.
The same timelines apply when outcome information is available.The PREGREP module in the eCRF is used to report the pregnancy.
8.3.10.2 Paternal Exposure 
Male participants should refrain from fathering a child or donating sperm during the study and 
for 12 weeks after the last administration of study intervention.
Pregnancy of the participantâ€™s partners is not considered to be an AE. However, the outcome 
of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth or congenital anomaly), occurring from the date of the first dose until the end of follow-up should, if possible, be followed up and documented in the Pregnancy Report Form. 
Consent from the partner must be obtained be fore the Pregnancy Report Form is completed.
8.3.11 Medication Error
If a medication error occurs in the course of the study, then the investigator or other site 
personnel informs the appropriate AstraZeneca representatives within 1 day ie, immediately but no later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the investigator to ensure that all 
relevant information is completed within  1 (Initial Fatal/Life-T hreatening or follow up 
Fatal/Life-Threatening) or 5 (other serious initial and follow up) calendar days if there is an SAE associated with the medication error (see Section 8.3.1)  and within 30 days for all other 
medication errors.
The definition of a Medication Error can be found in Appendix B.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGeport the preg the preg
ering a child or dog a child o
n of study intervenstudy i
ners is not consider s not co
miscarriage, elect arriage, ele iv
ccurring frorring fro m mthe
, be fofollolwed up awed u
must be obtained bt be obtainedmm
on Error or
or occurs in the co curs in th
appropriaterop
fw h
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 93 of 1558.4 Overdose
An overdose is defined as a participant receiving a dose of study intervention in excess of that 
specified in the IB, unless otherwise specified in this CSP.
!An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE modules in the eCRF and on the Overdose eCRF module.
!An overdose without associated symptoms is only reported on the Overdose eCRF 
module
If an overdose on an AstraZeneca study intervention occurs in the course of the study, the 
investigator or other site personnel inform appropriate AstraZeneca representatives immediately, but no later than 24 hours of when he or she becomes aware of it.
The designated AstraZeneca representative works with the investigator to ensure that all 
relevant information is provided to the AstraZen eca Pa ient Safety data entry site within 1 or 
5 calendar days for overdoses associated with an SAE (see Section 8.3.9)  and within 30 days 
for all other overdoses.
The designated sponsor representative works with the investigator to ensure that all relevant 
information is provided to the sponsor's Patient Safety data entry site.
8.5 Human Biological Samples
Instructions for the collection and handling of biological samples will be provided in the studyspecific laboratory manual. Samples should be stored in a secure storage space with adequate measures to protect confidentiality. For further details on Handling of Human Biological Sample see Appendix C.
Samples will be stored for a m ximum of 15 year s from the date of the issue of the CSR in 
line with consent and local requirements, after which they will be destroyed/repatriated. 
!PK samples will be disposed of after the Bioanalytical Report finalization or 6 months 
after issuance of the draft Bioanalytical Report (whichever is earlier), unless consented for future analyses. 
âˆ€PK samples may be disposed of or anonymised by pooling.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGwith with
eca Paa Pa ientien
an SAE (see Secti E (see S
works with the inve s with the i
's Patient Safettient Safe y d
l Samplesamples
and handling of biohandling o
Samples shoulples shoulmm d be
dentiaalitlity.y. FFor for furthff
.
red for a mfor a m ximumximum
d local requirem al 
os
CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 94 of 1558.5.1 Pharmacokinetics
Serum samples will be collected for measurement of serum concentrations of MEDI3506 as 
specified in the SoA (Section 1.3).
Samples may be collected at additional time poi nts during the study if warranted and agreed 
upon between the investigator and the sponsor eg, for safety reasons. The timing of sampling may be altered during the course of the study based on newly available data (eg, to obtain data closer to the time of peak or trough matrix concentrations) to ensure appropriate monitoring. 
Serum samples will be used to analyse th e PK of MEDI3506. Samples collected for analyses 
of MEDI3506 serum concentration may also be used to evaluate safety or efficacy aspects 
related to concerns arising during or after the study. Samples from participants who received placebo may be analysed at minimum selected time points to confirm no dosing with MEDI3506 took place.
Samples will be collected, labelled, stored, and shipped as detailed in the Laboratory Manual.
8.5.1.1 Determination of Study Intervention Concentration
Samples for determination of study intervention concentration in serum will be assayed by 
bioanalytical test sites operated by or on behalf of AstraZeneca, using an appropriatelyvalidated bioanalytical method. Full details of the analytical method used will be described in 
a separate bioanalytical report.
Study intervention concentration information th at may unblind the study will not be reported 
to investigative sites or blinded personnel until the study has been unblinded.
Incurred sample reproducibility analysis, if any, w ill be performed alongside the bioanalysis 
of the test samples. The results from the evaluation, if performed, will be reported in a separate Bioanalytical Report.
8.5.2 Immunogenicity Assessments
Blood samples for determination of ADA in serum will be assayed by bioanalytical test sites 
operated by, or on behalf of, AstraZeneca, using an appropriately validated bioanalyticalmethod. Tiered analyses will be performed to include screening, confirmatory, and titer assaycomponents. Full details of the methods used will be described in a separate report.
Anti-drug antibody samples may also be further tested for characterization of the ADA 
response, including possible assessment of neutralising antibody. No ADA samples will be collected after follow up period, ex cept if considered necessary by the sponsor in the event of 
a potentially relevant adverse event in an individual patient.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGSa
me points point
and shipped as det hipped 
nterventionvention Conc
ntervention concenvention
or on behalf on behalf fAs
Full details of the details of l
t.
tration informaton informa ioi
blinded personnelded personnel
producibilitucibilit y analyy analy
The results from esult
port.or
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 95 of 155Samples will be collected, labelled, stored, and shipped as detailed in the Laboratory Manual.
8.5.3 Pharmacodynamics
There are no established PD measures for MEDI3506. 
8.6
8.6.1
8.6.1.1
8.6.1.2
8.6.1.3'&3URWRFRO$PHQGPHQW_9970)_
Y CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCICCI
CCI
CCICCI
PPDCCI
CCI
CCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 96 of 1558.6.1.4 Collection of Samples
For storage, re-use and destruction of PD samples see Section 8.5andAppendix C.
8.6.2
8.7
8.8 Medical Resource Utilization and Health Economics
Not applicable.
8.9 Impact of COVID-19 Pandemic
To assess the impact of the COVID-19 pandemic on th e study, sites will be asked to complete 
the pandemic impact questions in the eCRF at each study visit, according to the SoA (Section 1.3).'&3URWRFRO$PHQGPHQW_9970)_
GCCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 97 of 1559 STATISTICAL CONSIDERATIONS
9.1 Statistical Hypotheses
The primary efficacy endpoint is th e Change from Baseline in pre-BD FEV 1at Week 12. A 
treatment policy estimand will be applied wh ereby all available data are included in the 
analysis, irrespective of whether a participant remains on study intervention or not.  
The null hypothesis is that the change from baseline in FEV 1at Week 12 on MEDI3506 is 
equal to the change from baseline in FEV 1at Week 12 on placebo. The alternative hypothesis 
is that the change from baseline in FEV 1at Week 12 on MEDI3506 is greater than the change 
from baseline in FEV 1at Week 12 on placebo, ie:
H0: Change from Baseline in FEV 1at Week 12 (MEDI3506-placebo) = 0.
H1: Change from Baseline in FEV 1at Week 12 (MEDI3506-placebo) > 0. 
Hypothesis testing will be performed at the one-sid ed 10% level. If the p-value is < 0.1, reject 
H0and accept H 1.
The primary analysis will act as a gate-keeper for hypothesis testing of secondary endpoints. 
Should the primary analysis hypothesis H 0be rejected, then multiplicity will be controlled for 
a subset of key secondary endpoints using Hochberg procedure. Details will be described in the SAP. 
9.2 Sample Size Determination
A sample size of 140 participants (70 participants per arm) will provide 80% power to detect a difference in mean change from baseline in FEV
1at Week 12 of 90 mL (assumed standard 
deviation of 250 mL) between the two randomized groups at a one-sided 10% level of statist ical signif icance. To allow for 2% of participants being ineligible for the primary
analysis, approximately 144 participants will be randomized in the study (72 per arm).'&3URWRFRO$PHQGPHQW_9970)_
MEDI350EDI35
ne-sided 10 % l ded 10% l evel
keeper for hypotheper for h
sis HH00be rejected, be r
ts usinging Hochberg Hoch
Determinationerminati
ticipants (70 particants (70 parti
nge from baseline om baseline
) between the twobetween the two
nce. To allow for To allow
144 partic44 p
CCICCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 98 of 1559.3 Populations for Analyses
The following populations are defined:
Table 9 Populations for Analysis
Population Description
ITT population Participants who are randomized and receive any study intervention. Participants 
will be analyzed according to their randomized study intervention group.
As-treated population Participants who are randomized and receive any study intervention. Participants 
will be analyzed according to the study intervention they actually receive.
PK population Participants who received at least one dose of MEDI3506 and had at least one 
detectable serum concentration measurement post first dose of study intervention. Participants will be analyzed according to the study intervention they actually receive.
ITT = Intention-to-treat; PK = Pharmacokinetics.
The ITT population will be used to summari ze all demographic and baseline characteristics, 
concomitant medications, and efficacy measures. The As-treated population will be used to summarize all safety measures (AEs, laboratory tests, ECG, and vital signs). The PK population will be  used to summarize PK measures.
9.4 Statistical Analyses
All personnel involved with the analysis of  the study will remain blinded until primary 
database lock and CSP deviations dentified. Analyses will be performed by AstraZeneca or its representatives. A comprehensive SAP will be developed and finalized before database 
lock and will describe the part cipant populations to be included in the analyses, and 
procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyse s of the primary and secondary endpoints. Any deviations 
from this plan will be reported in the CSR.
9.4.1 General Considerations
Efficacy analyses will be performed using the ITT population.
The primary estimand is a â€˜Treatment Policyâ€™ estimand, as follows: The difference in mean 
change from baseline in FEV 1at Week 12 (MEDI3506 â€“ placebo) will be estimated using a 
repeated measures mixed effects analysis of covariance model, for the ITT population. This will include all available data from all visits up to and including Week 12, irrespective of whether the participant discontinued study intervention or received reliever therapy.
Demography and baseline characteristics will be summarized by study intervention group for 
the ITT population.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGe all deml dem ographicograp
asures. The Ases. The A -tre
boratory orytests, ECGtests, y
PK measures.measures
es
e analysis oalysis o f f thte st
tionss dentdentified. Aifie
prehensive SAP whensive SAP 
he part cipant popu rt cipant popu
nting for missing, ting for missing,
stical analyses of al analyses of 
reported in thorted
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 99 of 1559.4.2 Efficacy 
9.4.2.1 Primary Endpoints
The difference in mean change from baseline in FEV 1at Week 12 (MEDI3506â€“placebo) will 
be estimated using a repeated measures mixed effects analysis of covariance model, for the 
ITT population. The model will include all available data from all visits up to and including 
Week 12, irrespective of whether the participant discontinued study intervention. Since a repeated measures model is being applied, no imputation will be made for missing data. The model will include fixed effects for baseline, eosinophil strata, background medication strata, visit, study intervention and the baseline by visit and study intervention by visit interactions. An unstructured covariance matrix will be used to describe the correlations between observations on a participant between visits. Estimates of the least square mean change from baseline in FEV
1for each study intervention, and the difference between them, together with 
80% CI, will be obtained from the model for each visit. The significance of the study 
intervention effect will be tested at a 10% one-sided level of significance as described in 
Section 9.1.
Additionally, the difference in mean change from baseline in FEV 1at each study visit will be 
analyzed using a repeated measures mixed effects analysis of covariance model as described above, including all available data from all visits through to Week 28.
9.4.2.2 Secondary Endpoints 
Time to first COPDCompEx event will be analyzed using a Cox proportional hazard model, 
with study intervention, eosinophil strata and background medication strata fitted as covariates. The data will also be displayed in  a Kaplan-Meier plot. The COPDCompEx event 
rate will be analyzed using negative binomial regression, with the l og(follow up time) 
included as an offset term. The dependent variable will be the number of COPDCompEx events through end of intervention, and the model will include study intervention group, eosinophil strata and background medication strata as fixed effects. 
Subgroup Analyses:
Subgroup analyses may be performed. These will be described in the SAP, including a 
subgroup analysis of extent of emphysema on mean change from baseline in lung function at Week 28.
9.4.2.3 Exploratory Endpoints
9.4.3 Safety
The occurrence of treatment-emergent AEs and SAEs will be described by system organ class, 
preferred term, severity, and relationship to the study intervention. Participants will be '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGisit. isi
ed leveld level  o ll
e froom m baseline inbaseli
ed effects analysisffects anal
m all visitvisits throughst h
s
ent will be analyz ill be an
nophil strata and b il strata an
so be displayed ine displaye
ng negative binoegative bino mm
erm. The dependenerm. The depe
of interventintervent ioion, ann, an
d background m kgroun
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 101 of 155er with 80% CI and one-sided p-values, will be 
obtained from the model for each visit.
9.4.4.4 Additional Analyses
The incidence rate of positive antibodies to MEDI3506 will be reported by study intervention 
group. If there is a high incidence of ADA, th  association of ADA with MEDI3506 concentration will be assessed. In addition  the relationship between ADA and PD, efficacy, and safety may be evaluated. MEDI3506 serum concentrations will be tabulated along with
descriptive statistics. Mean and individual serum MEDI3506 concentration-time profiles will be plotted. Population PK modeling may be pe rformed if data allow. The potential correlation 
between PK exposure and PD biomarkers, and efficacy/safety response may be evaluated.
9.5 Interim Analyses 
The study team may decide to conduct an administrative un-blinded analysis of the study, 
prior to the Primary Analysis, with the intent to trigger internal (AstraZeneca) investmentdecisions. The purpose of this interim analysis would be to inform decisions on future development options for MEDI3506 or other programs. No termination of this study, or adjustments to the study design are planned. Regardless of any interim analysis results, this study will be continued and completed. As a result, no alpha will be spent at the interim 
analysis. Additional details on the unblinding for interim analysis are provided in 
Section 6.3.3.1.
Details of any interim analyses, if conducted, will be included in the Interim Analysis Plan.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYes to MEDI3506 MEDI3
f ADA, th  associa A, th  a
addittioion  the relatn  the r
EDI3506 serum c 506 
nd individual serum dividual s
modeling meling m ay be pay
d PD bioD bio markers,markers,
Analysesaly
ocCCI
CCI
CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 102 of 155There are 3 planned analyses for this study. The Primary Analysis will occur once all 
participants have either completed the Week 12 assessments or withdrawn from the study. The End-of-Treatment analysis will occur once all participants have either completed the Week 28 
assessments or withdrawn from the study. The Fi nal Analysis will occur when all participants 
have completed the safety follow up period. Details relating to the unblinding for the Primary 
Analysis are in Section 6.3.3.1.
9.6 Data Monitoring Committee
An independent unblinded DSMB will perform evaluat ions of safety data, from this study and 
Studies D9181C00001 (in participants with asthma), D9182C00001 (in participants with atopic dermatitis) and D9183C00001 (in participants  with diabetic kidney disease). Details of 
the composition of the DSMB, the data to be reviewed, and the frequency of the meetings can be found in the DSMB Charter. The DSMB will make any necessary recommendations to the sponsor regarding further conduct of the studies bas d on their evaluations of emerging data. 
A blinded study-specific safety committee (or Medical Monitor) will also review SAEs and 
SUSARs. For details on DSMB, refer to Appendix A5'&3URWRFRO$PHQGPHQW_9970)_
as d onsd  o
Medical Monito al Moni
endix A5A5
PPD
Clinical Study Protocol â€“ Ame ndment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 103 of 15510 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS'&3URWRFRO$PHQGPHQW_9970)_
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 104 of 155Appendix A Regulatory, Ethical, and Study Oversight Considerations
Regulatory and Ethical Considerations
!This study will be conducted in accordan ce with the CSP and with the following:
âˆ€Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines
âˆ€Applicable ICH GCP Guidelines
âˆ€Applicable laws and regulations
!The CSP, CSP amendments, ICF, IB, and other relevant documents (eg, advertisements) 
must be submitted to an IRB/IEC by the investigator and reviewed and approved by the 
IRB/IEC before the study is initiated.
!Any amendments to the CSP will require IRB/IEC and applicable Regulatory Authority
approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.
!AstraZeneca will be responsible for obtaining the required authorisations to conduct the 
study from the concerned Regulatory Authority  This responsibility may be delegated to a 
Contract Research Organization but the accountability remains with AstraZeneca.
Regulatory Reporting Requirements for SAEs
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal
obligations and ethical responsibilities towards the safety of participants and the safety of a 
study intervention under clinical investig tion are met.
The sponsor has a legal responsibility to notify bo th the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The sponsor will comply with country specific regulato ry requirements relating to safety reporting 
to the regulatory authority, IRB/IEC, and investigators.
For all studies except those utilizing medical devices investigator safety reports must be 
prepared for SUSARs according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other specific 
safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.
Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGde tde
o studystudy papyy
ing the requi e requi red riiii
thoriitytyiiiThis respo This r
e accountabilitcountabil y re
s for SAEsr SAEs
ator to the sponsor o the sp
ilities towards the s towards 
al investvestigtig tioion ar
sponsibilitnsibilit y y to notito 
ut the safete safet y y of a sa sf
wiwithii country countryh specispec
thoriritytyiiii, IRB/IEC, , IRB/IEC, 
ose utilizie ut
din
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 105 of 155certification or disclosure statements to the a ppropriate regulatory authorities. Investigators 
are responsible for providing information on financial interests during the course of the studyand for 1 year after completion of the study.
Informed Consent Process
!The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorised representative and answer all questions regarding the study.
!Participants must be informed that their pa rticipation is voluntary and they are free to 
refuse to participate and may withdraw their consent at any time and for any reason 
during the study. Participants will be required to sign a statement of informed consent that 
meets the requirements of 21 CFR 50, local regulations,  ICH guidelines, HIPAA 
requirements, where applicable, and the IRB/IEC or study centre.
!The medical record must include a statemen t that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. The authorised person obtaining the informed consent must also sign the ICF.
!Participants must be re-consented to the most current version of the ICF(s) during their 
participation in the study.
!A copy of the ICF(s) must be provided to  the participant or the participantâ€™s legally
authorised representative.
Participants who are rescreened are requir d to sign a new ICF.
The ICF will contain a separate section that addresses and documents the collection and use of 
any mandatory and/or optional human biological samples. The investigator or authorised designee will explain to each participant the objectives of the analysis to be done on the 
samples and any potential future use. Participants will be told that they are free to refuse to 
participate in any optional mples or the future use and may withdraw their consent at anytime and for any reason during the retention period. 
Data Protection
!Participants will be assigned a unique identifier by the sponsor. Any participant records or 
datasets that are transferred to the sponsor will contain the identifier only; participant 
names or any information which would make the participant identifiable will not be 
transferred.
!The participant must be informed that his/her personal study-related data will be used by
the sponsor in accordance with local data protection law. The level of disclosure and use 
of their data must also be explained to  the participant in the informed consent 
!The participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorised personnel appointed by the 
sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGat wat
dyand theand thy
the informed con formed 
most current versit current v
ded to the participato the par
re requir d to signequir d to 
te section that addction that 
nal human bio uman bi log
each participant th participant th
ntial future use. Par ture use
tional mples or onal mples or 
ason during the r during t
ion
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 106 of 155
Committees Structure
An independent DSMB will be formed to evaluate safety data from concurrently conducted 
MEDI3506 Phase II clinical studies in other indications. 
Unblinded review of safety data will be required for indications where the potential risks of 
MEDI3506 are high due to the disease under study and the common comorbidities of particular participant populations. Safety data from this study will be provided to  the DSMB 
for oversight of all safety data. Details of the composition of the DSMB, the data to be 
reviewed, and the frequency of the meetings can be found in the DSMB Charter.
Dissemination of Clinical Study Data
A description of this clinical study will be available on http://astrazenecaclinicaltrials.com and http://www.clinicaltrials.gov as will the summary of the main study results when they are available. The clinical study and/or summary of main study results ma y also be available on 
other websites according to the regulations of the countries in which the main study is conducted.
Data Quality Assurance
!All participant data relating to the study will be recorded on eCRF unless transmitted to 
the sponsor or designee electronically (eg, laboratory data). The investigator is responsible for verifying that data entri s are accurate and correct by physically or 
electronically signi ng the eCRF.
!The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF
!The investigator must per mit study-rel ated monitoring, audits , IRB/IEC review, and 
regulatory agency inspection  and provide  direct access to source data documents.
!Monitoring details describing strategy (eg, risk -based initiatives in operations and quality 
such as Risk Management and Mitigati on Strategies and An alytical Risk-Based 
Monitoring), methods, responsib ilities and requi rements, including handling of 
noncompliance issues a nd monitoring techniques (central, remote, or on-site monitoring) 
are provided in the Monitoring Plan.
!The sponsor or designee is responsible for the data management of this study including 
quality checki ng of the data.
!The sponsor assumes accountab ility for actions delegated to  other individuals (eg, 
Contract Research Organizations).
!Study monitors will perform ongoing source d ata verification to confirm that data entered 
into the eCRF by authorised site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved CSP and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGfth
main studyin stud
he countries in w untries in
e
e studyudywill be recwill beyy
onically (eg, labora ly (eg, l
t data entri s are aa entri s a
eCRF.
maintain accurate d ain accura
the eCRFeCRF
ust permit study ermit stu -rere
y inspeys ction  and pon  and
tails describing str describing str
anagement and em
ds, respo re
nd
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 107 of 155!Records and documents, including signed ICFs, pertaining to the conduct of this study
must be retained by the investigator for 15 years after study completion unless local 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the sponsor. No 
records may be transferred to another location or party without written notification to the 
sponsor.
Source Documents
!Source documents provide evidence for the existence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the investigatorâ€™s site.
!Data reported on the eCRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study. Also, curre nt medical records must be available.
!Definition of what constitutes source data can be found in the monitoring plan.  
Study and Site Start and Closure
The sponsor designee reserves the right to clo se the study site or terminate the study at any
time for any reason at the sole discretion of th e sponsor. Study sites will be closed upon study
completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:
!Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the sponsor's procedures, or GCP guidelines
!Inadequate recruitment of participants by the investigator
!Discontinuation of further study intervention development
If the study is prematurely terminated or susp ended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
organisation(s) used in the study of the reas on for termination or suspension, as specified by 
the applicable regulatory requirements. The investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow-up.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGmmede
n be found i found i
Closureosure
to close the studylose th
ion of the sponsorof the spon
red cl osed when aosed w
site clclii osure visiosure vis t hii
 studydy--site clte cii osureo
ven in advance of t n advance of
closure of a studyclosure of a stu y
tigator to ato
ies, t
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 108 of 155
Publication Policy
The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before 
submission. This allows the sponsor to protect proprietary information and to provide 
comments.
The sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicentre studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator will be designated by mutual agreement.
Authorship will be determined by mutual agreement and in line with International Committee 
of Medical Journal Editors authorship requirements.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 109 of 155Appendix B Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
Definition of Adverse Events
An AE is the development of any untoward medical occurrence in a participant or clinical 
study participant administered a medicinal product and which does not necessarily have a causal relationship with this study intervention. An AE can therefore be any unfavourable and unintended sign (eg, an abnormal laboratory finding), symptom (for example nausea, chest pain), or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 
The term AE is used to include both serious and non-serious AEs and can include a 
deterioration of a pre-existing medical occurrence.  An AE may occur at any time, including 
run-in or washout periods, even if no study intervention has been administered.
Definitions of Serious Adverse Event
An SAE is an AE occurring during any study  phase (ie, run-in, intervention, washout, 
follow-up), that fulfils one or more of the following riteria:
!Results in death
!Is immediately life-threatening
!Requires in-participant hospitalisation or prolongation of existing hospitalisation 
!Results in persistent or significant disability or incapacity. 
!Is a congenital anomaly or birth defect
!Is an important medical event that may jeopardise the participant or may require medical 
treatment to prevent one of the outcomes listed above.
Adverse Events for malignant tumours reported during a st udy should gener ally be assessed 
as Serious AEs. If no other seriousness criteria apply, the â€˜Important Medical Eventâ€™ criterion 
should be used. In certain situations, however, medical judgement on an individual event basis should be applied to clarify that the malignant  tumour event should be assessed and reported 
as a Non-Serious AE. For example, if the tumour is included as medical history and 
progression occurs during the study, but the progression does not change treatment and/or prognosis of the malignant tumour, the AE may not  fulfil the attributes for being assessed as 
Serious, although reporting of the progression of the malignant tumour as an AE is valid and should occur. Also, some types of malignant tumours, which do not spread remotely after a 
routine treatment that doe s not require hospitalization, may be assessed as Non-Serious; 
examples in adults include Stage 1 basal cell carcinoma and Stage 1A1 cervical cancer 
removed via cone biopsy.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGttioin
se Eventvent
dyphase (iase (y e, run, -in
folloowing riwing ri teritiiiia
g
pitalisatsatii ioion or prol
gnificant disabilitficant disab
ly or bir birth derth deiii fectfe
dical event that ma event that ma
ent one of the outcent one of the o
malignant tum gnant t
her seriour se
ua
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 110 of 155Life Threatening
â€˜Life-threateningâ€™ means that the participant was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
participantâ€™s death. â€˜Life-threateningâ€™ does not mean that had an AE occurred in a more severe form it might have caused death (eg, hepatitis that resolved without hepatic failure).
Hospitalisation
Outpatient treatment in an emergency room is not in itself a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal edema). Hospital admissions and/or surgical 
operations planned before or during a study are not  considered AEs if the illness or disease 
existed before the participant was enrolled in th e study, provided that it did not deteriorate in 
an unexpected way during the study.
Important Medical Event or Medical Treatment
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important medical events may not be immediately life threatening or result in death, hospitalisation, disability or incapacity but may jeopardise the participant or may require medical treatment to prevent one or more outcomes listed in the definition of serious. 
These should usually be considered as serious.
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used.
!Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatment
!Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring treatment with 
N-acetylcysteine
!Intensive treatment in an emergency room or at home for allergic bronchospasm
!Blood dyscrasias  (eg, neutropenia or anaemia requiring blood transfusion, etc.) or 
convulsions that do not re sult in hospitalisation
!Development of drug dependency or drug abuse
Severity Rating Scale:
The determination of severi ty should be made by the investigator based upon medical 
judgment and the severity categories of Grade 1 to 5 (based on the CTCAE criteria; 
NCI 2017)  as defined below:
Grade 1 An event of mild intensity that is usually transient and may require only 
minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGrcised in decidi d in deci
aynyot be immediatot be imme
ty byut may jeopardt may je
or more outcomesmore outco
serious. us
does not mean that not mean
enough to requireugh to re
sed by paracetamo y paracetamo
ment in an emerge in an emerge
(eg, neutropneu
ot resut
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 111 of 155Grade 2 An event of moderate intensity that is usually alleviated with additional 
specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participant.
Grade 3 A severe event that requires intensive therapeutic intervention. The event 
interrupts usual activities of daily living, or significantly affects the clinical status of the 
participant.
Grade 4 An event, and/or its immediate sequelae, that is associated with an imminent 
risk of death.
Grade 5 Death as a result of an event.It is important to distinguish between serious and severe AEs. Severity is a measure of 
intensity whereas seriousness is defined by the criteria in Appendix B2 . An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for several hours may be considered severe nausea, but not an SAE unless it meets the criteria 
shown in Appendix B2 . On the other hand, a stroke that results in only a limited degree of 
disability may be considered a mild stroke but would be an SAE when it satisfies the criteria shown in Appendix B2 .
A Guide to Interpreting the Causality Question
When making an assessment of causali y consider the following factors when deciding if there 
is a â€˜reasonable possibilityâ€™ that an AE may have been caused by the study intervention.
!Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug? Did the AE occur in a reasonable temporal relationship to the administration of the suspect drug?
!Consistency with known drug profile. Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology a nd toxicology) or drugs of the same 
pharmacological class? Or could the AE be anticipated from its pharmacological 
properties?
!De-challenge experience. Did the AE resolve or improve on stopping or reducing the dose 
of the suspect drug?
!No alternative cause. The AE cannot be reasonably explained by another aetiology such 
as the underlying disease, other drugs, other host or environmental factors.
!Re-challenge experience. Did the AE reoccur if the suspected drug was reintroduced after 
having been stopped? AstraZeneca would not normally recommend or support a re-
challenge.
!Laboratory tests. A specific laboratory investigation (if performed) has confirmed the 
relationship.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGeria inria i
ous. For exam For exam
a, but not an SAE not an S
a stroke that resuloke tha
e but would be an would be
reting the Causng the C
causalialiy y consider
hat an AE mn AE m ay havay
ure to suspect drugto suspect dru
occur in a reasona in a reasona
ith known drug pnown dru
suspect drugpect
s? Or c?
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 112 of 155In difficult cases, other factors could be considered such as:
!Is this a recognised feature of overdose of the drug?
!Is there a known mechanism?
Causality of â€˜relatedâ€™ is made if following a review of the relevant data, there is evidence for a 
â€˜reasonable possibilityâ€™ of a causal relationship for the individual case. The expression â€˜reasonable possibilityâ€™ of a causal relationship is  meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal relationship.
The causality assessment is  performed based on the available data including enough 
information to make an informed judgment. With no available facts or arguments to suggest a 
causal relationship, the event(s) will be assessed as â€˜not relatedâ€™.
Causal relationship in cases where the diseas e under study has deteriorated due to lack of 
effect should be classified as no reasonable possibility.
Medication Error
For the purposes of this clinical study, a medication error is an unintended failure or mistake 
in the treatment process for an AstraZeneca study intervention that either causes harm to the 
participant or has the potential to cause harm to the participant. 
A medication error is not lack of efficacy of the study intervention, but rather a human or 
process related failure while the study intervention is in control of the study site staff or participant.
Medication error includes situ ations where an error: 
!occurred
!was identified and intercepted before the participant received the study intervention
!did not occur, but circumstances were recognised that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
!Study intervention name confusion
!Dispensing error eg, medication prepared incorrectly , even if it was not actually given to 
the participant
!Study intervention not administered as indicated, for example, wrong route or wrong site 
of administration
!Study intervention not taken as indicated eg, tablet dissolved in water when it should be 
taken as a solid tablet '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGder studyr stud
sibilit y.y
medicatidicati on error io
eneca studyca study iiyyntnerv
ause harm to the pa harm to 
of efficacy oficacy o f f the s
the studystudy iiyyntnerventer
des situat tuatioions whens whe
interceptederce
mst
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 113 of 155!Study intervention not stored as instructed eg, kept in the fridge when it should be at room 
temperature 
!Wrong participant received the medication (excluding RTSM system errors)
!Wrong study intervention administered to participant (excluding RTSM system errors)
Examples of events that do not require reporting as medication errors in clinical studies:
!Errors related to or resulting from the RTSM system - including those which lead to one 
of the above listed events that would otherwise have been a medication error 
!Participant accidentally missed study intervent ion dose(s) eg, forgot to take medication
!Accidental overdose (will be captured as an overdose)
!Participant failed to return unused medication or empty packaging
!Errors related to background and , or standard of care medication in 
open label studies, even if an AstraZeneca product 
Medication errors are not regarded as AEs but AEs may occur as a consequence of the 
medication error.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGduct duct 
AEs may occur a may occu
PPDCCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 114 of 155Appendix C Handling of Human Biological Samples
Chain of Custody
A full chain of custody is maintained for all samples throughout their lifecycle.
The investigator at each centre keep s full traceability of collected biologi cal samples from the 
participants while in storage at the centre until shipment or disposal (where appropriate) and records relevant processing information related to the samples whilst at site.
The sample receiver keeps full traceability of the samples while in storage and during use until 
used or disposed of or until further shipment and keeps record of receipt of arrival and onward 
shipment or disposal.
AstraZeneca or delegated representatives will keep oversight of the entire life cycle through 
internal procedures, monitoring of study sites , auditing or process checks, and contractual 
requirements of extern al laboratory  providers
Samples retained for further use will be stored in the AstraZeneca-assigned biobanks or other 
sample archive facilit ies and will be tracked by the a ppropriate AstraZeneca Team during for 
the remainder of the sample life cycle.
If required, AstraZeneca will ensure that remaining biological samples are returned to the site 
according to local regulations or at the end of the retention period, whichever is the sooner.
Withdrawal of Informed Consent for Donated Biological Samples 
If a participant withdraws consent to the use of donated biological samples, the samples will 
be disposed of/destroyed/repatriated, and the action documented. If samples are alreadyanalyzed, AstraZeneca is not obliged to destroy the results of this research.
Following withdrawal of consent for biological samples, further study participation should be 
considered in relation to the withdrawal processes outlined in the informed consent.
The investigator:
!Ensures participantâ€™s withdrawal of informed consent to the use of donated samples is 
highlighted immediately to AstraZeneca or delegate.
!Ensures that relevant human biological samples  from that participant, if stored at the 
study site, are immediately identified, di sposed of as appropriate, and the action 
documented
!Ensures that the participant and AstraZeneca are informed about the sample disposal.'&3URWRFRO$PHQGPHQW_9970)_
iting or ing o
ed in the AstraZen the As
ked by ythe approprthe appryy
e that remaining b remain
at the end of the re end of th
of Informed Conformed
s consent to the usnsent to the us
ed/repatriated, and atriated, and
ca is not obliged ta is not obliged t
ofconsent fconsf
e witii
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 115 of 155AstraZeneca ensures the organization(s) holdi ng the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of or repatriated as appropriate, and the action documented and study site notified.
International Airline Transportation Association (IATA) 6.2 
Guidance Document
LABELLING AND SHIPMENT OF BIOHAZARD SAMPLES
International Airline Transportation Association 
(https://www.iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infectious 
substances into 3 categories: Category A, Category B or Exempt
Category A Infectious Substances are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent disa bility, life-threatening or fatal disease in 
otherwise healthy humans or animals. Category A pathogens are e.g., Ebola, Lassa fever virus. Infectious substances meeting these 
criteria which cause disease in humans or both in humans and animals must be assigned to UN 2814. Infectious substances which cause disease only in animals must be assigned to UN 2900:
Category B Infectious Substances are infectious Substances that do not meet the criteria for 
inclusion in Category A. Category B pathogens are eg, Hepatitis A, C, D, and E viruses. Theyare assigned the following UN number and proper shipping name
!UN 3373 â€“ Biological Substa ce, Category B
!are to be packed in accordance with UN3373 and IATA 650
Exempt - Substances which do not contain infectious substances or substances which are 
unlikely to cause disease in humans or animals are not subject to these Regulations unless theymeet the criteria for inclusion in another class.
!Clinical study samples will fall into Category B or exempt under IATA regulations
!Clinical study samples will routinely be packed and transported at ambient temperature in 
IATA 650 compliant packaging 
(https://www.iata.org/whatwedo/cargo/dgr/Documents/DGR-60-EN-PI650.pdf).
!Biological samples transported in dry ice require additional dangerous goods specification 
for the dry-ice content.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGver vivirus. Inferus. Infiii
h in humans and ahumans a
se disease only in asease on
are infectnfect ioious Subs
B pathogens are eathogens 
number and proper er and pro
ubstaace, Categoce, Ca
ccordance with UNdance with U
s which do not conwhich do not con
sease in humans e in humans 
clusiosion nin an
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 116 of 155Appendix D'&3URWRFRO$PHQGPHQW_9970)_
CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 117 of 155'&3URWRFRO$PHQGPHQW_9970)_
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 118 of 155'&3URWRFRO$PHQGPHQW_9970)_
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 119 of 155Appendix E Actions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hyâ€™s Law
Introduction
This Appendix describes the process to be followed in order to identify and appropriately 
report PHL cases and HL cases. It is not intended to be a comprehensive guide to the management of elevated liver biochemistries. 
Specific guidance on managing liver abnormalities can be found in Section 8.3.7 of the CSP.
During the course of the study the investigator will remain vigilant for increases in liver 
biochemistry. The investigator is responsible for determining whether a participant meets PHL 
criteria at any point during the study.
All sources of laboratory data are appropriate for the determination of PHL and HL events; 
this includes samples taken at scheduled study vi sits and other visits including central and all 
local laboratory evaluations even if collected out side of the study visits; for example, PHL 
criteria could be met by an elevated ALT from a central laboratory and/or elevated TBL from 
a local laboratory. 
The investigator will also review AE data (for example, for AEs that may indicate elevations 
in liver biochemistry) for possible PHL events.
The investigator participates, together with AstraZeneca clinical project representatives, in 
review and assessment of cases meeting PHL criteria to agree whether HL criteria are met. Hyâ€™s law criteria are met if there is no alternative  explanation for the elevations in liver 
biochemistry other than Drug Induced Liver Injury caused by the IMP. 
The investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting SAEs and AEs according to the outcome of the review and assessment in line with standard safety reporting processes.
Definitions
Potential Hyâ€™s Law (PHL)
Aspartate aminotransferase or ALT â‰¥ 3 Ã— ULN together with TBL â‰¥ 2 Ã— ULN at any point
during the study following the start of study medication irrespective of an increase in ALP.
Hyâ€™s Law (HL)
Aspartate aminotransferase or ALT â‰¥ 3 Ã— ULN together with TBL â‰¥ 2 Ã— ULN, where no 
other reason, other than the IMP, can be found to explain the combination of increases, eg, elevated ALP indicating cholestasis, viral hepatitis, another drug. '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGhe detere det
isits and other and othe
outside of the studside of the 
oma centralcentralm llabor
data (for examplea (for e
PHL events.L events.
ogether with Astrather with A
ses meetmee ing PHL g 
if there is no alternere is no alter
n Drug Induced Liv g Induced Liv
responsible for reconsible for rec
AEs according acco
processro
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 120 of 155For PHL and HL the elevation in transaminases must precede or be coincident with (ie, on the 
same day) the elevation in TBL, but there is no specified timeframe within which the elevations in transaminases and TBL must occur.
Identification of Potential Hyâ€™s Law Cases
In order to identify cases of PHL it is importan t to perform a comprehensive review of 
laboratory data for any participant who meets any of the following identification criteria in 
isolation or in combination:
!ALT â‰¥ 3 Ã— ULN
!AST â‰¥ 3 Ã— ULN
!TBL â‰¥ 2 Ã— ULN
Central Laboratories Being Used:
When a participant meets any of the PHL identification criteria, in isolation or in combination, 
the central laboratory will immediately send an alert to the investigator (also sent to 
AstraZeneca representative). 
The investigator will also remain vigilant for any local laboratory reports where the PHL 
identification criteria are met, where this is the case the investigator will:
!Notify the AstraZeneca representa ive
!Request a repeat of the test (new blood draw) by the central laboratory without delay.
When the identification criteria are met from cen tral or local laboratory results the investigator 
will wit hout delay:
!Determine whether the participant meets PHL criteria (see Section E2for definition) by 
reviewing laboratory reports from all previous visits (including both central and locallaboratory results)
Local Laboratories Being Used:
The investigator will without delay review each  new laboratory report and if the identif ication 
criteria are met will:
!Notify the AstraZeneca representative
!Determine whether the participant meets PHL criteria (see Appendix E2Definitions 
within this Appendix for definition) by reviewing laboratory reports from all previous 
visits
!Promptly enter the laboratory data into the laboratory eCRF'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGification criteria, on crite
an alert to the invelert to the 
ant for any local laor any lo
e this is the case th is the c
resenta ive ta ive
est (new blood dranew blood
criteririiia are m a are m et fet froroffff
ether the participa the parti
oryreports frepoy
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 121 of 155
Follow-up
E 4.1 Potential Hyâ€™s Law Criteria Not Met
If the participant does not meet PHL criteria the investigator will:
!Inform the AstraZeneca represent ative that the participant has not met PHL criteria.
!Perform follow-up on subsequent laboratory results according to the guidance provided in 
the CSP.
E 4.2 Potential Hyâ€™s Law Criteria Met
If the participant does meet PHL criteria the investigator will:
!Determine whether PHL criteria were met at any study visit prior to starting study
intervention
Notify the AstraZeneca representative who will then inform th e central Study Team
!Within 1 day of PHL criteria being met, the investigator will report the case as an SAE of 
PHL; serious criteria â€˜Important medical eventâ€™ and causality assessment â€˜yes/relatedâ€™ 
according to CSP process for SAE reporting
!For participants that met PHL criteria pri r to starting IMP, the investigator is not 
required to submit a PHL SAE unless there is a significant change #in the participantâ€™s 
condition
!The AstraZeneca Study Physician contacts the investigator, to provide guidance, discuss 
and agree an approach for the study participantsâ€™ follow-up (including any further 
laboratory testing) and the continuous review of data
!Subsequent to this contact the investigator will:
âˆ€Monitor the parti ipant until liver bi ochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically indicated. Completes follow-up SAE Form as required.
âˆ€Investigate the aetiology of the event and perform diagnostic investigations as 
discussed with the AstraZeneca Study Physician.
âˆ€Complete the three Liver eCRF Modules as information becomes available 
A â€˜significantâ€™ change in the participantâ€™s condition refers to a clinically relevant change in 
any of the individual liver biochemistry parameters (ALT, AST or TBL) in isolation or in combination, or a clinically relevant change in associated symptoms. The determination of whether there has been a significant change will be at the discretion of the investigator, this may be in consultation with the AstraZeneca Study Physician if there is any uncertainty.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGyy
ill then inform thehen inform
t, the investe invest igator ig
dical eventâ€™ and ca eventâ€™ and
reportingorting
riteria pri r to staria pri r
E unless there is a less there
Physician contacts cian conta
for the studyhe study partic
nd the continuous r e continuous 
contact the investact the invest
e partiparti ipant until lipant until l
and signs rsign eturn et
mpletes foetes ll
lo
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 122 of 155
Review and Assessment of Potential Hyâ€™s Law Cases
The instructions in this Section should be followed for all cases where PHL criteria are met.
As soon as possible after the biochemistry abnormality was initially detected, the AstraZeneca 
Study Physician contacts the investigator in order to review available data and agree on whether there is an alternative explanation for meeting PHL criteria othe r than drug induced 
liver injury caused by the IMP, to ensure timely  analysis and reporting to health authorities 
within 15 calendar days from date PHL criteria was met. The AstraZeneca Global Clinical Lead or equivalent and Global Safety Physician will also be involved in this review together with other subject matter experts as appropriate. 
According to the outcome of the review and assessment, the investigator will follow the 
instructions below.
Where there is an agreed alternative explanation for the ALT or AST and TBL elevations, 
a determination of whether the alternative e xplanation is an AE will be made and 
subsequently whether the AE meets the criteria for an SAE:
If the alternative explanation is notan AE, record the alternative explanation on the 
appropriate eCRF
If the alternative explanation is an AE/SAE: update the previously submitted PHL SAE and 
AE eCRFs accordingly with the new information (reassessing event term; causality and seriousness criteria) following the AstraZeneca standard processes.
If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the IMP:
!Send updated SAE (report term â€˜Hyâ€™s Lawâ€™) according to AstraZeneca standard 
processes. 
âˆ€The â€˜Medically Importantâ€™ serious criterion s hould be used if no other serious criteria 
apply
âˆ€As there is no alternative explanation for the HL case, a cau sality asse ssment of 
â€˜relatedâ€™ should be assigned.
If, there is an unavoidable delay, of over 15 calendar days in obtaining the information 
necessary to assess whether or not the case meets the criteria for HL, then it is assumed that there is no alternative explanation until such time as an informed decision can be made:
!Provides any further update to the previously submitted SAE of PHL, (report term now 
â€˜Hyâ€™s Law caseâ€™) ensuring causality assessment is related to IMP and seriousness criteria 
is medically importan t, according to CSP process for SAE reporting.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGionfofor the r th
anatio nn is an AE an A
ria for an SAE:or an SAE
AE, record the alter ecord the 
n AE/SAE: update /SAE: upd
new inform info ation 
g the AstraZenecae AstraZen
no explanatexplanat ioion thn t
he IMP: P:
SAE (report term (report term 
mport
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 123 of 155!Continue follow-up and review according to agreed plan. Once the necessary
supplementary information is obtained, repeat the review and assessment to determine 
whether HL criteria are still met. Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if an alternative explanation for the liver biochemistry
elevations is determined.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 124 of 155
Laboratory tests
Hyâ€™s Law Laboratory Kit for Central Laboratories 
Additional standard chemistry and coagulation tests GGT
Lactate dehydrogenase
Prothrombin time
International normalized ratio
Viral hepatitis IgM anti- HAV 
IgM and IgG anti-HBc
HBsAg
HBV DNAa
IgG anti-HCV
HCV RNA a
IgM anti HEV
HEV RNA
Other viral infections IgM & IgG anti-CMV
IgM & IgG anti-HSV
IgM & IgG anti-EBV
Alcoholic hepatitis CD-transferrin b
Autoimmune hepatitis Antinuclear antibody (ANA)
Anti-Liver/Kidney Microsomal Ab (Anti-LKM)
Anti-Smooth Muscle Ab (ASMA)
Metabolic diseases alpha-1-antitrypsin
Ceruloplasmin
Iron
Ferritin
Transferrinb
Transferrin saturation
aHCV RNA; HCV DNA are only tested when IgG anti-HCV is positive or inconclusive
bCD-transferrin and Transferrin are not available in China. Study teams should amend this list accordingly
Ab = Antibody; CD-t ransferrin = Carbohydr ate deficient transferrin; CMV = Cytomegalovirus; 
DNA = Deoxyribonucleic acid; EBV = Epstein-Barr virus; GGT = Gamma-glutamyl transferase; HAV = Hepatitis A virus; HBc = Hepatitis B core antibody; HBsAg = Hepatitis B surface antigen; HBV = Hepatitis B virus; HCV = Hepatitis C virus; HEV = Hepatitis E virus; HSV = Herpes simplex virus; Ig = Immunoglobulin; RNA = Ribonucleic acid.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGV RV
gM antiantiHEVH
HEV RNARN
IgM & IgG antiIgM & IgHGIgM & IgG aIgM & IYIgM & IgIgMYRYCD-traRYRYRYRYAntRRRRARRS
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 125 of 155
References
Aithal et al 2011
Aithal GP, Watkins PB, Andrade RJ, Larrey D,  Molokhia M, Takikawa H, et al. Case 
Definition and Phenotype Standardization in Drug â€Induced Liver Injury. Clin Pharmacol Ther 
2011;89(6):806-15.
FDA Guidance for Industry, July 2009
FDA Guidance for Industry (issued July 2009) â€˜D rug-induced liver injury: Premarketing 
clinical evaluationâ€™. Available from URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver -injury-premarketing-clinical-evaluation.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 126 of 155Appendix F Contraception Guidance
Women are considered to be of childbearing potential unless they meet either of the criteria, 
as follows:
!Surgically sterilized (including bilateral tubal ligation, bilateral oophorectomy, or
!hysterectomy), or
!Post-menopausal.
For women aged < 50 years, post-me nopausal is defined as having both:
!A history of â‰¥ 12 months amenorrhea, without an alternative cause, following cessation of
!exogenous sex-hormonal treatment and,
!A follicle-stimulating hormone level in the post-menopausal range.
For women aged â‰¥ 50 years, post-menopausal is defined as having a history of â‰¥ 12 months 
amenorrhea, without an alternative cause, following ces ation of exogenous se x-hormonal
treatment.
A highly effective method of contraception is defined as one that results in a low failure rate 
(ie, less than 1% per year) when used consistently and correctly. The acceptable methods of contraception are described in Table 10 below.
Periodic abstinence, the rhythm method, and withdrawal are NOT acceptable methods of 
contraception.
Table 10 Highly Effective Methods of Contraception
Barrier Methods Hormonal Methods
â€¢ Intrauterine device
â€¢ Intrauterine hormone-releasing system (IUS) a
â€¢ Bilateral tubal occlusion
â€¢ Vasectomized partner b
â€¢ Sexual abstinence c Combined (estrogen and progestogen containing 
hormonal contraception)
â€¢ Oral (combined pill)
â€¢ Injectableâ€¢ Transdermal (patch)â€¢ Progestogen-only hormonal contraceptionâ€¢ Desogestrel
aThis is also considered a hormonal method.
bWith appropriate post-vasectomy medical testing of surgical success (ie, absence of sperm in ejaculate).
cSexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of the study and if it is the preferred and usual lifestyle of the 
participant.'&3URWRFRO$PHQGPHQW_9970)_
$ce$SSURYHGm
s defined as hav ned as h
owing ces atng ces at ioin o
ption is defined as is defin
d consistentnsistent ly and 
le100below.below.
m method, and witethod, and
y Effective Methfective Meth
$Sreleasing syeasi$S
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 127 of 155Appendix G Major and Minor Symptoms of COPD
The following questions and response options (or their translations) will be presented by the 
eDiary device to capture major and minor symptoms of COPD.
Question: How breathless have you been in the last 24 hours?
Response Options:
!Less breathlessness than usual
!Usual level of breathlessness
!More breathless than usual
Question: How much mucus (phlegm) did you have in the last 24 hours?
Response Options:
!Less than usual or no mucus (phlegm)
!Usual amount of mucus (phlegm)
!More mucus (phlegm) than usual
Question: What color was your mucus (phlegm) in the last 24 hours?
Response Options:
!No mucus (phlegm)
!Mucus (phlegm) was the usual color
!Mucus (phlegm) was a darker or a different color than usual
Question: How much have you coughed in the last 24 hours?
Response Options:
!Less cough than usual
!Usual level of cough
!More cough than usual
Question: How much have you wheezed in the last 24 hours?
Response Options:
!Less wheeze than usual
!Usual level of wheeze'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGucus (phlegm) in th phlegm
as the usual coe usual c lolorr
was a darker or a dwas a darker or a
ch have y veou cou
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 128 of 155!More wheeze than usual
Question: Have you had a sore throat in the last 24 hours?
Response Options:
!No
!Yes, I had a sore throat
Question: Have you had the symptoms of a cold such as a runny nose or nasal congestion in 
the last 24 hours?
Response Options:
!No symptoms of a cold
!Yes, I had symptoms of a cold
Question: Have you had a fever in the last 24 hours?
Response Options:
!No
!Yes, I had a fever'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG24 hours? urs?
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 129 of 155Appendix H National Institute of Allergy and Infectious Diseases and 
Food Allergy and Anaphylaxis Network Guidance for Anaphylaxis Diagnosis
National Institute of Allergy and Infectious Diseases and Food Allergy and Anaphylaxis 
Network define anaphylaxis as a serious allergic reaction that is rapid in onset and may cause death (Sampson et al 2006) . They recognize 3 categories of anaphylaxis, with criteria 
designated to capture from 80% of cases (Category 1) to > 95% of all cases of anaphylaxis (for all 3 categories). 
1 Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula) AND AT LEAST 1 OF THE FOLLOWING:
(a) Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia).
(b) Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia 
[collapse], syncope, incontinence).
2 Two or more of the following that occur rapidly after exposure to a likely allergen for that 
participant (minutes to several hours):
(a) Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen 
lips-tongue-uvula).
(b) Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia).
(c) Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, 
incontinence)
(d) Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting).
3 Reduced BP after exposure to known allergen for that participant (minutes to several 
hours):
(a) Adults: systolic BP of less than 90 mmHg or greater than 30% decrease from that 
personâ€™s baseline.
For the purpose of AE reporting, the above criteria should be used to guide retrospective 
judgment as to whether an event was true anaphylaxis. Guidance on the recognition of possible anaphylaxis at the time of the event is provided (Appendix I) .'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGez
of end --organ dyorgan d sf
cur rapidly after exapidly aft
rs):
cosal tl tisissue (eg, gesue
se (eg, dyspnea, wg, dyspn
sociated symptomated symp
strointestinal sympstrointestinal sym
fter exposure to kn xposure to kn
Po f
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 130 of 155Appendix I Signs and Symptoms and Management of Acute Anaphylaxis
Appropriate drugs, such as epinephrine, antihistamines, corticosteroids, etc, and medical
equipment to treat anaphylactic reactions must be immediately available at study sites, and 
study personnel should be trained to recognize and treat anaphylaxis. Local or national guidelines for the recognition and management of acute anaphylaxis should be followed where available. Where not available, guidance is provided below.
Signs and Symptoms of Acute Anaphylaxis
Anaphylaxis is an acute and potentially lethal mult i-system allergic reaction in which some or 
all of the following signs and symptoms occur:
!Diffuse erythema.
!Pruritus.
!Urticaria and/or angioedema.
!Bronchospasm.
!Laryngeal edema.
!Hypotension.
!Cardiac arrhythmias.
!Feeling of impending doom.
!Unconsciousness.
!Shock.
Other earlier or concomitant signs and symptoms can include:
!Itchy nose, eyes, pharynx, genitalia, palms, and soles.
!Rhinorrhea.
!Change in voice.
!Metallic taste.
!Nausea, vomiting, diarrhea, abdominal cramps, and bloating.
!Light-headedness.
!Headache.
!Uterine cramps.
!Generalized warmth.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGmitant signs and sy signs and sy
s,pharynx, genitaharynx, genita
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 131 of 155
Management of Acute Anaphylaxis
I 2.1 Immediate Intervention
1 Assessment of airway, breathing, circul ation, and adequ acy of mentation.
2 Administer epinephrine intramuscularly every 5 to 15 minutes, in appropriate doses, as 
necessary, depending on the presenting signs and symptoms of anaphylaxis, to control signs and symptoms and prevent progression to more severe symptoms such as respiratory distress, hypotension, shock and unconsciousness.
I 2.2
Possibly Appropriate, Subsequent Measures Depending on Response to 
Epinephrine
1 Place participant in recumbent pos ition and elevate lower extremities.
2 Establish and maintain airway.
3 Administer oxygen.
4 Establish venous access.5 Normal saline IV for fluid replacement.
I 2.3
Specific Measures to Consider after Epinephrine Injections, Where 
Appropriate
1 Consider epinephrine infusion.
2 Consider H1 and H2 antihistamines
3 Consider nebulized beta-2 ag nist [eg, albuterol (salbutamol)] for bronchospasm resistant 
to epinephrine.
4 Consider systemic corticosteroids.
5 Consider vasopressor (eg, dopamine).
6 Consider glucagon for participant taking b-blocker.
7 Consider atropine for symptomatic bradycardia.
8 Consider transportation to an emergency department or an intensive care facility.9 For cardiopulmonary arrest during anaphylaxis, high-dose epinephrine and prolonged 
resuscitation efforts are encouraged, if necessary.
If a suspected anaphylactic reaction occurs during or within a 24-hour period after 
administration of study intervention, blood samples for serum tryptase should be collected as soon as possible after the event, at 60 Â± 30 minutes after the event, at discharge, and between 2 and 4 weeks post discharge. Immediate care of the participant and treatment of the reaction must take priority over collecting blood samples.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGnt.
Consider after Ensider 
sion.
ihistaminesamines
eta-2 ag nist [eg, 2 ag nist [eg
mic corticosteroidsc corticosteroids
ressor (eg, dopaor (eg, d
or particp
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 132 of 155Adapted from Kemp et al 2008.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 133 of 155Appendix J Example of Patient COVID-19 Screening Questionnaire
1 Have you experienced unexplained fever, cough, shortness of breath, chills, muscle pain, 
headache, sore throat, and/or new loss of taste or smell within the past 14 days?
2 Have you been in contact with anyone who is sick or with symptoms in the last 14 days? 
Note to site: probe on the same symptoms as Q1.
3 Have you been exposed to someone diagnos ed with COVID-19 in the last 14 days?
4 Have you been practicing social distancing over the last 14 days? Note to site: please 
refer to region/city/country regulations.
5 Have you travelled in the last 14 days, if so, where? Note to site: recent travel including 
to countries/regions with Centers for Dis ease Control and Prevention Level 2 or higher 
travel warning, or equivalent, or known COVID-19 hot spots.
6 Have you been in isolation or quarantine for any reason in the past 14 days?7 Have you been diagnosed with COVID-19 at any time, if so, where and when?
8 Have you been vaccinated against COVID-19?'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGy ry
anynytime,  timyy
-19?
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 134 of 155Appendix K Changes Related to Mitigation of Study Disruptions Due to 
Cases of Civil Crisis, Natural Disaster, or Public Health Crisis
Note: Changes below should be implemented only during study disruptions due to any of or a 
combination of civil crisis, natural disaster, or public health crisis (eg, during quarantines and 
resulting site closures, regional travel restrictions and considerations if site personnel or studyparticipants become infected with SARS-CoV-2 or similar pandemic infection) during which participants may not wish to or may be unable to visit the study site for study visits. These changes should only be implemented if allowable by local/regional guidelines and following notification from the Sponsor, and instructions on how to perform these procedures will be provided at the time of implementation.
Reconsent of Study Participants During Study Interruptions
During study interruptions, it may not be possi ble for the participants to complete study visits 
and assessments on site and alternative means for carrying out the visits and assessments may be necessary, eg, remote visits. Reconsent s hould be obtained for the alternative means of 
carrying out visits and assessments and should be obtained prior to performing the procedures 
described in Sections K2toK6 . Local and regional regulations and/or guidelines regarding 
reconsent of study participants should be checked  and followed. Reconsent may be verbal if 
allowed by local and regional guidelines (note, in  the case of verbal reconsent the ICF should 
be signed at the participantâ€™s next contact with the study site). Visiting the study sites for the sole purpose of obtaining reconsent should be avoided.
Rescreening of Participants To Reconfirm Study Eligibility
Additional rescreening for screen failure due to study disruption can be performed in 
previously screened participants  The investigator should confirm this with the designated 
AstraZeneca Study Physician.
In addition, during study disruption there may be a delay between confirming eligibility of a 
participant and either enrolment into the study or commencing of dosing with IP. If this delay is outside the screening window specified in the SoA (see Section 1.3) the participant will 
need to be rescreened to reconfirm eligibility before commencing study procedures. This will provide a nother opportunity to re-screen a participant in addition to that detailed in 
Section 5.4.The procedures detailed in Section 5.1must be undertaken to confirm eligibility 
using the same randomization number as for the participant.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGDGe for theor the parparpp
for carrying out th rrying ou
hould be obtained d be obtain
ould be obtained pd be obtain
and regional regulregion
d be checked and f checked a
elines (note, i (note, n theii
xt contact with the ntact with 
nsent should be avnt should b
g of Parti ci Partici panpa
 for screen failure creen failure
partarticicipants  The iipants  The i
Physician. icia
isrupt
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 135 of 155
Home or Remote Visit to Replace On-site Visit (where applicable)
A qualified HCP from the study site or TPV servi ce will visit the participants home / or other 
remote location as per local SOPs, as applicable. Supplies will be provided for a safe and 
efficient visit. The qualified HCP will be expected to collect information per the CSP.
Telemedicine Visit to Replace On-site Visit (where applicable)
In this appendix, the term telemedicine visit refers to remote contact with the participants
using telecommunications technology including phone calls, virtual or video visits, and 
mobile health devices.
During a civil crisis, natural disaster, or public health crisis, on-site visits may be replaced by 
a telemedicine visit if allowed by local/regional guidelines. Having a telemedicine contact with the participants will allow AEs, concomitant medication, and adherence to the eDiary and ePRO measures to be reported and documented.
At-home or Remote Location IP Administration Instructions
If a site visit is not possible, at-home or remote location administration of IP may be 
performed by a qualified HCP, provided this is  acceptable within local regulation/guidance, or 
by the participant or his/her caregiver. The option of at-home or remote location IP administration ensures participants safety in cas es of a pandemic where participants may be at 
increased risk by traveling to the site/clinic. This will also minimize interruption of IP administration during other study disruptions, eg, site closures due to natural disaster. 
Section  K 5.1 to be used only when applicable for the IP formulation being used, eg, with 
injectable biologics. 
K 5.1
At-home or Rem te Location IP Administration by a Qualified HCP or 
TPV Service
A qualified HCP from the study site or TPV service should administer the IP at the 
participantâ€™s home or other remote location according to the CSP. All necessary supplies and 
instructions for administration and documentati on of IP administrati on will be provided. 
Additional information related to the visit can be obtained via a telemedicine or home visit.
K 5.2 At-home or Remote Location IP Administration by the Participant or 
His/Her Caregiver
Prior to at-home or remote location IP administration the investigator must assess the 
participant or his/her caregiver to deter mine whether they are appropriate for at-home or 
remote location administration of IP. Once the par ticipant or his/her caregiver is deemed 
appropriate for at-home or remote location administration, he/she must receive appropriate training. All necessary supplies and instructions for administration and documentation of IP '&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGed
ed.d
on IP AdministIP Admi
mote location adme location
d this is acceptables is acc
r. The option of athe option o
safet y y in cases of in cas
site/clinic. This w/clinic. Th
udydisruptidisruptiy ons, egon
nly when applicabwhen applica
me or Rem te Loor Rem te Lo
ervicece
studyst
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 136 of 155administration will be provided. More information related to the visit can be obtained via a 
telemedicine or home / remote visit.
Data Capture During Telemedicine or Home / Remote Visits
Data collected during telemedicine or home / remote visits will be captured by the qualified HCP from the study site or TPV service, or by the participant themselves by use of the eDiary.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHG
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 137 of 155Appendix L Abbreviations
Abbreviation or special 
termExplanation
ACM Ambulatory Cough Monitoring
ADA Anti-drug Antibody 
AE Adverse Event
AECOPD Acute Exacerbation of Chronic Obstructive Pulmonary Disease
AESI Adverse Event of Special Interest
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
Anti-HBs Antibody to hepatitis B core antigen
AO Airwave Oscillometry
AST Aspartate Aminotransferase
ATS American Thoracic Society
AUC Area under the Concentration Time Curve
AUC 0-4 weeks Area under the Concentration Tim  Curve from Weeks 0 to 4
AX Area of Reactance
B Blood
BCSS  Breathlessness, Cough and Sputum Scale
BD Bronchodilato
BMI Body mass ind x
BP Blood Press re
CAT COPD Assessment Test
CI Confidence Interval
CIOMS Council for International Organizations of Medical Sciences 
Cmax,ss Maximum Concentration at Steady State
COPD Chronic Obstructive Pulmonary Disease
COPDCompEx COPD Composite Exacerbations
COVID-19 Coronavirus disease 2019
CSP Clinical Study Protocol
CSR Clinical Study Report
CT Computed Tomography 
CTCAE Common Terminology Criteria for Adverse Events'&3URWRFRO$PHQGPHQW_9970)_
$MaximM$SSURYHGGyGtration Time Curve n Time CurHGcentration Tim  Curv ation Tim  HeYHY
ness, Cough and Sput Cough andR odilato oUR y mass ind x s ind xSUlood Press re ress reSSS$COPD Assessme Assessm$$$S$Confidence Inonfidence In$$$S$Council foCoun$$$$$CCI
CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 138 of 155Abbreviation or special 
termExplanation
dD a y
DBP Diastolic Blood Pressure
DSMB Data Safety Monitoring Board
E/A Exacerbation Assessment
ECG Electrocardiogram
eCRF Electronic Case Report Form
E/D Early Study Intervention Discontinuation Visit
eDiary Electronic Diary
ePRO Electronic Patient Reported Outcome
EOT End of Treatment
E-RS:COPD Evaluating Respiratory Symptoms of COPD
ERS European Respiratory Society
EXACT Exacerbations of Chronic Pulmonary Disease Tool
FDA Food and Drug Administration
FEV 1 Forced Expiratory Volume in 1 Second
FSH Follicle Stimulating Hormone
FVC Forced Vital Capacity
GCP Good Clinical Prac ice
GGT Gamma-glutamy  Transferase
Hb Hemoglobin
HbA1c Hemoglobin A1c
HBc He titis B Core Antibody
HBsAg Hepatitis B Surface Antigen
HCP Healthcare Provider
HCV Hepatitis C virus
HIPAA Health Insurance Portability and Accountability Act
HIV Human Immunodeficiency Virus
HL Hyâ€™s Law
HRT Hormone Replacement Therapy
IATA International Airline Transportation Association
IB Investigatorâ€™s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation
ICS Inhaled Corticosteroids'&3URWRFRO$PHQGPHQW_9970)_
mptoms of COPD ms of COPGociety yGonic Pulmonary Dise ulmonaryHG dministration strationYHory Volume in 1 Seco olume in 1Ymulating Hormone ng HormRYVital Capacity CapacityURClinical Prac iceical Prac iceU
mma -glutamy  Transglutamy  SU Hemoglobin oglobinSSHemoglobin A1cmoglobin $SS$He titis B CoHe titis B Co$$$S$Hepatitis B Hepatit$$$$Healthcaea$$$$CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 139 of 155Abbreviation or special 
termExplanation
IEC Independent Ethics Committee 
Ig Immunoglobulin
IgG1 Immunoglobulin G1
IGRA Interferon Gamma Release Assay
IL-33 Interleukin-33
IMP Investigational Medicinal Product
IP Investigational Product
IRB Institutional Review Board 
ITT Intention-to-Treat
IV Intravenous
LABA Long Acting Beta 2 Agonist
LAMA Long Acting Muscarinic Receptor Antagonist
LTBI Latent tuberculosis infection
LVEF Left Ventricular Ejection Fraction
mAb Monoclonal Antibody
MMP Matrix Metalloproteinases 
NIMP Non-investigational Medicinal Product
NT-proBNP N-terminal pro-brain natriuretic peptide
OCS Oral Cort osteroids
PD Pharmacodynamics
PDE4 Inhibitor Phospohidiesterase-4 Inhibitor
PEF Pe k Expiratory Flow
PHL Potential Hyâ€™s Law
PI Principal Investigator 
PK Pharmacokinetics
PNV Predicted Normal Values
Q4W Every 4 Weeks
R Randomization
R5/20 Resistance at 5/20 Hz
RBC Red Blood Cell
RTSM Randomization and Trial Supply Management
S Serum
SABA Short-Acting Beta Agonists'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGeceptor or AntagoAntago noGtionGtion Fraction actioHG bodyYHproteinases nases YRYestigational Medicina tional MediURminal pro l pro--brbrain natriuain nU
al Cort osteroids rt osteroiSU PharmacodynamicsmacodynamicsSSPhospohidiesterasospohidies$SS$Pe k ExpiratorPe k Expirator$$$S$$$$$Potentialote$$$$CCICCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 140 of 155Abbreviation or special 
termExplanation
SAE Serious Adverse Event 
SAMA Short-Acting Muscarinic Antagonists
SAP Statistical Analysis Plan
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
SBP Systolic Blood Pressure
SC Subcutaneous
SGRQ St Georgeâ€™s Respiratory Questionnaire
SID Subject Identification
SoA Schedule of Activities
SOP Standard operating procedure
SUSAR Suspected Unexpected Serious Adverse Reaction
SV Study Visit
TB Tuberculosis
TBL Total Bilirubin
TC Telephone Contact
TPV Third party vendor
UU r i n e
UK United Kingdom
ULN Up r Limit of Normal
V Visit
VAS Visual Analogue Scale
w/v Weight per Volume'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHd Serious Adverse ous AdveHYHYbinRYe ContactntacURparty vendory vendorU
UrineeSSUnited Kingdomited Kingd$SS$Up r Limit ofUp r Limit of$$$S$VisitVi$$$$Visual Aisu$$$$CCI
CCICCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 141 of 155Appendix M Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.
Amendment 4 (23 July 2021)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union because it either significantly impacts the safety or physical/mental integrity of participants or 
the scientific value of the study.
Overall Rationale for the Amendment:
To reflect emerging evidence supporting coexistence of significan t mucus hypersecr etion in all 
extents of emphysema , to adjust for the impact of COVID-19 on exacerbation frequency globally, 
and to clarify wording on various points.
Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-
substantial
Section 5.2
(Exclusion criteria)
Section 2.2
(Background) and Section 2.3.1
(Risk Assessment)
Section 3
(Objectives)
Section 4.2
(Scientific rationale for study design)Remove exclusion 
criterion 4 (predominant 
emphysema).
Provide rationale for change.
Additional secondary  
 objective to 
assess response to 
MEDI3506 by extent of emphysema on baseline CT scan in main study.
Provide rationale for change.Emerging evidence supporting 
coexistence of significant mucus 
hypersecretion in all extents of 
emphysema (Dunican et al 2021;Kim et al 2021)  and therefore 
amended to investigate impact of MEDI3506 in all patients regardless Substantial'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGVID
Brief RaBriGYH dominant nant 
vide rationale for chan rationale forEmerginEm
coexi
hyYYY
$$RY
CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 142 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-
substantial
Section 8.1.9
(Chest CT)
Section 9.4.2.2
(Subgroup analyses)Removal of reference to 
exclusion criteria for extent 
of emphysema.
Addition of emphysema 
subgroup analysis for primary endpoint.
Table 2 (Screening 
Procedures) and Section 4.1.1 (Study 
[and Sub-Study] 
Conduct and Planned 
Mitigations During COVID-19 Pandemic)PCR analysis changed to 
nucleic acid analysis.To account for countries that 
use a test equivalent to PCR that is not technically PCR.
Non-
substantial 
Section 4.1(Overall 
Design)Added information in the 
event that automated calculation of emphysema percentage is not technically possible.For clarification.
Non-
substantial 
Section 4.2.1
(Rationale for study 
population)Update to text on h w BCSS 
inclusion criterion helps to 
identify patients most likely 
to respond t  MEDI3506. (Criteri n itself unchanged).For clarification.
Non-
substantial 
Section 5.1
(Inclusion criteria)
Section 4.1
(Overall design)
Section 4.2.1
(Rationale for study 
population)Chang  t  â‰¥1 exacerbation 
of COPD in 24 months from 12 months.
Rationale for change to 
exacerbation inclusion criteria.Impact of COVID-19 on 
exacerbation frequency globally due to changed behaviour/shielding of vulnerable patients with respiratory disease.
During the ongoing COVID-19 
pandemic, as a result of changed patient behaviour, there has been a significant reduction in exacerbation frequency compared with previous years. Data from the UK suggested a 50% reduction in exacerbation related-hospital admissions compared with pre-pandemic Non-
substantial'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGHe
hysema ma 
t technicallyhnicallyFor clarificatFor claHHHG
RYHtext on h w BCSS n h w BC
on criterion helps to erion helps
ifypatients most likelients mos y
respond t  MEDI3506 nd t  MEDI350
(Criteri rin itself unchan itself unchaURRR
$R
Chang  tChang  t  â‰¥â‰¥1 exex
of COPD in 24f COPD i
12 months.mon$$$S$
PPD
Clinical Study Protocol â€“ Amend ment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 143 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-
substantial
(Alsallakh et al 2021;Tan et al 2020) , and a 39% 
reduction in primary care 
consultations related to COPD. This picture is replicated in other countries. Leaving the requirement for at least one moderate or severe exacerbation in the previous 12 months unchanged would lead to the exclusion of patients who in previous years would have been 
included.
Section 5.1
(Inclusion criteria)Change BMI to 18-35 kg/m2
from 19-35 kg/m2.Correcting error in wording to 
all w all patients of BMI range within normal limits to be included in study.Non-
substantial
Section 5.2
(Exclusion criteria)Clarify wording on lung 
resection exclusion.To better clarify exclusion for 
lung resection is based upon significant resection (pneumonectomy) which would 
impact upon lung function or 
where lung volume reduction surgery has been carried out where COPD was the indication. Clarification to allow stable patients who have previously undergone lobar or wedge resection due to causes other than COPD.Non-
substantial
Section 5.2
(Exclusion criteria)Clarification on testing for 
hepatitis C infection.Provide greater clarification that 
positive HCV antibodies would 
exclude a participant from the study.Non-
substantial
BCSS = Breathlessness, Cough and Sputum Scale; BMI = Body mass index; COPD = Chronic obstructive 
pulmonary disease; COVID-19 = Coronavirus diseas e 2019; CT = Computed tomography; HCV = Hepatitis C 
virus; PCR = Polymerase chain reaction; UK = United Kingdom.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGncludedclud
Correcting error rrecting er
all w all patienall w all pa
within nowithin rmaoo
included inncludG
RYHon lungung o
$usion.To bet
lung
siRYRYRY
$RY
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 144 of 155Amendment 3 (01 June 2021)
This amendment is considered to be non-substantial based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union because it neither significantly impacts the safety or physical/mental integrity
of participants nor the scientific value of the study.
Overall Rationale for the Amendment:
To clarify wording on various points, to remove unnecessary tests, and add flexibility in 
regard to SARS-CoV-2 testing.
Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-substantial
Section 1.3
(Schedule of Activities)
Section 5.1
(Inclusion Criteria; Criterion 14)Clarification that pregnancy 
tests should be carried out in WOCBP only.Removal of unnecessary testing 
of women not of childbearing potential that causes inconvenie ce to patients when not cli ically relevant or appropriate and causes 
co f sion to site staff.Non-substantial
Section 1.3
(Schedule of 
Activities)Clarified urine pregnancy tes  
at SV2 is not required if CT 
scan is not performed.Unnecessary test in that 
circumstance.Non-substantial
Section 1.3
(Schedule of 
Activities), Section 
4.1.1 and Section 8.2.6
(Clinical Safety LaboratoryAssessments)Permitted local laboratories to 
perform SARS-Cov-2 nucleic 
acid testing (nasopharyngeal 
swab), as well as the central laboratory and permit less frequent testing dependent on pr valence of covid infection.To avoid delays in this result 
and to avoid unnecessary 
duplication where local 
procedures also require local testing. To permit less frequent testing in areas of low or very low incidence after agreement with medical monitor.Non-substantial
Section 5.1
(Inclusion Criteria)Inclusion Criterion 3: 
Clarification of influenza and pneumococcal vaccine requirementsTo ensure vaccination 
requirements are compatible with national practices and seasonal vaccine availability.Non-substantial
Section 5.2
(Exclusion Criteria; Criterion 25)Clarification of a positive 
IGRA test in the context of treated latent TB infection.Participants with a positive 
IGRA test and no active disease, who have undergone or who undergo full treatment for LTBI are not excluded from the study 
by virtue of a positive test 
(which can remain positive despite treatment).Non-substantial
Section 5.2
(Exclusion Criteria)To remove unnecessary 
effective prohibition on Exclusion Criterion 42 serves to 
limit total radiation exposure to Non-substantial'&3URWRFRO$PHQGPHQW_9970)_
$nclusion Criteusion
ficationc$SSURYHGfw o mwo
potential thaotential t
inconvenie ce toonvenie c
not cli ically relnot cli ical
appropriate anappropr
co f sion toco f siYHancy tes tes  
ired if CT f CT 
ormed.UnUneces
circumYHYHYHRYHal laboratories to oratories to
ARS -CovCov-2 nucleic 2 nucl
ing (nasopharyngealnasopharyng
, as well as the centrawell as the c
orato ryryoo and permit les and permit lesyy
requent testing depend testing depend
pr valence of covid pr valence of covid TURRR
$R
$
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 145 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-substantial
Section 5.4
(Screen Failures)
Section 8.1.9
(Chest CT)
Section 5.4
(Screen Failures)In the case of re-screening, to 
permit echocardiogram and IGRA (TB test) results no 
more than 3 months old, to be 
re-used.Results are not likely to have 
changed significantly within a 3 month period unless there has 
been a new significant medical 
event (which would be captured within Exclusion Criterion 3). These tests are costly and time-consuming both for patient 
and/or perator.Non-substantial
Section 6.3.2
(Methods to Ensure Blinding)Included that the 
randomisation schedule may be provided to limited personnel.To facilitate in-stream analysis 
of PK and ADA samplesNon-substantial
Section 6.5.6
(COVID-19 vaccination)Clarification of information to 
be recorded in the event of a participant receiving a COVID-19 vaccineTo ensure necessary data is 
captured.Non-substantial
Section 8.1.8.8 Clarified that agreement to 
participate in t e Study Participant F dback Question aire will be included in the ICFClarification Non-substantial
Section 8.3.10
(Pregnancy)
Appendix BCongenital abnormality 
changed to congenital anomalyTo meet regulatory 
requirements on good pharmacovigilance practicesNon-substantial
Section 8.5.1
(Pharmacokinetics)Clarification of processing of 
PK samples from participants 
who received placebo.Clarification added to avoid 
unnecessary analysis on samples 
where no IMP administered.Non-substantial
Section 8.5.2
(Immunogenicity 
Assessments)Included that neutralising 
antibody may also be assessedTo further assess 
immunogenicityNon-substantial
Throughout Minor typographical changes For clarification Non-substantial
ADA = Anti-drug Antibody; COVID-19 = Coronavirus  disease 2019; CT = Computed tomography; 
ICF = Informed Consent Form; IMP = Investigational medicinal product; LTBI = Latent tuberculosis infection; PK = Pharmacokinetic; SARS-Cov-2 = Severe acute respir atory syndrome coronavirus 2; SV = Study Visit; 
TB = Tuberculosis; WOCBP = Women of childbearing potential.'&3URWRFRO$PHQGPHQW_9970)_
$SCongenital abnormongenital abnorm$SSURYHGmeme-co
and/oor perar peoooo
yTo facilitate in facilitate -s
of PK and ADAof PK and GYHrmation to t
e event of a nt of a 
eiving a g a
accine eTo ensuTo
captuYYYRY
that agreement to greement to
pate in t e Study t e Study
cipant F dback t F dback 
uestion aire will be in n aire will be in
n the ICFSU
changed to congnge
omalyaly$S$
i
PPDCCI CCI
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 146 of 155Amendment 2 (08-Feb-2021)
This amendment is considered to be non-substantial based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the EU because it neither significantly impacts the safety or physical/mental integrity of participants nor the scientific value of the study. 
Overall Rationale for the Amendment:
To clarify restrictions applicable to newl y available vaccines against COVID-19 and to 
remove the induced sputum and capnography sub-studies.
Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-substantial
1.1 Synopsis
1.3 Schedule of Activities2.3.1 Risk Assessment
3 Objectives and Endpoints
4.1 Overall Design
4.2 Scientific Rationale for 
Study Design
5 Study Population
5.1 Inclusion Criteria
5.2 Exclusion Criteria8.1.1 Clinic Spirometry
8.6.1.5 Induced Sputum
9.2 Sample Size 
DeterminationAs a result of the COVID-19 
pandemi  sputum induction and 
required local processes have proven not to be feasible at the required number of sites. Spontaneous sputum sampling remains a part of the protocol.Non-substantial
1.1 Synopsis
1.3 Schedule of Activities
3 Objectives and Endpoints
4.1 Overall Design
4.2 Scientific Rationale for 
Study Design
5 Study Population5.1 Inclusion Criteria
8.1.12 Capnography Sub-
study
9.2 Sample Size 
Determinationprior to inclusion of any 
participants in that sub-studyGiven the practical difficulties 
for sites conducting this study 
during the COVID-19 pandemic, the exploratory sub-study has been removed to reduce site burden.Non-substantial'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGAs a resus a re
pandemi  spudemi  sp
required local pruired loca
proven not to bproven not
required numrequire
Spontaneo t
remainsreG
$RYH
$$$$CCI
CCI
CCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 147 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-substantial
1.3 Schedule of Activities Addition of PK and 
immunogenicity samples at SV11To better characterize the PK 
profileNon-substantial
3 Objectives and Endpoints Added exploratory 
endpoints  Correction of erroneous 
omission in protocol (data was collected in previous version)Non-substantial
4.1.1.1 Vaccination Against 
COVID-19
5.2 Exclusion Criteria
6.5.5 Restricted and 
Prohibited MedicationsAddition of instructions 
on when COVID-19 
vaccination should be 
given to study participantsTo respond to recent emergency 
use authorizations of COVID-19 
vaccines and mitigate any 
potential risksNon-substantial
4.4.1 Study Stopping 
CriteriaAddition of specific 
study stopping criteria (individual IP 
discontinuation criteria 
already present)To comply with a request from 
the FDANon-substantial
5.2 Exclusion Criteria Exclusion Criterion 15:
Addition of clarificationTo comply with a request from 
n Ethics CommitteeNon-substantial
5.2 Exclusion Criteria Exclusion Criterion 
9(g):  Removing 
requirement for 
surveillan  CT s ans as exclusion for main study
Exclusion Criterion 43:
Adding need for future 
CT scans (eg, 
surveillance scans) as exclusion for CT sub-studyGiven available scientific 
literature on natural history of 
chest CT findings requiring CT 
scan, and lack of relationship to mechanism of action, it was considered that exclusion was unnecessary. However, it was recognized that the total radiation burden of surveillance scans should not be added to by end of study scans.Non-substantial
5.2 Exclusion Criteria 6.5.5 
Restricted and Prohibited 
MedicationsExclusion 
Criterion 34(d):  Added 
clarification for vaccines with adenoviral vectors that are unable to replicateTo clarify that these are not 
considered live or attenuatedNon-substantial
6.5.6 COVID-19 
Vaccination 
8.2.1 Medical, Surgical and 
COPD HistoryAdded clarification on 
recording of COVID-19 vaccinationTo ensure this information is 
accurately recordedNon-substantial'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGia o compo com
the FDAFDA
YHion155:
arification ationTo comply
n EthicnYHYHYHRYHCriterion rion 
moving ng
ement for t for 
veillan n CT s ans CT s an
s exclusion for main usion for 
studydy
Exclusion Criterioxclusion Criterio
Adding need foding ne
CT scans (egCT scans (eg
surveillancsurvei
exclusioex
studysGive
liteRYRY
$RY
$RYCCI
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 148 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-substantial
Appendix J Example of Patient COVID-19 Screening QuestionnaireNew question added for 
COVID-19 vaccinationTo provide an example question 
for sites on COVID-19 vaccinationNon-substantial
COPD = Chronic Obstructive Pulmonary Disease; COVID-19 = Coronavirus disease 2019; CT = Computed 
Tomography; FDA = Food and Drug Administration; PK = Pharmacokinetics; SV = Study Visit.
Amendment 1 (01-Oct-2020)
This amendment is considered to be non-substantial based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union because it neither significantly impacts the safety or physical/mental integrity
of participants nor the scientific value of the study.
Overall Rationale for the Amendment:
The FDA recommended changes to the protocol, including amending the study intervention 
discontinuation criteria and using a standardized toxicity grading scale.
Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-substantial
1.3 Schedule of ActivitiesAdjustment of footnotes 
regarding timing of repeat attempts in case of failure to successfully obtain spontaneous and induced sputum samplesTo improve flexibility for sites 
and thereby minimise the chance of failure to obtain a sample.Non-substantial
5 Study Population Addition of ext regarding 
par i ipants who meet eligibility criteria for main study but not  sub-study.To clarify that participants 
found to be ineligible for the sub-study should not automatically be discontinued 
from the main study.Non-substantial
5.1 Inclusion Criteria Correction of typographical 
error in Inclusion Criterion 6- Non-substantial
5.2 Exclusion Criteria Addition of clarification 
regarding quantitative 
assessment of CT scan 
showing emphysema in Exclusion Criterion 4 (c).To avoid confusion with other 
quantitative assessments of 
CT scan.Non-substantial
5.2 Exclusion Criteria Correction of typographical 
error in Exclusion Criterion 34 
(h)- Non-substantial
6.2.2 Dose 
Preparation StepsCorrection of a typographical 
error- Non-substantial'&3URWRFRO$PHQGPHQW_9970)_
$SSAddition of ext regard n of ext r$SSURYHGcol, including amen ncluding a
dized toxicit toxicit y ygrad
hange e BYHYHYHRYHfootnotes otes 
ming of repeat f repeat 
case of failure to of failure t
ully obtaiobta n
neous and induced s and induc
um samples amplesTo 
aRYRYRYRY
par i ipants who mepar i ipants who me
eligibility criteriagibility criteria
study but not suy but$SS$$
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 149 of 155Section Number and 
NameDescription of Change Brief Rationale Substantial/
Non-substantial
7.1 Discontinuation of Study InterventionCriteria for discontinuation 
amended.To address recommendations 
from the FDA.Non-substantial
8.2.5 
EchocardiogramAddition of detail regarding 
how the echocardiogram should be performed.To ensure consistency 
between sites.Non-substantial
8.2.6 Clinical Safety 
LaboratoryAssessmentsAddition of urine specific 
gravity to Table 8 (Laboratory Safety Variables)Correction of omission in 
original protocol.Non-substantial
8.2.6 Clinical Safety 
LaboratoryAssessmentsRemoval of â€˜Hepatitis Aâ€™ 
from other safety tests.Correction of erroneous 
inclusion in original protocol.Non-substantial
Appendix B Adverse 
Events: Definitions and Procedures for 
Recording, 
Evaluating, Follow-up, and ReportingReplacement of Intensity 
Rating Scale with Severity Rating Scale based on the 
CTCAE criteria.To address recommendations 
from the FDANon-substantial
CT = computed tomography; CTCAE = Common Termin logy Criteria for Adverse Events; FDA = Food and 
Drug Administration.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGom thom 
YYHYYmon Termin logy Crit ermin log
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 150 of 15511 REFERENCES
Adeloye et al 2015
Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional 
estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015;5(2):020415.
Aithal et al 2011
Aithal GP, Watkins PB, Andrade RJ, Larrey D,  Molokhia M, Takikawa H, et al. Case 
definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 
2011;89(6):806-15.
Allinne et al 2019
Allinne J, Scott G, Lim WK, Birchard D, ErjefÃ¤lt JS SandÃ©n C, et al. IL-33 blockade affects 
mediators of persistence and exacerbation in a model of chronic airway inflammation. J 
Allergy Clin Immunol 2019;144(6):1624-37.
Alsallakh et al 2021
Alsallakh MA, Sivakumaran S, Kennedy S, Vasileiou E, Lyons RA, Roberston C, et al. 
Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease: national interrupted time series analyses for Scotland and Wales. BMC Med 2021;19(1):124.
Anzueto 2010
Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010;19(116):113-8.
Bhowmik et al 2000
Bhowmik A, Seemungal TA, Sapsford RJ, and Wedzicha JA. Relation of sputum 
inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55(22):114-20.
Burgel and Nadel 2008
Burgel PR and Nadel JA. Epidermal growth factor receptor-mediated innate immune 
responses and their roles in airway diseases. Eur Respir J 2008;32(4):1068-81.
Calverley et al 2017
Calverley PM, Tetzlaff K, Dusser D, Wise R, Mueller A, Metzdorf N. Determinants of 
exacerbation risk in patients with COPD in the TIOSPIR study. Int J Chron Obstruct Pulmon 
Dis 2017;12:3391â€“405. 
Caramori et al 2004
Caramori G, Di Gregorio C, Carlstedt I, Ca solari P, Guzzinati I, Adcock IM, et al. Mucin 
expression in peripheral airways of patients with chronic obstructive pulmonary disease. 
Histopathology 2004;45(5):477-84.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGelel of ll
, Vasileiou E, Lyoasileiou E
ncidence and mortence and m
: national nalintinterrupe
24.
bations on COPD. ns on COP
al TA, Sapsford RJ , Sapsford RJ
rs to symptoms andto symptoms an
):1144-20.-20.
d
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 152 of 155Hurst et al 2010
Hurst JR, Vestbo J, Anzueto A, Locantore N,  MÃ¼llerova H, Tal-Singer R, et al. Susceptibility 
to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 
2010;363(12):1128-38.
Jones et al 1991
Jones PW, Quirk FH and Baveystock CM. The St  George's Respiratory Qu estionnaire.  Respir 
Med 1991;85 Suppl B:25-31.
Jones and Forde 2009
Jones PW and Forde Y. St Georgeâ€™s resp iratory questionnaire manual. 2009. Version 2.3. 
Available from URL: http://www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ%20Manual%20June%202009.pdf.
Jones et al 2009
Jones PW, Harding G, Berry P, Wiklund I, Chen  WH and Kline Leidy N. Development and 
first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648-54.
Jones et al 2011 
Jones PW, Chen WH, Wilcox TK, Sethi S,  Leidy NK and EXACT-PRO Study Group. 
Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest 2011;139(6):1388â€“94.
Kearley et al 2015
Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N, et al. Cigarette smoke silences 
innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent 
response to infection. Immunity 2015;42(3):566-79.
Kemp et al 2008
Kemp SF, Lockey RF and Simons FE; World Allergy Organization ad hoc Committee on 
Epinephrine in Anaphylaxis. Epinephrine: the drug of choice for anaphylaxis. A statement of 
the World Allergy Organization. Allergy 2008;63(8):1061-70.
Kim et al 2011
Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, et al. The chronic bronchitic 
phenotype of COPD: an analysis of the COPDGene Study. Chest 2011;140(3):626-33.
Kim et al 2021
Kim V, Dolliver WR, Nath HP, Grumley SA, Terry N, Ahmed A, et al. Mucus plugging on 
computed tomography and chronic bronchitis in  chronic obstructive pulmonary disease. 
Respir Res 2021;22(1):110.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGen WH and Kline H and Kl
st. Eur Respir J. 20ur Respir J
hi S, Leidy NK an Leidy N
symptomat tomat ic icfeatu
n C, Liu Z, Berlin Liu Z, Be
tion and facilitaten and facilitate
mmunit nity y 2015;422015;42
F and Simd S ons
xis. Epis
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 153 of 155Kim and Criner 2013
Kim V and Criner GJ. Chronic bronchitis and chron ic obstructive pulmonary disease. Am J 
Respir Crit Care Med 2013;187(3):228-37.
Lahousse et al 2017
Lahousse L, Seys LJM, Joos GF, Franco OH, Stricker BH and Brusselle GG. Epidemiology
and impact of chronic bronchitis in chronic obstructive pulmonary disease. Eur Respir J 2017;50(2):1602470.
Leidy et al 2003
Leidy NK, Schmier JK, Jones MK, Lloyd J and Rocchiccioli K. Evaluating symptoms in 
chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. Respir Med 2003;97 Suppl A:S59-70.
Leidy et al 2011 
Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S, et al. Standardizing 
measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011;183(3):323â€“9.
Leidy et al 2014a
Leidy NK, Sexton CC, Jones PW, Notte SM, Monz BU, Nelsen L, et al. Measuring 
respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. 
Thorax 2014;69(5):443-9. 
Leidy et al 2014b
Leidy NK, Murray LT, Monz BU, Nelsen L,  Goldman M, Jones PW, et al. Measuring 
respiratory symptoms of COPD: performance of the EXACT â€“ Respiratory Symptoms Tool(E-RS) in three clinical trials. Respir Res 2014;15(1):124.
Martin and Martin 2016
Martin NT and Martin MU. Interleukin-33 is a guardian of barriers and a local alarmin. Nat 
Immunol 2016;17(2):122-31. 
Martinez et al 2015
Martinez FJ, Calverley PM, Goehring U-M, Brose M, Fabbri LM, Rabe KF. Effect of 
roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. 
Lancet 2015;358(9971):857-66.
Miller et al 2005
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation 
of spirometry. Eur Respir J 2005;26(2):319-38.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGwers JH, Seers JH, S
ydisease exacerbaase exac
Care Med 2011;1e Med 201
te SM, Monz BU, M, Monz
ls of COPD: reliabf COPD
nz BU, NelU, Ne sen L, Ge
COPD: performanPD: performan
l trials. Respir Res. Respir Res
n 201616
n MU. InterleU.
31.1
PPD
Clinical Study Protocol â€“ Amendment Number 5.0 AstraZeneca
MEDI3506 - D9180C00002
CONFIDENTIAL AND PROPRIETARY 155 of 155Segal and Martinez 2018
Segal LN and Martinez FJ. Chronic obstructive pulmonary disease subpopulations and 
phenotyping. Allergy Clin Immunol 2018;141(6):1961-71.
Smith et al 2006
Smith J, Owen E, Earis J and Woodcock A. Cough in COPD: correlation of objective 
monitoring with cough challenge and subjective assessments. Chest 2006;130(2):379-85.
Sylvester et al 2017
Sylvester K, Carter J, Walsh J, Foord J, Mahadeva R, Altrip J. A novel device for the 
measurement of carbon dioxide during tidal breathing in COPD. Eur Respir J 2017;50(Suppl 61):PA3013. Available from URL: https://erj.ersjournals.com/content/50/suppl_61/PA3013.
Tan et al 2020
Tan JY, Conceicao EP, Wee LE, Sim XYJ, and Venka achalam I. COVID-19 public health 
measures: a reduction in hospital admissions for COPD exacerbations. Thorax 2021;76(5):512-3.
Vandenberk et al 2016
Vandenberk B, Hnatkova K, Goovaerts G, Garweg C, Ector J, Van Huffel S, et al. 
Inappropriate ICD shocks do not induce pro-arrhythmic electrocardiographic changes in men. Scand Cardiovasc J 2017;51(1):47-52.
Vestbo et al 2011
Vestbo J, Edwards LD, Scanlon PD  Yates JC, Agusti A, Bakke P, et al. Changes in forced 
expiratory volume in 1 second overtim  in COPD. N Engl J Med 2011;365(13):1184-92.
Woodruff et al 2016
Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, et al. Clinical 
Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med 
2016;374(19):1811-21.'&3URWRFRO$PHQGPHQW_9970)_
$SSURYHGVenka achanka ach
r COPD exacerb PD exac
s G, Garweg C, EcGarweg 
duce pro pro-arrhythmarr
7-52.
nlon PD  Yates JCPD  Yat
econd overtim  in d overtim  in
RG, Bleecker E, , Bleecker E, 
ptoms i s in Smok
PPD
6,*1$785(3$*(
7KLVLVDUHSUHVHQWDWLRQRIDQHOHFWURQLFUHFRUGWKDWZDVVLJQH G
HOHFWURQLFDOO\DQGWKLVSDJHLVWKHPDQLIHVWDWLRQRIWKHHOHFWU RQLFVLJQDWXUH
'RFXPHQW1DPH GFFVSDPHQGPHQW
'RFXPHQW7LWOH '&&OLQLFDO6WXG\3URWRFRO$PHQGPHQW
'RFXPHQW,'
9HUVLRQ/DEHO &855(17/$7(67$33529('
6HUYHU'DWH
GG000\\\\++PPÂµ87&Â¶=6LJQHGE\ 0HDQLQJRI6LJQDWXUH
)HE87& &RQWHQW$SSURYDO
)HE87& $XWKRU$SSURYDO
)HE87& &RQWHQW$SSURYDO
)HE87& $XWKRU$SSURYDO'&3URWRFRO$PHQGPHQW_9970)_
GG67$3357$33
YHGGGYHGGG0YHRYRYRRSUSUSCCI
CCIPPD
PPD
PPD
PPD
PPD